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Chronic kidney disease (CKD) is a prevalent condition and is associated with an 
increased risk of serious adverse outcomes, including kidney failure and death. The 
identification of prognostic factors that improve our ability to predict an individual’s risk of 
these adverse outcomes and identify potential targets for new treatments could bring 
significant benefits to the care of patients with CKD. In this work, data and samples from 
prospective cohort studies of participants with CKD were used to examine four potential 
prognostic factors: serum free light chains (FLC), urine FLC, monoclonal gammopathy, and 
serum endotrophin. Serum FLC and endotrophin concentrations were both associated with the 
risk of death in patients with CKD after adjustment for established prognostic factors, and 
serum FLC concentration was also independently associated with the risk of kidney failure. 
Urine FLC and monoclonal gammopathy were not associated with the risk of adverse 
outcomes. Possible explanations for the identified associations are discussed, as are 
suggestions for the next steps needed to assess the potential use of these prognostic factors in 
clinical practice with a view to improving the care of patients with CKD.
 
Acknowledgments 
First and foremost, I thank my lead supervisor, Prof Paul Cockwell, who first gave me 
the opportunity and encouragement to get involved in clinical research, and who has provided 
me with tireless support and guidance throughout, without which this work would not have 
happened. 
I also wish to acknowledge my co-supervisors, Prof Charles Ferro and Prof Iain 
Chapple, for their invaluable advice and feedback on my work throughout. 
The RIISC study has been a collaborative effort, and the work presented in this thesis 
would not have been possible without the contributions of many people. Dr Mark Jesky and 
Dr Stephanie Stringer were earlier RIISC fellows who made considerable contributions to the 
study and collected some of the baseline data used in this thesis. The whole Queen Elizabeth 
Hospital renal research team, led by Mary Dutton, and the Heartlands renal research team, led 
by Prof Indranil Dasgupta and Margaret Carmody, were vital in the smooth running of the 
study and data and sample collection. I would also like to acknowledge the contributions of 
Dr Stephen Harding and Dr Petros Kampanis from The Binding Site. 
I would like to thank the following people who provided invaluable contributions to 
the work presented in several chapters: 
Chapter III: Dr Simon Fraser, for his collaboration on the meta-analysis. 
Chapter V: Prof Maarten Taal and Dr Latha Gullapudi from the RRID study, and Prof 
Phil Kalra and Dr Rajkumar Chinnadurai from the SKS study, for their collaboration, 
providing data from their respective studies, and for their feedback on my work. 
Chapter VI: Dr Federica Genovese and Prof Morten Karsdal from Nordic Bioscience 
for their collaboration, including the Pro-C6 assays and their feedback on my work. 
 
Over the last year, Dr Kunigal Shivakumar and the whole renal team at Russells Hall 
Hospital have been incredibly supportive, in particular by allowing me dedicated time to 
prepare this thesis. For that, I am very grateful. 
Finally, I cannot thank enough my wife Charlotte, my parents, my sister, and 
Charlotte’s parents, who have all been incredibly supportive throughout. Their allowing me to 
escape with my laptop, just as there was housework or decorating to be done, will be forever 
appreciated.
 
Table of Contents 
Chapter I: Introduction ........................................................................................................ 4 
1.1. Kidney function and markers of kidney disease ............................................... 5 
1.1.1. Glomerular filtration rate (GFR) ....................................................... 5 
1.1.1.1. Estimation of the GFR ........................................................ 7 
1.1.2. Decreased GFR as a marker of kidney disease ................................ 10 
1.1.3. Other markers of kidney disease ..................................................... 11 
1.1.3.1. Albuminuria ...................................................................... 11 
1.1.3.2. Haematuria ........................................................................ 12 
1.1.3.3. Radiographic abnormalities of the kidneys ...................... 13 
1.1.3.4. Others ................................................................................ 13 
1.2. Chronic kidney disease (CKD) ....................................................................... 14 
1.2.1. Definition of CKD ........................................................................... 14 
1.2.2. Staging of CKD ............................................................................... 15 
1.2.3. Prevalence of CKD .......................................................................... 16 
1.2.4. Financial cost of CKD ..................................................................... 19 
1.2.5. Causes of CKD ................................................................................ 20 
1.2.6. Common disease pathways and fibrosis in CKD ............................ 21 
1.3. Prognosis ........................................................................................................ 25 
1.3.1. The role of prognosis in clinical practice ........................................ 25 
1.3.2. The PROGRESS Framework .......................................................... 27 
1.3.2.1. Fundamental prognosis research ...................................... 28 
1.3.2.2. Prognostic factor research ................................................ 29 
1.3.2.3. Prognostic model research ................................................ 29 
1.3.2.4. Stratified medicine research ............................................. 31 
1.4. Prognosis in CKD ........................................................................................... 32 
1.4.1. Kidney failure .................................................................................. 33 
1.4.1.1. Prognostic factors for kidney failure ................................ 34 
1.4.1.2. Prognostic models for kidney failure ................................ 37 
1.4.1.3. Interventions to reduce the risk of kidney failure ............. 40 
1.4.2. Mortality .......................................................................................... 41 
1.4.2.1. Cardiovascular disease ..................................................... 43 
1.4.2.2. Prognostic factors for mortality ........................................ 45 
1.4.2.3. Prognostic models for mortality ....................................... 47 
1.4.2.4. Interventions to reduce the risk of mortality .................... 48 
1.5. The need for more prognosis research in CKD .............................................. 51 
1.6. Summary and research aims ........................................................................... 53 
1.6.1. Hypotheses ....................................................................................... 53 
1.7. Thesis structure ............................................................................................... 54 
Chapter II: General Methods ............................................................................................. 55 
2.1. The Renal Impairment in Secondary Care study ............................................ 56 
2.1.1. Ethics ............................................................................................... 56 
2.1.2. Setting .............................................................................................. 56 
2.1.3. Participants ...................................................................................... 56 
2.1.4. Baseline study visit .......................................................................... 57 
2.1.4.1. Demographic and lifestyle factors .................................... 57 
2.1.4.2. Health-related quality of life ............................................. 58 
2.1.4.3. Clinical history ................................................................. 59 
2.1.4.4. Physical assessment .......................................................... 59 
2.1.4.5. Samples ............................................................................. 61 
2.1.4.6. Assays ............................................................................... 61 
2.1.5. Follow-up ......................................................................................... 62 
2.1.5.1. Data and sample collection ............................................... 62 
2.1.5.2. Outcomes .......................................................................... 63 
2.2. Role in the RIISC study .................................................................................. 64 
2.3. Bias ................................................................................................................. 65 
2.3.1. Selection bias ................................................................................... 65 
2.3.2. Information bias ............................................................................... 66 
2.4. Sample size ..................................................................................................... 67 
2.4.1. RIISC ............................................................................................... 67 
2.4.2. Other studies .................................................................................... 67 
2.5. Statistical methods .......................................................................................... 68 
2.5.1. Preliminary data cleaning and assessment ....................................... 68 
2.5.2. Description of the study population ................................................. 68 
2.5.3. Relationship of a prognostic factor with other variables ................. 69 
2.5.4. Association between prognostic factor and outcomes ..................... 70 
2.5.4.1. Regression model development ........................................ 71 
2.5.4.2. Continuous variables ........................................................ 71 
2.5.5. Analysis of data from multiple studies ............................................ 72 
2.5.6. Missing data ..................................................................................... 72 
2.5.7. Sensitivity analyses .......................................................................... 73 
2.5.8. Software ........................................................................................... 74 
Chapter III: Serum Free Light Chains ............................................................................... 75 
3.1. Abstract ........................................................................................................... 76 
3.2. Introduction .................................................................................................... 78 
3.2.1. Structure and physiology of FLCs ................................................... 78 
3.2.2. Serum FLCs in CKD ....................................................................... 81 
3.2.3. Serum FLCs and prognosis .............................................................. 83 
3.3. Hypotheses ...................................................................................................... 85 
3.4. Methods .......................................................................................................... 86 
3.4.1. Eligibility criteria ............................................................................. 86 
3.4.2. Search strategy ................................................................................. 87 
3.4.3. Data collection ................................................................................. 88 
3.4.4. Risk of bias assessment ................................................................... 89 
3.4.5. Data synthesis .................................................................................. 89 
3.4.6. Assays .............................................................................................. 90 
3.5. Results ............................................................................................................ 91 
3.5.1. Study selection and IPD obtained .................................................... 91 
3.5.2. Study characteristics ........................................................................ 92 
3.5.3. Data integrity ................................................................................... 92 
3.5.4. Risk of bias within studies ............................................................... 93 
3.5.5. Results of individual studies ............................................................ 93 
3.5.6. Meta-analysis ................................................................................... 95 
3.5.6.1. Baseline characteristics ..................................................... 95 
3.5.6.2. Relationship between cFLC and other prognostic factors 96 
3.5.6.3. Kidney failure ................................................................. 100 
3.5.6.4. Death ............................................................................... 108 
3.6. Discussion ..................................................................................................... 116 
3.6.1. Kidney failure ................................................................................ 116 
3.6.2. Death .............................................................................................. 118 
3.6.3. Strengths and limitations ............................................................... 120 
3.6.4. Future research .............................................................................. 121 
3.7. Conclusion .................................................................................................... 122 
Chapter IV: Urine Free Light Chains .............................................................................. 123 
4.1. Abstract ......................................................................................................... 124 
4.2. Introduction .................................................................................................. 126 
4.2.1. Urine FLCs .................................................................................... 127 
4.2.2. Urine FLCs in CKD ....................................................................... 127 
4.3. Hypotheses .................................................................................................... 131 
4.4. Methods ........................................................................................................ 132 
4.4.1. Patients ........................................................................................... 132 
4.4.2. Urine FLCs .................................................................................... 132 
4.4.3. Other variables ............................................................................... 132 
4.4.4. Follow-up ....................................................................................... 133 
4.4.5. Statistical methods ......................................................................... 133 
4.4.5.1. Risk stratification ............................................................ 134 
4.5. Results .......................................................................................................... 136 
4.5.1. Baseline characteristics .................................................................. 136 
4.5.2. Relationships with other baseline variables ................................... 138 
4.5.3. Kidney failure ................................................................................ 141 
4.5.3.1. Risk stratification ............................................................ 148 
4.5.4. Death .............................................................................................. 149 
4.6. Discussion ..................................................................................................... 152 
4.6.1. Kidney failure ................................................................................ 153 
4.6.2. Death .............................................................................................. 154 
4.6.3. Strengths and limitations ............................................................... 155 
4.6.4. Future research .............................................................................. 155 
4.7. Conclusion .................................................................................................... 156 
Chapter V: Monoclonal Gammopathy ............................................................................ 157 
5.1. Abstract ......................................................................................................... 158 
5.2. Introduction .................................................................................................. 160 
5.2.1. Malignant monoclonal gammopathies ........................................... 160 
5.2.2. Non-malignant monoclonal gammopathies ................................... 160 
5.2.3. Kidney disease in monoclonal gammopathies ............................... 161 
5.2.4. Non-malignant MG and survival ................................................... 162 
5.3. Hypotheses .................................................................................................... 164 
5.4. Methods ........................................................................................................ 165 
5.4.1. Patients ........................................................................................... 165 
5.4.2. Definition of monoclonal gammopathy ......................................... 167 
5.4.3. Study design .................................................................................. 167 
5.4.4. Statistical analysis .......................................................................... 168 
5.5. Results .......................................................................................................... 170 
5.5.1. Any non-malignant MG ................................................................. 170 
5.5.1.1. Kidney failure ................................................................. 172 
5.5.1.2. Death ............................................................................... 176 
5.5.2. Non-malignant LC-MG ................................................................. 177 
5.5.2.1. Kidney failure ................................................................. 178 
5.5.2.2. Death ............................................................................... 183 
5.6. Discussion ..................................................................................................... 186 
5.6.1. Kidney failure ................................................................................ 186 
5.6.2. Death .............................................................................................. 187 
5.6.3. Strengths and limitations ............................................................... 187 
5.6.4. Future research .............................................................................. 188 
5.7. Conclusion .................................................................................................... 189 
Chapter VI: Serum Endotrophin ...................................................................................... 190 
6.1. Abstract ......................................................................................................... 191 
6.2. Introduction .................................................................................................. 192 
6.2.1. Collagen type VI ............................................................................ 192 
6.2.2. Endotrophin ................................................................................... 194 
6.3. Hypotheses .................................................................................................... 196 
6.4. Methods ........................................................................................................ 197 
6.4.1. Patients ........................................................................................... 197 
6.4.2. Assay ............................................................................................. 197 
6.4.3. Follow-up ....................................................................................... 197 
6.4.4. Statistical methods ......................................................................... 197 
6.5. Results .......................................................................................................... 199 
6.5.1. Study population characteristics .................................................... 199 
6.5.2. Relationships between endotrophin and other variables ............... 201 
6.5.3. Kidney failure ................................................................................ 203 
6.5.4. Death .............................................................................................. 210 
6.6. Discussion ..................................................................................................... 213 
6.6.1. Kidney failure ................................................................................ 213 
6.6.2. Death .............................................................................................. 214 
6.6.3. Strengths and limitations ............................................................... 216 
6.6.4. Future research .............................................................................. 216 
6.7. Conclusions .................................................................................................. 217 
Chapter VII: General discussion ...................................................................................... 218 
7.1. Introduction .................................................................................................. 218 
7.2. Serum free light chains ................................................................................. 219 
7.3. Urine free light chains .................................................................................. 220 
7.4. Monoclonal gammopathy ............................................................................. 221 
7.5. Serum endotrophin ....................................................................................... 222 
7.6. Strengths and limitations .............................................................................. 223 
7.7. Cause-specific hazard models ...................................................................... 223 
7.8. Future research ............................................................................................. 224 
Appendix 1. SOP: Blood pressure measurement using the BpTRU device .................... 227 
Appendix 2. SOP: Measurement of arterial stiffness using the Vicorder device ............ 228 
Appendix 3. SOP: Measurement of AGEs using the AGE reader .................................. 229 
Appendix 4. SOP: Plasma, serum, and urine sample handling and processing .............. 230 
Appendix 5. Results from Cause-Specific Hazard Models (Chapter III) ........................ 231 
Appendix 6. Results from Cause-Specific Hazard Models (Chapter IV) ........................ 233 
Appendix 7. Results from Cause-Specific Hazard Models (Chapter V) ......................... 234 
Appendix 8. Results from Cause-Specific Hazard Models (Chapter VI) ........................ 236 
References ....................................................................................................................... 237 
 
 
List of Tables 
Table 1.1. Criteria for the definition of CKD .................................................................... 15 
Table 1.2. GFR categories for the staging of CKD ........................................................... 16 
Table 1.3. Albuminuria categories for the staging of CKD ............................................... 16 
Table 1.4. Estimates of the UK prevalence of CKD stage G3 to G5 ................................ 17 
Table 1.5. Common causes of CKD .................................................................................. 20 
Table 1.6. Causes of CKD in patients with incident kidney failure .................................. 21 
Table 1.7. Types of prognosis research ............................................................................. 28 
Table 1.8. Examples of prognostic factors for kidney failure in CKD .............................. 37 
Table 1.9. Examples of prognostic factors for mortality in CKD ..................................... 47 
Table 2.1. Demographic and lifestyle data collected at the baseline RIISC study visit .... 58 
Table 2.2. Clinical history recorded at the baseline RIISC study visit .............................. 59 
Table 3.1. Search strategy for MEDLINE ......................................................................... 87 
Table 3.2. Variables collected for all eligible studies ........................................................ 88 
Table 3.3. Characteristics of each included study ............................................................. 92 
Table 3.4. Reported results from each study ..................................................................... 94 
Table 3.5. Summary of baseline data ................................................................................ 95 
Table 3.6. Relationships between cFLC and other baseline factors .................................. 97 
Table 3.7. Univariable and multivariable associations between baseline factors and risk of 
kidney failure ................................................................................................................... 100 
Table 3.8. Univariable and multivariable associations between baseline factors and risk of 
death ................................................................................................................................. 109 
Table 4.1. Baseline characteristics of the study population ............................................ 137 
Table 4.2. Relationships of urine κCR, λCR, and ACR with other baseline variables ... 139 
Table 4.3. Univariable associations between baseline factors and kidney failure .......... 142 
Table 4.4. Multivariable models for the risk of kidney failure ........................................ 146 
Table 4.5. Logistic regression models for the prediction of kidney failure at two years 148 
Table 4.6. Univariable associations between baseline factors and risk death ................. 149 
Table 4.7. Multivariable models for the risk of death ..................................................... 150 
Table 5.1. Number of participants included and characteristics of each cohort study .... 166 
Table 5.2. Baseline characteristics by MG status ............................................................ 171 
Table 5.3. Association between baseline variables and risk of kidney failure and death 173 
Table 5.4. Baseline characteristics by LC-MG status ..................................................... 178 
Table 5.5. Association between baseline variables and risk of kidney failure and death 180 
Table 6.1. Characteristics of the study population .......................................................... 200 
Table 6.2. Relationship between serum endotrophin and other variables ....................... 202 
Table 6.3. Univariable and multivariable associations with kidney failure .................... 204 




List of Figures 
Figure 1.1. Reference ranges for GFR. ................................................................................ 6 
Figure 1.2. Incidence, prevalence, and deaths due to CKD in the UK .............................. 18 
Figure 1.3. Financial costs to the NHS of CKD ................................................................ 19 
Figure 1.4. Prognosis of CKD by GFR and albuminuria category .................................... 33 
Figure 1.5. Association between eGFR and kidney failure in CKD ................................. 35 
Figure 1.6. Association between urine ACR and risk of kidney failure in CKD .............. 36 
Figure 1.7. Association between eGFR and risk of death in CKD .................................... 46 
Figure 3.1. Structure of an immunoglobulin molecule ...................................................... 79 
Figure 3.2. Renal handling of free light chains ................................................................. 80 
Figure 3.3. Box plot of serum FLC concentration by CKD stage ..................................... 81 
Figure 3.4. Serum κ\λ FLC ratio by stage of CKD ............................................................ 82 
Figure 3.5. Flow diagram of studies screened, assessed, and included ............................. 91 
Figure 3.6. Risk of bias within each study ........................................................................ 93 
Figure 3.7. Histogram of serum cFLC concentration ........................................................ 96 
Figure 3.8. Relationship between serum albumin and serum cFLC concentration ........... 98 
Figure 3.9. Relationship between eGFR and serum cFLC concentration ......................... 99 
Figure 3.10. Relationship between urine ACR and serum cFLC concentration ............... 99 
Figure 3.11. Unadjusted SHR for kidney failure according to serum cFLC concentration101 
Figure 3.12. Unadjusted SHR for kidney failure according to age ................................. 102 
Figure 3.13. Unadjusted SHR for kidney failure according to urine ACR ..................... 102 
Figure 3.14. Unadjusted SHR for kidney failure according to eGFR ............................. 103 
Figure 3.15. Unadjusted SHR for kidney failure according to serum albumin ............... 103 
Figure 3.16. Unadjusted SHR for kidney failure according to serum calcium ............... 104 
Figure 3.17. Unadjusted SHR for kidney failure according to serum phosphate ............ 104 
Figure 3.18. Adjusted SHR for kidney failure according to serum cFLC concentration 105 
Figure 3.19. Forest plot for risk of kidney failure ........................................................... 106 
Figure 3.20. Adjusted SHR for kidney failure according to age ..................................... 107 
Figure 3.21. Adjusted SHR for kidney failure according to urine ACR ......................... 107 
Figure 3.22. Adjusted SHR for kidney failure according to eGFR ................................. 108 
Figure 3.23. Unadjusted HR for death according to serum cFLC concentration ............ 110 
Figure 3.24. Unadjusted HR for death according to systolic BP ..................................... 111 
Figure 3.25. Unadjusted HR for death according to urine ACR ..................................... 111 
Figure 3.26. Unadjusted HR for death according to eGFR ............................................. 112 
Figure 3.27. Unadjusted HR for death according to serum albumin ............................... 112 
Figure 3.28. Adjusted HR for death according to serum cFLC concentration ................ 113 
Figure 3.29. Forest plot for risk of death ......................................................................... 114 
Figure 3.30. Adjusted HR for death according to serum albumin ................................... 115 
Figure 4.1. Urine FLC excretion by stage of CKD ......................................................... 128 
Figure 4.2. Abnormal urine FLC/creatinine ratios according to urine ACR ................... 129 
Figure 4.3. Histograms of urine κCR and λCR ............................................................... 138 
Figure 4.4. Relationship between urine κCR and λCR and their counterpart serum FLC140 
Figure 4.5. Relationship between urine κCR and λCR and urine ACR .......................... 141 
Figure 4.6. Unadjusted SHR for kidney failure according to urine κCR and λCR ......... 143 
Figure 4.7. Unadjusted SHR for kidney failure according to age ................................... 144 
Figure 4.8. Unadjusted SHR for kidney failure according to urine ACR ....................... 144 
Figure 4.9. Unadjusted SHR for kidney failure according to serum FLCs ..................... 145 
Figure 4.10. Adjusted SHR for kidney failure according to eGFR ................................. 147 
Figure 4.11. Adjusted SHR for kidney failure according to urine ACR ......................... 147 
Figure 5.1. Cumulative incidence of kidney failure by MG status .................................. 174 
Figure 5.2. Unadjusted SHR for kidney failure, according age, eGFR and urine ACR .. 175 
Figure 5.3. Adjusted SHR for kidney failure according to age, eGFR, and urine ACR . 176 
Figure 5.4. Kaplan-Meier survival curves by MG status ................................................ 177 
Figure 5.5. Cumulative incidence of kidney failure by LC-MG status ........................... 181 
Figure 5.6. Unadjusted SHR for kidney failure according to age, eGFR, and urine ACR182 
Figure 5.7. Adjusted SHR for kidney failure according to age, eGFR, and urine ACR . 182 
Figure 5.8. Kaplan-Meier survival curves by LC-MG status .......................................... 183 
Figure 5.9. Unadjusted HR for death according to MAP, eGFR, and urine ACR .......... 184 
Figure 5.10. Adjusted HR for death according to urine ACR ......................................... 185 
Figure 6.1. Organisation of domains in the α1, α2 and α3 chains of collagen type VI ... 193 
Figure 6.2. The assembly of collagen type VI microfibrils from the three α chains ....... 194 
Figure 6.1. Histogram of serum endotrophin concentration ............................................ 201 
Figure 6.2. Relationship between eGFR and serum endotrophin concentration ............. 203 
Figure 6.3. Unadjusted SHR for kidney failure according to serum endotrophin ........... 205 
Figure 6.4. Unadjusted SHR for kidney failure according to age ................................... 206 
Figure 6.5. Unadjusted SHR for kidney failure according to MAP ................................ 206 
Figure 6.6. Unadjusted SHR for kidney failure according to eGFR ............................... 207 
Figure 6.7. Unadjusted SHR for kidney failure according to urine ACR ....................... 207 
Figure 6.8. Adjusted SHR for kidney failure according to age ....................................... 208 
Figure 6.9. Adjusted SHR for kidney failure according to eGFR ................................... 209 
Figure 6.10. Adjusted SHR for kidney failure according to urine ACR ......................... 209 
Figure 6.11. Unadjusted HR for death according to serum endotrophin concentration .. 211 







ACEi angiotensin-converting enzyme inhibitor 
ACR albumin-to-creatinine ratio  
AER albumin excretion rate 
AGEs advanced glycation end products  
ANOVA analysis of variance  
APOL1 apolipoprotein L1 
ARB angiotensin II receptor blocker 
BMI body mass index  
BP blood pressure 
BSA body surface area  
BTP beta-trace protein  
cFLC combined free light chains 
CGA cause of CKD, GFR, albuminuria 
CI confidence interval 
CINAHL cumulative index to nursing and allied health literature 
CKD chronic kidney disease 
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration 
COPD chronic obstructive pulmonary disease 
CRF case report form  
CRIB Chronic Renal Impairment in Birmingham  
CRISIS Chronic Renal Insufficiency Standards Implementation Study  
CRP C-reactive protein 
CVD cardiovascular disease 
DM diabetes mellitus 
DNA deoxyribonucleic acid 
ECM extracellular matrix  
EDTA ethylenediamine tetra-acetic acid  
eGFR estimated glomerular filtration rate 
ELISA enzyme-linked immunosorbent assay 
EQ EuroQol 
ESKD end-stage kidney disease 
ESRD end-stage renal disease 
ESRF end-stage renal failure 
FLC free light chains 
FP fractional polynomials 
 
2 
GFR glomerular filtration rate 
HR hazard ratio 
HRQL health-related quality of life  
IDI integrated discrimination index  
IDMS isotope dilution mass spectrometry  
IHD ischaemic heart disease 
IMD index of multiple deprivation  
IPD individual participant data  
IQR interquartile range 
KDIGO Kidney Disease: Improving Global Outcomes  
KDOQI Kidney Disease Outcomes Quality Initiative  
KFRE kidney failure risk equation 
KRT kidney replacement therapy 
LC-MG light chain monoclonal gammopathy 
MAP mean arterial pressure 
MDRD Modification of Diet in Renal Disease  
MG monoclonal gammopathy 
MGCS monoclonal gammopathy of clinical significance 
MGRS monoclonal gammopathy of renal significance 
MGUS monoclonal gammopathy of undetermined significance 
NHS national health service 
NICE National Institute for Health and Care Excellence  
NT-pro-BNP N-terminal pro-brain natriuretic peptide 
NURTuRE National Unified Renal Translational Research Enterprise 
PAD peripheral artery disease 
PCR protein-to-creatinine ratio 
PMH past medical history 
PROGRESS Prognosis Research Strategy  
PWV pulse wave velocity 
RAASi renin-angiotensin-aldosterone system inhibitor 
REC research ethics committee  
RIISC Renal Impairment in Secondary Care  
RR relative risk 
RRID Renal Risk in Derby  
SD standard deviation 
SHARP Study of Heart and Renal Protection  
SHR subhazard ratio 
SKS Salford Kidney Study  
SOP standard operating procedure 
SPEP serum protein electrophoresis  
STROBE Strengthening the Reporting of Observational studies in Epidemiology 
 
3 
TGF transforming growth factor 
UK United Kingdom 
US United States 
USRDS United States Renal Data System 
vWF von Willebrand factor  
 
 4 
CHAPTER I: INTRODUCTION 
Chronic kidney disease (CKD) is a common long-term condition, affecting over 9% of 
the global population, and is associated with an increased morbidity and mortality risk, which 
is directly related to the severity of CKD. Some individuals with CKD progress to kidney 
failure, a level of kidney function at which those affected will die without replacement of 
kidney function by dialysis treatment or kidney transplantation. 
Understanding the factors associated with worse outcomes in CKD is crucial, for 
communication, risk stratification, and identification of targets for treatment. The work 
presented in this thesis is focused on novel risk factors in CKD. To provide the context for the 
experimental chapters reported in this thesis, this introductory chapter will provide an 
overview of the assessment of kidney function, markers of kidney disease, CKD, the concept 
of prognosis, and prognosis in patients with CKD. The chapter will conclude by making a 
case for more prognosis research in CKD. 
 
5 
1.1. Kidney function and markers of kidney disease 
The kidneys perform multiple functions, and each particular function can be assessed 
in various ways. However, it is generally accepted that the best overall measure of kidney 
function is the glomerular filtration rate (GFR). Throughout this thesis, where the term 
‘kidney function’ is used, it is used synonymously with GFR. 
1.1.1. Glomerular filtration rate (GFR) 
The GFR, expressed in ml/min, is the sum of the filtration rates across the glomeruli 
of all functioning nephrons. Thus, the GFR approximately reflects the total number of 
functioning nephrons. To account for differences in kidney size, which is proportional to body 
size, the GFR is adjusted for body surface area (BSA) and is expressed per 1.73 m2 BSA (1.73 
m2 was the average adult BSA from historical data (1)). This scaling allows a comparison of 
the GFR between individuals or comparison with normal values. 
The ‘normal’ GFR (in ml/min/1.73 m2) varies by age and sex. It is approximately 100 
ml/min/1.73 m2 in young adults and then declines after 35 years of age (2). The decline is 





Figure 1.1. Reference ranges for GFR. 
Age- and sex-specific ranges for GFR were developed based on measured GFRs from 2974 
prospective living kidney donors. The solid lines represent the mean GFR for a given age and 
sex, and the interrupted lines are two standard deviations above and below the mean. From 
reference (2). 
Assessment of the GFR involves the measurement of solutes, termed filtration 
markers, that undergo glomerular filtration and urinary excretion. The gold standard method 
is to administer an intravenous dose of an exogenous filtration marker (such as inulin or 
ethylenediamine tetra-acetic acid [EDTA]), and then to measure its clearance (measured 
GFR). There are several methods of doing this, but they are all relatively time-consuming, 
expensive, and cumbersome. Therefore, they are generally performed only in clinical 
situations where it is essential to have a precise measure of the GFR; for example, in 




however, the GFR is estimated using equations based on the serum concentration of 
endogenous filtration markers. 
 
1.1.1.1. Estimation of the GFR 
The endogenous filtration marker used routinely in clinical practice is creatinine. Creatinine is 
derived from the metabolism of creatine in skeletal muscle, after which it is released into the 
circulation and then freely filtered across the glomerulus to be excreted in the urine. The 
serum creatinine concentration itself was previously used as a surrogate for kidney function. 
However, its use in this way is limited by significant variation between individuals in the non-
GFR determinants of serum creatinine concentration, particularly muscle mass. Equations 
have been developed to calculate an estimated GFR (eGFR) that, in addition to serum 
creatinine concentration, include variables that are surrogates for muscle mass (age, sex, and 
ethnicity), such that they improve upon serum creatinine alone. Until recently, the equation 
used in the UK and internationally has been the Modification of Diet in Renal Disease 
(MDRD) equation. The MDRD equation is now being replaced in clinical use by the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 
 
The Modification of Diet in Renal Disease (MDRD) equation. 
The MDRD study was established to evaluate the effect of dietary protein restriction on the 
progression of kidney disease. In 1999 the study group used data from the study to develop an 
equation to estimate GFR from the serum creatinine concentration. This was a six-variable 
equation containing age, sex, ethnicity, serum creatinine, serum urea, and serum albumin (3). 
The equation was simplified to a four-variable equation (containing age, sex, ethnicity, and 
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serum creatinine) (4) and was later re-expressed for use with a standardized creatinine assay 
(5, 6). This MDRD equation for calculating eGFR is as follows: 
!"#$ = 175 × *+!"."$% × ,-!!&.'&( × 1.212	(23	45,67) × 0.742	(23	3!;,5!) 
where eGFR is expressed in ml/min/1.73 m2, Cr is the serum creatinine concentration in 
mg/dl (serum creatinine concentration can be converted from µmol/l to mg/dl by dividing it 
by 88.4), and age is in years. 
The equation was developed using data from individuals with CKD and the accuracy 
of the MDRD formula for estimating the GFR in patients with CKD has been validated. 
However, in individuals with a normal or near-normal GFR, it is relatively imprecise and 
systematically underestimates the GFR (7-10). This issue prompted the development of the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 
 
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). 
The CKD-EPI equation was developed in 2009. Unlike the MDRD equation, it was developed 
using data from individuals both with and without CKD (11). It contains the same four 
variables as the four-variable MDRD equation (age, sex, ethnicity, and serum creatinine) but 
is more accurate in those with a GFR ≥ 60 ml/min/1.73 m2 and is as accurate as the MDRD 
equation in those with a GFR < 60 ml/min/1.73 m2 (11-14). The use of the CKD-EPI equation 
to estimate the GFR results in lower estimates of the prevalence of CKD and several studies 
have shown that those who are reclassified as not having CKD are at a lower risk of adverse 
health outcomes, suggesting the equation provides a more accurate discrimination of risk 
compared with the MDRD equation (15-21). The CKD-EPI equation for eGFR is as follows: 
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!".'&* × 0.993+,- × 1.018	(23	3!;,5!)
× 1.159	(23	45,67) 
where eGFR is expressed in ml/min/1.73 m2, Cr is serum creatinine concentration in mg/dl 
(serum creatinine concentration can be converted from µmol/l to mg/dl by dividing it by 
88.4), k is 0.7 for females and 0.9 for males, a is -0.329 for females and -0.411 for males, min 
indicates the minimum of Cr/k or 1, and max indicates the maximum of Cr/k or 1. 
Because of the advantages of the CKD-EPI equation over the MDRD equation, the 
National Institute for Health and Care Excellence (NICE) CKD guideline recommends that 
clinical laboratories in the UK should use the creatinine-based CKD-EPI equation to calculate 
the eGFR (22). 
 
Cystatin C based equations. 
Given the issues around the non-GFR determinants of serum creatinine concentration, 
including the variation between individuals in muscle mass, several other endogenous 
filtration markers have been studied. Of these, cystatin C is the most established. Cystatin C is 
a cysteine protease inhibitor produced by all nucleated cells and is freely filtered at the 
glomerulus before being metabolised in the tubules. In 2012, the CKD-EPI group developed 
an equation to estimate the eGFR based on serum cystatin C concentration, as follows: 






!".('. × 0.996+,- × 0.932	(23	3!;,5!) 
where eGFR is expressed in ml/min/1.73 m2, Cys is the serum cystatin C concentration in 




Despite hopes that cystatin C-based equations may provide more accurate estimates of 
the GFR, the cystatin C-based CKD-EPI equation is not more accurate than the creatinine-
based CKD-EPI equation (23). One reason for this is that the serum cystatin C concentration, 
like the serum creatinine concentration, has many non-GFR determinants (24-28). 
However, cystatin C-based equations for estimating the GFR may be useful in certain 
situations. For example, the NICE CKD guidelines recommend the use of the cystatin C-
based CKD-EPI equation to confirm or rule out CKD in individuals with a creatinine-based 
eGFR between 45 and 59 ml/min/1.73 m2 but without any other markers of kidney disease 
(22). It may also provide a more accurate estimate of the GFR in individuals with extremes of 
muscle mass or with a diet unusually high in creatinine in whom a creatinine-based eGFR is 
likely to be inaccurate (23). Further, cystatin C may be useful in combination with creatinine; 
numerous estimating equations which incorporate both cystatin C and creatinine are more 
accurate than equations that use cystatin C or creatinine alone (29-33). 
1.1.2. Decreased GFR as a marker of kidney disease 
A GFR below a specific cut-off may be used as a marker of kidney disease. A GFR < 
60 ml/min/1.73 m2 is the cut-off used as part of the current definition for CKD (discussed 
below). However, there is some debate about the use of such a blanket cut-off, in part because 
GFR declines as part of normal healthy ageing such that the lower limit of the reference range 
falls below 60 ml/min/1.73 m2 after the age of 55 years, as shown in Figure 1.1. A cut-off of 
60 ml/min/1.73 m2 could, therefore, result in an over-diagnosis of CKD in individuals older 
than 55 years. Further, some adults younger than 55 years may have a GFR ≥ 60 ml/min/1.73 
m2, but actually below the reference range for their age, and could, therefore, be missed by the 
current definition of CKD in the absence of other markers of kidney disease. However, the 
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cut-off of a GFR < 60 ml/min/1.73 m2 was included in the definition of CKD on the basis that 
this level of GFR is associated with a higher risk of adverse health outcomes (although an 
interaction with age means that the excess risk associated with a lower GFR diminishes with 
increasing age). 
1.1.3. Other markers of kidney disease 
There are other markers of kidney disease, which may occur with or without a 
decreased GFR, the most commonly identified being increased albuminuria. It is increasingly 
recognised that albuminuria is a powerful marker of kidney damage and, independent of GFR, 
increased albuminuria is a strong risk factor for adverse clinical outcomes, including mortality 
and progression of CKD. 
 
1.1.3.1. Albuminuria 
Although the total level of proteinuria has played an important role in the assessment 
of kidney disease, and the term ‘proteinuric’ kidney disease may still be used where 
proteinuria is high, there is now a general shift towards measuring albuminuria. 
The rate of urinary albumin excretion per 24 hours (albumin excretion rate, AER) is 
an essential parameter in the assessment of kidney health (or disease). In the glomerulus, a 
filtration barrier limits the filtration of albumin from the plasma into the urinary space based 
on its size and charge. In health, the AER is < 20 mg per 24 hours, and levels higher than this 
may reflect kidney disease, especially of the glomerulus where damage to or dysfunction of 
the filtration barrier results in increased albumin filtration. 
The gold standard measure of the AER is from a 24-hour urine collection, calculated 
as the product of the urine volume and the albumin concentration. However, a 24-hour urine 
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collection is cumbersome to collect and is often performed incorrectly. Therefore in routine 
clinical practice, the concentrations of albumin and creatinine in an untimed single-void urine 
specimen are often used to estimate the AER. Based on the principle that the average urine 
excretion of creatinine in adults is 1 g (equivalent to 8.8 mmol) per 24 hours, the AER can be 
estimated from the untimed specimen by calculating the urine albumin-to-creatinine ratio 
(ACR). For example, a urine ACR of 500 mg/g (or 56.8 mg/mmol) would be approximately 
equivalent to an AER of 500 mg per 24 hours (thus suggesting kidney disease). 
As with the serum creatinine concentration, urinary creatinine excretion correlates 
with muscle mass. Therefore, in individuals with unusually high or low levels of muscle 
mass, the urine ACR may not be an accurate estimate of the AER. For this reason, AER 
estimating equations have been developed which, similar to the eGFR equations, incorporate 
surrogates for muscle mass (age, sex, and ethnicity) in addition to the urine creatinine 
concentration. This allows the urine albumin concentration to be adjusted for the expected 
urinary creatinine excretion rather than the average 1 g (8.8 mmol) per 24 hours. However, 
such estimating equations are not currently used in routine clinical practice in the UK, and the 
ACR (expressed in mg/mmol) continues to be recommended by NICE as the preferred 
method for estimating the AER (22). 
A urine ACR of 3 mg/mmol or higher (approximately equivalent to an AER ³ 30 mg 
per 24 hours) is generally considered to represent increased albuminuria and is a marker of 
kidney disease.  
 
1.1.3.2. Haematuria 
Glomerular damage may also result in the passage of red blood cells into the urine, 
resulting in haematuria. This may be visible (previously termed “macroscopic haematuria”) 
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but is more often non-visible and detected on urinalysis (previously termed “microscopic 
haematuria”). 
Haematuria may be a manifestation of disease in the urinary tract, rather than the 
glomerulus. However, haematuria in the presence of other markers of kidney disease such as a 
decreased GFR or increased albuminuria increases the likelihood that the haematuria is 
glomerular in origin. 
 
1.1.3.3. Radiographic abnormalities of the kidneys 
Multiple radiological techniques may be employed in the assessment of kidney 
disease, but ultrasound is the most commonly used. Common radiographic markers of kidney 
disease include decreased kidney size, thinning or scarring of the renal cortex, increased 
echogenicity of the renal parenchyma, and cysts, among others. 
 
1.1.3.4. Others 
There are many other potential markers of kidney disease, such as the presence of 
certain casts in the urine or histological abnormalities in those who undergo a kidney biopsy. 
These are described further in section 1.2.1. 
 
14 
1.2. Chronic kidney disease (CKD) 
Numerous different disease pathways can result in a persistent alteration of the 
function or structure of the kidneys, ultimately resulting in CKD (34). CKD is usually 
irreversible and is manifest by the markers of kidney disease described above. 
1.2.1. Definition of CKD 
CKD was first defined in 2002, in the ‘Kidney Disease Outcomes Quality Initiative 
(KDOQI) clinical practice guidelines for CKD’, as the presence of kidney damage (resulting 
in structural or functional abnormalities) or a decreased GFR (< 60 ml/min/1.73 m2) for at 
least three months, and this definition has been broadly accepted internationally (35). It is 
recognised, however, that not all persistent abnormalities of kidney structure or function are 
associated with adverse health consequences, and therefore the Kidney Disease: Improving 
Global Outcomes (KDIGO) group have recommended the addition of ‘with implications for 
health’ to the above definition (36). Thus, the current definition of CKD and that pertained to 
in this thesis is ‘abnormalities of kidney structure or function, present for at least three 
months, with implications for health’ (36). Abnormal kidney function is considered to be a 
GFR < 60 ml/min/1.73 m2, and the myriad potential markers of kidney damage that may 
precede the development of a decreased GFR are shown in Table 1.1 (36). 
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Table 1.1. Criteria for the definition of CKD 
Criteria 
Markers of kidney damage (one or 
more) 
Albuminuria (ACR ³ 3 mg/mmol) 
 Urine sediment abnormalities 
 Electrolyte and other abnormalities due to tubular 
disorders 
 Abnormalities detected by histology 
 Structural abnormalities detected by imaging 
 History of kidney transplantation 
Decreased GFR GFR < 60 ml/min/1.73 m2 
One or more markers of kidney damage or a decreased GFR present for > 3 months. From 
(36). 
1.2.2. Staging of CKD 
Once CKD has been identified, disease staging may help guide management and 
provides information on prognosis. The original staging system consisted of five GFR stages 
(1 to 5) only. Later, stage 3 was divided into stages 3a and 3b, based on analysis of data on 
the risk of adverse clinical outcomes associated with the level of GFR, and more recently the 
staging system has been developed further to also include the cause of CKD and the level of 
albuminuria (CGA [cause of CKD, GFR, albuminuria] staging) (36).  
The cause of CKD in an individual is most often inferred from the presence of co-
morbid conditions that may cause kidney disease (e.g. diabetes mellitus, vascular disease, 
hypertension) and an assessment of the potential markers of kidney disease as described 
above. A minority of patients with CKD undergo a kidney biopsy which may more 
definitively establish the underlying cause. Specific causes of CKD are discussed in section 
1.2.5, but many patients with CKD, especially those who present for the first time at a late 
stage of the disease, have CKD of unknown cause. 
The GFR is categorized into six stages, as shown in Table 1.2. The associated 
terminology for each category is relative to the GFR expected in a young adult. 
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Table 1.2. GFR categories for the staging of CKD 
GFR Category GFR (ml/min/1.73 m2) Terms 
G1 ³ 90 Normal or high 
G2 60 to 89 Mildly decreased 
G3a 45 to 59 Mildly to moderately decreased 
G3b 30 to 44 Moderately to severely decreased 
G4 15 to 29 Severely decreased 
G5 < 15 Kidney failure 
In the absence of other evidence of kidney damage, neither GFR category G1 nor G2 fulfils 
the criteria for CKD. From (36). 
Albuminuria categories, based on the AER, are shown in Table 1.3. The approximate 
equivalent urine ACR levels are also shown. The terms here also describe the AER relative to 
that expected in a young adult. 
Table 1.3. Albuminuria categories for the staging of CKD 
Category AER (mg/24 hours) Urine ACR (mg/mmol) Terminology 
A1 < 30 < 3 Normal to mildly increased 
A2 30 to 300 3 to 30 Moderately increased 
A3 > 300 > 30 Severely increased* 
*Including nephrotic syndrome (AER usually > 2.2g per 24 hours [ACR > 220 mg/mmol]). 
From (36). 
As an example of the use of the CGA staging system, an individual with a long history 
of DM and an eGFR of 24 ml/min/1.73 m2 and an ACR of 18 mg/mmol would be classed as 
having CKD stage G4 A2 due to diabetic kidney disease. 
1.2.3. Prevalence of CKD 
CKD is common, with a prevalence in adults of approximately 10%. Differences in 
study populations, methods, and definitions have resulted in varying estimates of prevalence. 
Importantly, estimates have often been made based on single measures of kidney function or 
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structure that do not strictly meet the chronicity assumption for the accepted definition of 
CKD. 
Most studies have identified CKD using only the GFR (and no other markers of 
kidney damage). Table 1.4 provides a summary of CKD prevalence estimates in the UK based 
on eGFR. 
Table 1.4. Estimates of the UK prevalence of CKD stage G3 to G5 







Primary care 38,262 1 8.5 (37) 
2002 to 
2008 
Primary care 6,048,159 2 4.5 (38) 
2004 Primary and 
secondary care 
123,121 1 5.4 (39) 
2005 Acute hospital 
admissions 
6,073 1 17.7 (40) 
2007 to 
2010 






123,121 1 5.6 (39) 
2009 to 
2010 
General population 6,046 1 6.1 (43) 
2009 to 
2011 
Primary care 175,671 1 14.5 (44) 
2010 Primary care 2,836,476 2 5.9 (45) 
CKD defined as an eGFR < 60 ml/min/1.73 m2. 
There are few estimates of the prevalence of increased albuminuria or the other 
markers of CKD. However, in the UK, among over 20,000 individuals recruited from the 
general population between 1993 and 1997 (the EPIC-Norfolk Study), the estimated 
prevalence of a urine ACR of 2.5 to 25 mg/mmol was 11.8% and for a urine ACR of > 25 
mg/mmol was 0.9% (based on a single urine specimen) (46). International estimates of CKD 
prevalence that include both the eGFR and albuminuria to define CKD, albeit based on single 
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assessments, include estimates of between 3% and 17% in the countries of Europe (47) and 
14.8% in the US (not including those with established kidney failure) (48). 
Globally, the prevalence of CKD has been estimated to be 13.4 % for all CKD stages 
and 10.6% for stages G3 to G5, based on a meta-analysis of 100 general population studies 
(49). The global burden of CKD may be increasing: data from the ‘Global Burden of Disease’ 
study showed that between 1990 and 2013 the rates of death and disability-adjusted life-years 
associated with CKD increased, in contrast to other non-communicable diseases, including in 
Western Europe (50). 
Based on data obtained via the Global Burden of Disease Results Tool (51) (which 
incorporates CKD data from the Office for National Statistics and the UK Renal Registry), 
Figure 1.2 shows the incidence, prevalence, and deaths due to CKD in the UK from 2004 to 
2017. The figure shows there is an increasing trend in all three parameters. 
 
Figure 1.2. Incidence, prevalence, and deaths due to CKD in the UK 
Estimates between 2004 and 2017, with 95% confidence intervals, based on data from the 
Office for National Statistics and the UK Renal Registry. Incidence and deaths due to CKD 
are expressed in thousands, and prevalence in millions. 
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1.2.4. Financial cost of CKD 
There is considerable uncertainty as to the cost to the NHS of CKD. The total cost 
includes direct costs (associated with CKD itself and its progression, including kidney 
failure), and indirect costs incurred for non-renal care in cases where people with CKD have 
excess risk or consume excess health care resources relative to the non-CKD population such 
as excess length of hospital stay, CVD, and infection (52). The cost to the NHS of CKD in 
England in 2009–10 was estimated to be £1.45 billion, accounting for 1.3% of all NHS 
spending (53). As can be seen in the cost breakdown in Figure 1.3, the provision of KRT for 
those who have progressed to kidney failure is particularly expensive. 
 
Figure 1.3. Financial costs to the NHS of CKD 














Figure 1. Direct and indirect NHS expenditure on CKD, England 2009–10











































There are no comparable estimates of current NHS expenditure on CKD that have 
been published, but it is highly likely to be higher than in 2009-10, especially given the 
increasing incidence and prevalence of CKD. The economic burden of CKD among 
individuals with DM in the UK is projected to rise markedly over time and has been 
forecasted at approximately £11.4 billion in 2025 (54). 
1.2.5. Causes of CKD 
Multiple heterogeneous disease pathways can result in CKD. The traditional way of 
classifying kidney disease has been to consider aetiologies that are pre-renal (reduced kidney 
perfusion), intrinsic to the kidneys (which can be further subdivided into diseases that 
primarily damage the vessels, the glomerulus, or the tubulointerstitium), and post-renal 
(urinary tract obstruction). Using this classification, the common causes of CKD are shown in 
Table 1.5. 
Table 1.5. Common causes of CKD 
 Causes of CKD 
Pre-renal Heart failure, cirrhosis 
Intrinsic  
Vascular Renal artery stenosis, hypertensive nephrosclerosis 
Glomerular Diabetic nephropathy, IgA nephropathy 
Tubulointerstitial Polycystic kidney disease, reflux nephropathy 
Post-renal Prostatic disease, abdominal or pelvic tumour 
Causes of CKD by the traditional classification system of pre-renal, intrinsic, and post-renal 
causes. 
Diabetes mellitus is the most common cause of CKD and the most common cause of kidney 
failure (that is, the need for dialysis or a kidney transplant). Table 1.6 shows the cause of 
CKD in patients with incident kidney failure in the UK in 2017. 
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Table 1.6. Causes of CKD in patients with incident kidney failure 
Cause of CKD % 
Diabetes 29.4  
Glomerulonephritis 14.1 
Hypertension 6.3 
Polycystic kidney disease 6.8 
Pyelonephritis 5.7 




Cause of CKD in adults with incident kidney failure in the UK in 2017, from the UK Renal 
Registry 21st Annual Report (55). 
The underlying causes of CKD are different in the nature and site of the initial injury. 
For example, the immune-mediated injury to the glomeruli in glomerulonephritis compared to 
a genetic defect leading to cyst formation affecting the tubulointerstitium in polycystic kidney 
disease. Although the initial kidney insult may predominantly injure a particular kidney 
structure (i.e. the vessels, glomeruli, tubules, or interstitium), progression of CKD, 
irrespective of the primary cause, is associated with pathogenetic processes that result in 
damage and fibrosis to all components of the kidney resulting in altered structure and loss of 
function. Thus glomerulosclerosis, tubulointerstitial fibrosis, and vascular sclerosis are the 
pathological hallmarks of established CKD. 
1.2.6. Common disease pathways and fibrosis in CKD 
All primary causes of CKD share a common yet complex pathogenetic pathway of 
progressive injury and destruction of the normal kidney parenchyma due to fibrosis. There 
may be ongoing injury from the primary cause of CKD, but secondary maladaptive 
haemodynamic and metabolic factors play a pivotal role. 
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With nephron loss, there is an increase in pressure within the remaining glomeruli 
(intraglomerular hypertension) and an increase in filtration in the preserved nephrons 
(glomerular hyperfiltration). These adaptive responses allow the GFR to be preserved 
initially, even after nephron loss. However, intraglomerular hypertension and glomerular 
hyperfiltration are associated with increasing wall stress and damage to the glomerular 
endothelial cells (56). Further, intraglomerular hypertension leads to excessive expansion of 
the relatively elastic glomeruli and repetitive cycles of distension contraction, resulting in 
mechanical strain on mesangial cells which stimulates their production of cytokines 
(including transforming growth factor-beta [TGF-b]) and more extracellular matrix (56). 
Intraglomerular hypertension and glomerular hyperfiltration are also associated with 
proteinuria, which itself has an important role in progressive fibrosis. Filtered proteins or 
albumin-bound factors (such as fatty acids) may cause tubular cell toxicity and local release 
of pro-inflammatory molecules and cytokines with the promotion of interstitial fibrosis (57, 
58). 
The development of interstitial fibrosis can be summarised by the response to injury of 
four cells: macrophages, myofibroblasts, tubular epithelial cells, and endothelial cells (59): 
1. There is an interstitial inflammatory cell infiltrate composed primarily of 
macrophages. Depending upon local environmental cues, these macrophages can 
synthesise and secrete products that can influence fibrogenesis, such as cytokines (e.g. 
TGF-b), growth factors (e.g. platelet-derived growth factor), procoagulant factors, and 
matrix proteins (60). 
The macrophages can differentiate, depending upon local stimuli, into either pro-
inflammatory (M1) or anti-inflammatory (M2) subtypes. M1 responses are associated 
with ‘maladaptive’ tissue repair with irreversible parenchymal loss and CKD, whereas 
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M2 responses are associated with ‘adaptive’ tissue repair, minimal scarring, and the 
restoration of normal parenchyma (59). 
2. Myofibroblasts appear in the interstitium, derived primarily from resident kidney 
fibroblasts and pericytes. In severely damaged kidneys, they are also derived from the 
transdifferentiation of tubular epithelial cells and endothelial cells. These 
myofibroblasts are the primary source of scar-forming extracellular matrix proteins, 
and their presence is essential for scar formation (59). 
3. Tubular epithelial cells can synthesise numerous products which can enter the 
interstitium such as reactive oxygen species, inflammatory chemokines, and 
profibrotic molecules (e.g. TGF-b) (59, 61). Proteinuria may be an important factor in 
this pathway, as filtered urinary proteins such as those of the complement cascade, 
cytokines, and biochemically modified or conjugated albumin may bind receptors 
expressed by tubular epithelial cells activating intracellular signalling pathways and 
cellular responses (57, 59). Tubular epithelial cells may also be stimulated to 
transdifferentiate into myofibroblasts. In severe fibrosis, the tubular epithelial cells 
lose their ability for regeneration, resulting in apoptosis, and non-functional atubular 
glomeruli (59). 
4. Loss of interstitial capillary integrity with leakage into the interstitium of plasma 
proteins such as fibrinogen and albumin conjugates triggering an inflammatory and 
profibrotic response (59). There is also inadequate reparative angiogenesis and loss of 
the interstitial capillary network, compromised oxygen delivery, and hypoxia–oxidant 
stress, accentuating injury and fibrosis (59). 
The importance of TGF-b as a molecular driver of fibrosis is well known. It is 
produced by tubular and interstitial cells and engages cellular receptors to stimulate 
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fibroblasts and myofibroblasts (59). However, many other fibrosis-promoting molecules 
contribute, and in particular angiotensin II, through activation of type 1 receptors on 
glomerular cells with the generation of various profibrotic factors, and cytokine- and 
chemokine-mediated recruitment of inflammatory cells into the kidney (62). 
The processes described result in fibrotic tissue that is a sophisticated collection of 
multifunctional macromolecules that change in composition and structure over time (59). 
Collagen types I and III predominate, but other collagens and matrix molecules are important 
(59). The matrix molecules elicit cellular responses via cellular receptors that result in 
fibrosis-induced cellular loss and parenchymal destruction (59). 
Remodelling and degradation of the fibrotic tissue can occur through multiple 
enzymatic pathways, such as the family of matrix metalloproteinases, and cellular endocytosis 




The primary focus of this thesis is on prognosis and prognostic factor research in 
CKD. The concept of prognosis is generally understood to entail a prediction about the likely 
outcome for somebody with a given disease (the original Greek word, prognōsis, was derived 
from pro- ‘before’ + gignōskein ‘know’). This section introduces the context and importance 
of prognosis within clinical practice, the relevant definitions, and a framework for considering 
prognosis research. 
1.3.1. The role of prognosis in clinical practice 
Prognosis, along with diagnosis and treatment, is incorporated into the traditional 
model of clinical practice. It has a vital role in informing and guiding the decision-making of 
patients, healthcare providers, and policymakers (63, 64). Although the practice of 
prognostication has existed since prehistory, the value placed upon prognosis has varied 
greatly over the millennia. 
In the time of Hippocrates (the fifth and fourth centuries BC), diagnostic tools and 
medical therapies were immature and therefore estimating prognoses was prominent in the 
role of the physician, as is evident from the well-known opening sentence of Hippocrates’ 
Prognostics (64, 65): 
“It appears to me a most excellent thing for the physician to cultivate 
Prognosis; for by foreseeing and foretelling, in the presence of the sick, the 
present, the past, and the future, and explaining the omissions which patients 
have been guilty of, he will be the more readily believed to be acquainted with 
the circumstances of the sick; so that men will have confidence to intrust 
themselves to such a physician.” 
Making prognoses remained central to the role of the physician over the next two 
millennia, and were based primarily on the physician’s cumulative observations of previous 
patients (64). However, from the 17th century, there were significant advances in biology and 
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the understanding of mechanisms of disease, and the perceived value of prognosis in the role 
of the physician declined (64). By the mid-19th century, further developments in the 
biomedical sciences and diagnostic tools such as the stethoscope, the microscope, and 
radiology, meant that diagnosis, rather than prognosis, reigned supreme in the role of the 
physician, and within this zeitgeist, prognoses were considered a characteristic of a disease 
rather than an individual (64, 66).  
Recently, there has been a significant revival in the value placed upon prognosis. 
Scientific advances, in particular in the '-omics' (e.g. genomics, proteomics, and 
metabolomics) allow for the possibility of understanding, at the molecular level, why 
prognoses differ between individuals with the same disease and why there is variation in 
response to treatments (64). 
Further, the availability of big data, incorporating not just routine demographic and 
health information but novel biological variables such as the '-omics' mentioned above, allows 
the discovery of characteristics which may be associated with variation in prognosis in certain 
health conditions (64). 
These developments have coincided with an increasing interest in the practice of 
stratified (or personalised) medicine. This involves stratifying patients with a health condition 
by their likelihood of a particular outcome or response to a specific treatment. In contrast to a 
one-size-fits-all approach, treatments can be focused on those who will benefit, and the 
unnecessary costs and side effects associated with treating those who will not benefit can be 
avoided (64). 
Finally, population-level prognosis information has played an increasingly important 
role at a managerial and political level to understand the performance of healthcare systems 
and the impact of changes in healthcare delivery and policy (64). 
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Despite a revival in the role of prognostication, there had been little progress in the 
development of its methodology over the centuries, the terminology used was inconsistent, 
and concepts were muddled (67). A group of healthcare professionals, researchers, and 
journal editors (the PROGnosis RESearch Strategy [PROGRESS] Partnership) addressed this 
by developing a framework which provides precise definitions and a clear framework for the 
understanding of prognosis and prognosis research (64). 
1.3.2. The PROGRESS Framework 
The PROGRESS framework was set out in a series of four papers published in 2013 
(68-72). The framework provides standardised terminology and recommendations for the 
optimal study designs and statistical analyses of four distinct types of prognosis research, as 
outlined in this section (64). 
Prognosis is the risk of future health outcomes in people with a given disease or health 
condition, and prognosis research is the investigation of the relations between future 
outcomes (endpoints) among people with a given baseline health state in order to improve 
health (68). The four types of prognosis research, as set out in the PROGRESS framework, 
are summarised in Table 1.8, and described in the following paragraphs. 
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Table 1.7. Types of prognosis research 
Type of research Objective 
Fundamental 
prognosis research 
Estimate the average outcome risk in a population with a given 




Establish which characteristics are associated with changes in the 
average prognosis across individuals with a given health condition 
Prognostic model 
research 
The development, validation, and impact evaluation of models 




Establish which characteristics predict whether or not an individual 
responds to a particular treatment 
Adapted from (72). 
1.3.2.1. Fundamental prognosis research 
Fundamental prognosis research (PROGRESS framework type I) provides an overall 
estimate of prognosis for a given health condition, i.e. an estimate of the average risk of a 
particular outcome among a group of individuals with a particular disease or health condition, 
in the context of the nature and quality of healthcare available at the time and place of the 
study (72). This is distinct from the natural history of a disease, which is the prognosis in the 
absence of care (68). 
Examples of fundamental prognosis research include: (i) an estimated 22% of patients 
who sustain a wrist or hand fracture will have persistent pain at four months following the 
injury (73); (ii) among patients who have a spontaneous intracerebral haemorrhage, an 
estimated 46% will be alive at one year (74). 
Information on overall prognosis from fundamental prognosis research can be 
essential to inform the decision-making of patients, clinicians, and healthcare planners. The 
overall prognosis (i.e. patient outcomes) for a particular health condition may be used as a 
measure of the performance of a health service, facilitating audit and the assessment of 
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change in response to particular measures, and may also allow a comparison between health 
services (e.g. between different countries). 
 
1.3.2.2. Prognostic factor research 
Prognostic factor research (PROGRESS framework type II) studies aim to identify 
prognostic factors. Prognostic factors are characteristics associated with differences in the 
outcome risk between individuals with a given health condition. A different value (or 
category) of a prognostic factor is associated with a different outcome risk, and prognostic 
factors, therefore, explain variation in outcomes across individuals with a given disease. 
Examples of prognostic factor research include: (i) among patients admitted to 
hospital with an acute coronary syndrome, a higher serum uric acid concentration is 
associated with a higher risk of all-cause mortality (75); (ii) among patients with bipolar 
disorder, a higher level of physical activity is associated with a lower risk of requiring 
psychiatric hospitalisation (76). 
Prognostic factors may provide information on pathophysiology, may identify targets 
for developing novel treatments, and may be used as a marker of treatment effect. Prognostic 
factors are also required to develop prognostic models. 
 
1.3.2.3. Prognostic model research 
Prognostic model research (PROGRESS framework type III) involves the 
development and validation of models which combine prognostic factors. A prognostic model 
incorporates multiple prognostic factors and allows the risk of a specific outcome to be 
calculated for individual patients, based on their values for the prognostic factors included in 
the model (70, 72). Synonyms for ‘prognostic model’ that are encountered in the medical 
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literature are prognostic (or prediction) index or rule, risk (or clinical) prediction model, and 
predictive model. 
An example of prognostic model development was the derivation of a model which, 
for patients with primary melanoma, accurately predicts the risk of death at ten years from the 
point of diagnosis (77). The model allows the risk to be calculated based on the values of four 
readily available prognostic factors: patient age, sex, site of the primary melanoma, and 
tumour thickness (77). 
Prognostic model research may also be performed to update a previously developed 
prognostic model (70, 72). This could be the recalibration of a prognostic model for use in a 
new setting, or the addition of new prognostic factors to the existing model (72). With regard 
to the latter, it may be expected that the addition of prognostic factors with a causal effect on 
the outcome results in models that perform better and are more generalisable since they are 
linked to biological pathways rather than merely based on statistical association (70). 
However, the inclusion of novel prognostic factors that are expensive or not readily available 
could be a barrier to the use of a prognostic model (70). 
Where the information from a prognostic model leads to changes in clinical 
management, prognostic models can influence the patient outcome or the cost-effectiveness of 
care (positively or negatively). Prognosis research may, therefore, include clinical impact 
studies that aim to evaluate the impact of implementing a prognostic model on clinical 
practice and patient outcomes (70, 72). Although there are various potential designs for such 
clinical impact studies, it ideally includes a comparison of two cohorts, one in which usual 
care is provided and the other in which prognostic model predictions are made available to 
health professionals to guide treatment decisions (70). 
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1.3.2.4. Stratified medicine research 
Information on the effectiveness of a particular therapeutic intervention can be 
obtained from randomised trials, but an individual’s response to the intervention may deviate 
from average (71). Stratified medicine research (PROGRESS framework type IV) aims to 
identify factors that predict treatment effects (benefits or harms) in individuals with a 
particular health condition (72). These factors may then be used to practice stratified 
medicine. In contrast to ‘all-comer’ or ‘empirical’ medicine, stratified medicine seeks to 
target therapy to those who are predicted to benefit the most or sustain the least harm (71).  
For example, in patients with breast cancer, human epidermal growth factor receptor 2 
(HER-2) status, in addition to its baseline prognostic information, is used to determine 
whether a patient will respond to treatment with trastuzumab (an antibody against HER-2), 
such that trastuzumab is now given to patients who are HER-2 positive, but not to those 
testing negative (71, 78). 
Stratified medicine may also be practised when the relative effect of a particular 
treatment is the same for all patients. In this situation, treatment may be targeted at those with 
the highest absolute risk and who will, therefore, have the largest absolute benefit from 
treatment (71). An example of this is the decision to give a statin to individuals with 
cardiovascular risk, estimated from a prognostic model, above a certain threshold (71, 79). 
In part related to the enormous growth in ‘-omics’ studies, and the availability of 
expensive new treatments, there is growing consensus that treatment decisions should be 
guided by stratified care and personalised medicine to maximise benefit and reduce harm and 
costs. As such, stratified medicine research is likely to play an increasingly important role in 
the coming decades. 
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1.4. Prognosis in CKD 
There are many complications and adverse outcomes associated with CKD that can 
contribute to the overall burden of illness (80). There is an increased risk of early mortality, 
most often due to cardiovascular disease (CVD) (81-83), and an increased risk of adverse 
kidney outcomes, including progression to kidney failure (83-85). There is a myriad of other 
potential complications, including anaemia, mineral-bone disorder, malnutrition, infection 
(86), frailty (87), and impairment of learning and concentration (88). 
The primary outcomes assessed in this thesis are kidney failure and death. While some 
patients with CKD will suffer an early cardiovascular death or have rapidly progressive CKD 
that results in kidney failure, some individuals have CKD that never progresses and who live 
to a healthy life expectancy. For kidney failure, death, and most other CKD complications, the 
risks vary depending on the cause of CKD, the GFR, the degree of albuminuria, and other 
factors such as co-morbid conditions (36). The most recent CKD staging approach (CGA 
staging) reflects the contribution that each component makes to prognosis, as each CGA 
component provides prognostic information independent of the other components (36). Figure 





Figure 1.4. Prognosis of CKD by GFR and albuminuria category 
The shaded areas reflect the risk of adverse outcomes, such as death and progression to 
kidney failure by GFR and albuminuria category: green is low risk, yellow is moderately 
increased risk, orange is high risk, and red is very high risk. Adapted from the KDIGO CKD 
guideline (89). 
As an example, a patient with CKD with an eGFR of 24 ml/min/1.73 m2 and an ACR 
of 18 mg/mmol should be considered to be at a very high risk of adverse outcomes. 
1.4.1. Kidney failure 
Kidney failure is defined as CKD with the requirement for KRT, i.e. either dialysis or 
kidney transplantation. Common synonyms for kidney failure in the medical literature are 
end-stage kidney disease (ESKD), end-stage renal disease (ESRD), and end-stage renal 
failure (ESRF). 
It is well established that individuals with CKD are at a higher risk of kidney failure 
compared to those without CKD (82, 90, 91). The CKD Prognosis Consortium performed a 
meta-analysis of nine general population cohorts incorporating 845,125 participants and 
showed that having an eGFR < 60 ml/min/1.73 m2 or increased albuminuria (a urine ACR > 3 
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mg/mmol), i.e. markers of CKD, are associated with a higher risk of kidney failure (82). 
Compared to those with an eGFR ≥ 60 ml/min/1.73 m2, those with an eGFR of 45 to 59, 30 to 
44, and 15 to 29 ml/min/1.73 m2 had HRs (95% CI) for kidney failure of 9.6 (7.0 to 13.2), 
98.1 (61.8 to 156), and 573 (241 to 1362), respectively (after adjustment for age, sex, race, 
CVD history, smoking status, DM, systolic blood pressure [BP], serum total cholesterol, and 
urine ACR) (82). 
Compared to those with a urine ACR < 3 mg/mmol, those with a urine ACR of 3 to 29 
or ≥ 30 mg/mmol had HRs for kidney failure of 12.0 (7.9 to 18.1) and 72.1 (43.0 to 121) 
respectively (after adjustment for age, sex, race, CVD history, smoking status, DM, systolic 
BP, serum total cholesterol, and eGFR) (82). 
The same paper also included a separate meta-analysis of eight cohort studies of 
patients with DM, hypertension, or CVD (incorporating 173,892 participants) (82). This 
meta-analysis showed that in individuals with these co-morbidities, an eGFR < 60 
ml/min/1.73 m2 or a urine ACR > 3 mg/mmol is associated with a higher risk of kidney 
failure, with similar risk associations as those seen in the general population (82). 
 
1.4.1.1. Prognostic factors for kidney failure 
Each component of the CGA staging framework provides prognostic information 
concerning the risk of kidney failure in patients with CKD. 
With regard to the cause of CKD, both polycystic kidney disease and diabetic 
nephropathy are associated with a higher risk of kidney failure compared to other causes of 
CKD. In a prospective cohort study incorporating 729 patients with CKD, compared to those 
with hypertensive nephropathy, those with CKD due to polycystic kidney disease had a five-
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fold higher risk of kidney failure (adjusted HR 5.46 [2.28 to 10.6]), and there was also a 
higher risk in those with diabetic nephropathy (adjusted HR 1.96 [1.28 to 2.99]) (92). 
The GFR and degree of albuminuria have also been shown in multiple studies of 
patients with CKD to be independently associated with the risk of progression to kidney 
failure (90, 93, 94). There is an independent inverse association between eGFR and the risk of 
kidney failure. In a meta-analysis of 13 prospective cohort studies incorporating 21,688 
patients with CKD, a lower eGFR was associated with a higher risk of kidney failure (HR 
6.24 [4.84 to 8.05] per 15 ml/min/1.73 m2 lower eGFR, adjusted for age, sex, race, prior 
CVD, smoking status, DM, systolic BP, serum total cholesterol concentration and 
albuminuria) (95). A graphical representation of the association is shown in Figure 1.5. 
 
Figure 1.5. Association between eGFR and kidney failure in CKD 
Relationship between eGFR and kidney failure, by age category, in a meta-analysis of 13 
CKD cohort studies. Adjusted HR for kidney failure is relative to an eGFR of 50 ml/min/1.73 
m2, adjusted for sex, race, body mass index (BMI), systolic BP, total cholesterol, history of 
CVD, DM, smoking status, and albuminuria. From (96). 
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In the same meta-analysis, a higher urine ACR was also independently associated with 
a higher risk of kidney failure  (HR 3.04 (95% CI 2.27 to 4.08) per eight-fold higher ACR, 
adjusted for age, sex, race, prior CVD, smoking status, DM, systolic BP, serum total 
cholesterol concentration and eGFR) (95). A graphical representation of the risk of kidney 
failure by urine ACR is shown in Figure 1.6. 
 
Figure 1.6. Association between urine ACR and risk of kidney failure in CKD 
Relationship between urine ACR and kidney failure, by age category, in a meta-analysis of 13 
CKD cohort studies. Adjusted HR for kidney failure by urine ACR, within age categories, 
compared to a urine ACR of 100mg/g (black diamond), adjusted for sex, race, BMI, systolic 
BP, total cholesterol, history of CVD, DM, smoking status, and eGFR. From (96). 
Among the other prognostic factors for the risk of kidney failure, age is important: 
younger patients with CKD have a higher risk of kidney failure compared to older patients 

















Age categories with 55-64 years as the reference
Adjusted for traditional risk factors and eGFR spline
Reference at ACR=100
End Stage Renal Disease in CKD Cohorts
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kidney failure was higher in younger age groups at all levels of eGFR (97). For example, 
among those with an eGFR of 15 to 29 ml/min/1.73 m2, the adjusted rate of kidney failure for 
those aged 18 to 44 years was 24.0 per 1000 person-years, compared to 1.5 per 1000 person-
years for those aged 85 years or older (P < 0.001) (97). 
Examples of other reported prognostic factors for kidney failure in patients with CKD 
are given in Table 1.8. 
Table 1.8. Examples of prognostic factors for kidney failure in CKD 
Prognostic factor Measure Reference Adjusted HR (95% CI) Study 
Ethnicity Black White 4.8 (2.9 to 8.4) (98) 
Systolic BP (mmHg) > 157 ≤ 128 1.28 (1.01 to 1.61) (99) 
≥ 150 < 130 1.36 (1.02 to 1.85) (100) 
Per +10  1.26 (1.18 to 1.34) (101) 
Diastolic BP 
(mmHg) 
> 80 ≤ 64 1.36 (1.07 to 1.73) (99) 
≥ 90 60 to 74 1.81 (1.33 to 2.45) (100) 
Incident co-
morbidities 
Atrial fibrillation  3.2 (1.9 to 5.2) (102) 
Major depressive 
episode 
 3.51 (1.77 to 6.97) (103) 
APOL1 gene 
variants 
2 copies 0 copies 2.21 (1.56 to 3.14) (104) 
APOL1 = apolipoprotein L1; BP = blood pressure; CI = confidence interval; HR = hazard 
ratio. 
1.4.1.2. Prognostic models for kidney failure 
A prognostic model to predict the 5-year risk of kidney failure in patients with CKD 
was published in 2010 (105). It was developed in 382 patients with CKD stages G3a to G5 
from the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study, and 
incorporates sex, serum creatinine, serum phosphate, and urine ACR. The 5-year risk (%) of 
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where serum creatinine and phosphate are in mg/dl, urine ACR is in mg/g, and sex is 0 for 
males and 1 for females.  
External validation in a cohort of 213 patients with CKD suggested the model has 
moderate ability to predict kidney failure with a C statistic of 0.91 (95% CI 0.87 to 0.96), but 
the model was not taken up in routine clinical practice. 
More recently, Tangri et al. have developed models that accurately predict the two- 
and five-year risk of kidney failure in patients with CKD. Multiple models were developed 
using data from patients referred to nephrology services in Canada with a GFR < 60 
ml/min/1.73 m2 (i.e. stages G3a to G5) (106). A four-variable equation (age, sex, eGFR, and 
urine ACR) and an eight-variable equation (the four variable plus serum calcium, phosphate, 
bicarbonate, and albumin) have both since been validated using data from 31 cohort studies 
incorporating over 700,000 individuals with CKD G3a-G5 in more than 30 countries 
worldwide (107). 
The two-year risk (%) of kidney failure is calculated from the four-variable equation 
as follows: 
1	– 	0.9832-(A$.!!$4	×	(-B,/4$	–	D.$?;)	3	$.!5;D	×	(:,@	–	$.6;5!)	–	$.66;D	×	(,EF>/6	–	D.!!!)	3	$.564$	×	('9B<=>	–	6.4?D)) 
where age is in years, sex is 1 for males and 0 for females, and urine ACR is in mg/g. 
This four-variable equation (known as the ‘Kidney Failure Risk Equation’ [KFRE]) is 
readily available as a web calculator (https://kidneyfailurerisk.com) and is likely to start being 
used more widely in clinical practice in the coming years. A planned update of the NICE 
CKD guideline is likely to include for the first time a recommendation that the KFRE should 
be used to aid patient decision making and prognostication (108). For example, when 
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deciding whether a patient with CKD should be managed in primary care or secondary care or 
when a patient should have dialysis access formed or transplant workup initiated, the 
prognostic information provided by KFRE may aid decision-making. 
In 2018, Grams et al. developed models for patients with an eGFR < 30 ml/min/1.73 
m2 that are arguably even more sophisticated. Developed using data from 264,296 individuals 
in 30 countries from 29 cohorts participating in the CKD Prognosis Consortium, the models 
estimate not only the two- and four-year risk of kidney failure, CVD events, and death, but 
also the relative order of these outcomes (109). The models incorporate nine demographic and 
clinical prognostic factors: age, sex, ethnicity, history of CVD, smoking status, DM, systolic 
BP, eGFR, and urine ACR. Substantial risk factors for developing kidney failure as a first 
event included younger age, black ethnicity, higher systolic BP, lower eGFR, and higher urine 
ACR (109). The model demonstrated good calibration for estimating the risk of kidney failure 
and also showed good agreement with the KFRE for the prediction of kidney failure at two 
years (109). 
This model has been made available as a web calculator making it readily accessible 
for use in clinical practice (http://ckdpcrisk.org/lowgfrevents/). As an example of the use of 
this prognostic model, a 60-year-old white man with a history of CVD, systolic BP of 140 
mmHg, eGFR of 25 ml/min/1.73 m2, and urine ACR of 3 mg/mmol but no DM and not a 
current smoker is predicted, at two years, to have a 74% chance of remaining event-free, a 
17% chance of having a CVD event, a 9% chance of death, and a 5% chance of kidney 
failure. The prognostic information, in this case, may reinforce the relative importance of 




1.4.1.3. Interventions to reduce the risk of kidney failure 
Although patients with CKD have a higher risk of kidney failure compared to those 
without CKD, their risk may be reduced by measures to slow the rate of GFR decline. These 
measures may include specific therapy for treatable causes of CKD, such as 
immunosuppression for immune-mediated kidney disease. However, irrespective of the cause 
of CKD, therapies to achieve BP control and to achieve a reduction in proteinuria are the two 
main strategies shown to reduce the risk of kidney failure. 
Elevated BP in patients with CKD is associated with a higher risk of kidney failure 
(see Table 1.8), and treatment to lower BP has been shown to reduce this risk, particularly in 
those with proteinuria (110-116). For example, in a meta-analysis incorporating data on over 
5000 individuals from six cohorts, intensive BP control (< 130/80 mmHg), compared to 
standard BP control (< 140/90 mmHg), was associated with a lower risk of kidney failure 
(risk ratio 0.91 [95% CI 0.85 to 0.99]) (115). A separate meta-analysis, incorporating seven 
trials and 5308 participants, also showed that intensive BP control was associated with a 
lower risk of kidney failure (HR 0.79 [95% CI 0.67 to 0.93]) (113). However, a subgroup 
analysis showed that, while intensive BP lowering reduced the risk of kidney failure in people 
with proteinuria (HR 0.73 [95% CI 0.62 to 0.86]), it did not affect the risk of kidney failure in 
patients without proteinuria (HR 1.12 [95% CI 0.67 to 1.87]) (113). Both the NICE and 
KDIGO CKD guidelines recommend a BP target of < 140/90 mmHg and a lower target of < 
130/80 mmHg in those with increased albuminuria (22, 36). The NICE CKD guideline also 
recommends the lower target of < 130/80 mmHg for those with DM (22). 
In proteinuric kidney disease, reducing the level of proteinuria with renin-angiotensin-
aldosterone system inhibitors (RAASi) such as angiotensin-converting enzyme inhibitors 
(ACEi) and angiotensin II receptor blockers (ARB) has been shown to reduce the risk of GFR 
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decline and progression to kidney failure (117-121). For example, in meta-analyses 
examining the effects of ACEi and ARB in patients with moderately or severely increased 
albuminuria, treatment with an ACEi (9 studies, 7988 patients, relative risk [RR] 0.67 [95% 
CI 0.54 to 0.84] or an ARB (3 studies, 3298 patients, RR 0.78 [95% CI 0.66 to 0.90]) were 
associated with a lower risk of kidney failure compared to placebo or no treatment (121). In 
another meta-analysis, including 21 cohorts and 78,342 participants, a 30% reduction in 
albuminuria was associated with a 23.7% (95% CI 11.4 to 34.2%) lower risk of kidney failure 
(120). 
Other measures that may reduce the risk of kidney failure in patients with CKD 
include: 
• Treatment of the metabolic acidosis which commonly complicates CKD with 
supplemental bicarbonate. In a study of 134 patients with CKD and metabolic acidosis 
in which patients were randomized to either treatment with oral sodium bicarbonate or 
standard care, those treated with sodium bicarbonate had a lower risk of kidney failure 
(RR 0.13 [95% CI 0.04 to 0.40]) (122). 
• In patients with DM, intensive glycaemic control has been shown to reduce the risk of 
CKD progression and kidney failure (123, 124). In a trial of intensive (target HbA1c < 
6.5%) versus standard (target HbA1c based on local guidelines) glycaemic control in 
11,140 patients with type 2 DM, the risk of kidney failure was approximately halved 
in the intensive control group (HR 0.54 [95% CI 0.34 to 0.85]) (123). 
1.4.2. Mortality 
There is a wealth of data showing that patients with CKD have a higher risk of death 
compared to those without CKD (81, 82, 90, 125-129). For example, in the 2018 United 
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States Renal Data System (USRDS) annual data report, mortality rates were 103 and 43.1 per 
1,000 patient-years for those with and without CKD, respectively (adjusted for age, sex, and 
ethnicity) (130). In a cohort study involving 1,120,295 adults, an increased risk of death was 
evident at a GFR < 60 ml/min/1.73 m2 and substantially increased at a GFR < 45 ml/min/1.73 
m2 (126). Compared to an eGFR ³ 60 ml/min/1.73 m2, the adjusted HR for death was 1.2 
(95% CI 1.1 to 1.2) with an eGFR of 45 to 59 ml/min/1.73 m2, 1.8 (95% CI 1.7 to 1.9) with 
an eGFR of 30 to 44 ml/min/1.73 m2, 3.2 (3.1 to 3.4) with an eGFR of 15 to 29 ml/min/1.73 
m2, and 5.9 (95% CI 5.4 to 6.5) with an estimated GFR < 15 ml/min/1.73 m2 (126). 
In a CKD Prognosis Consortium meta-analysis of 14 general population cohorts with 
105,872 participants, there was no increased mortality risk associated with having an eGFR of 
60 to 89 ml/min/1.73 m2 compared to a ‘normal’ eGFR of 90 to 104 ml/min/1.73 m2 (81). 
However, having an eGFR < 60 ml/min/1.73 m2 was associated with a significantly increased 
risk of all-cause mortality: an eGFR of 45 to 59, 30 to 44, and 15 to 29 ml/min/1.73 m2 was 
associated with HRs for all-cause mortality of 1.28 (1.05 to 1.57), 1.97 (1.59 to 2.43), and 
5.39 (3.30 to 8.80), respectively (adjusted for age, race, sex, CVD history, systolic BP, DM, 
smoking, and total cholesterol) (81). 
In the same meta-analysis cited above, within the group with normal kidney function 
(eGFR 90 to 104 ml/min/1.73 m2), the presence of increased albuminuria was also associated 
with an increased risk of mortality: compared to those with an ACR < 1.1 mg/mmol, an ACR 
of 1.1 to 3.3, 3.4 to 33.8, and ≥ 33.9 mg/mmol was associated with HRs for all-cause 
mortality of 1.48 (1.29 to 1.69), 1.61 (1.39 to 1.87), and 3.65 (2.13 to 6.27), respectively 




Similar associations between the eGFR and level of albuminuria with the risk of death 
were also demonstrated in a meta-analysis of 10 cohort studies incorporating 266,975 
individuals with a history of hypertension, DM, or CVD (82).  
The higher mortality risk associated with CKD is due primarily to an excess of 
cardiovascular disease (CVD), as discussed in the following section.  
 
1.4.2.1. Cardiovascular disease 
Both the prevalence and the incidence of CVD are higher in patients with CKD 
compared to those without CKD. In the 2018 USRDS annual data report, a wide range of 
cardiovascular conditions were more common in patients with CKD compared to those 
without CKD, including stable coronary artery disease, acute myocardial infarction, heart 
failure, valvular heart disease, stroke, transient ischaemic attack, peripheral arterial disease 
(PAD), atrial fibrillation, sudden cardiac arrest, ventricular arrhythmias, venous 
thromboembolism, and pulmonary embolism (130). The overall prevalence of CVD among 
patients aged 66 years and older was 65.1% in those with CKD, compared to 32.6% in those 
without CKD (130). 
There is also a large body of evidence showing that CKD is associated with a higher 
risk of incident CVD (90, 125-129, 131-136). The CKD Prognosis Consortium meta-analyses 
discussed above, demonstrating a higher risk of mortality associated with a lower eGFR or 
higher urine ACR also showed independent graded associations specifically with 
cardiovascular mortality (81, 82). Increased albuminuria, even if only moderate and in the 
presence of a normal GFR, is associated with CVD and cardiovascular death and adds to the 
cardiovascular risk in those with existing traditional cardiovascular risk factors such as DM or 
hypertension (90, 131, 137-139). A population-level cohort study from Canada suggested that 
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CKD is a stronger risk factor for an incident myocardial infarction than DM (135). It has been 
recommended therefore that CKD be considered a ‘coronary heart disease risk equivalent’, 
other examples of which include DM and PAD because the risk of a coronary event is at least 
as high as those who have known coronary heart disease (140). 
The cardiovascular risk in patients with CKD is partly explained by an excess of 
traditional cardiovascular risk factors such as hypertension, DM, and dyslipidaemia. 
Therefore the management of individuals with CKD includes conventional cardiovascular risk 
management such as lifestyle measures, BP control, statin therapy, glycaemia control, and in 
some patients, antiplatelet therapy. However, even after adjustment for traditional risk factors, 
the presence of CKD is associated with a higher risk of CVD, and the non-traditional factors 
and underlying mechanisms for this association are the subjects of much research (126). 
Until recently, there were no prognostic models available to accurately predict the risk 
of cardiovascular events in individuals with CKD (141). The Framingham risk score is a risk 
calculator used in clinical practice to estimate the 10-year cardiovascular risk of an individual 
that was developed in the general population (142). When its utility for risk prediction in 
patients with CKD was assessed using data from two CKD cohorts with nearly 1000 
participants, it had poor discriminative and calibration ability, underestimating risk at five and 
ten years (143). The latest QRISK cardiovascular risk prediction score (QRISK3) includes the 
presence of CKD G3a to G5 as a risk factor, but only as a binary yes/no, which does not 
adequately take into account the graded association between the level of GFR and 
albuminuria with cardiovascular risk (144). 
However, for patients with an eGFR < 30 ml/min/1.73 m2, the prognostic models 
developed by Grams et al. in 2018 (discussed in section 1.4.1.2) may be used to predict the 
risk of cardiovascular events at two- and four-years and the relative order of such events in 
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relation to progression to kidney failure or death (109). In this model, the factors associated 
with having a CVD event as a first event include older age, a previous history of CVD, and 
DM (109). 
 
1.4.2.2. Prognostic factors for mortality 
As previously discussed, each component of the CGA staging system (cause of CKD, 
GFR, and level of albuminuria) provides prognostic information in patients with CKD, and 
this includes the risk of mortality. 
With regard to the cause of CKD, diabetic nephropathy and atherosclerotic 
renovascular disease may be associated with a higher risk of death. In a Swedish prospective 
cohort study of nearly 1000 patients with CKD, relative to those with CKD due to 
glomerulonephritis, there was an independent higher risk of death associated with CKD due to 
diabetic nephropathy (adjusted HR 3.1 [2.3 to 4.3]) or atherosclerotic renovascular disease 
(adjusted HR 1.47 [1.23 to 1.76]) (145). 
There is a wealth of evidence showing that, among patients with CKD, there is a 
graded and inverse relationship between the GFR and risk of death. For example, in a meta-
analysis incorporating data from eight CKD cohorts, the adjusted HR for mortality was 1.47 





Figure 1.7. Association between eGFR and risk of death in CKD 
From a meta-analysis of 13 CKD cohort studies. Hazard ratios, by categories of age, are 
relative to an eGFR of 50 ml/min/1.73 m2, adjusted for sex, race, BMI, systolic BP, total 
cholesterol, history of CVD, DM, smoking status, and albuminuria. Reference (96). 
There is also a significant independent association between level of albuminuria and 
risk of death in CKD. In the same meta-analysis, an eightfold higher urine ACR was 
associated with an adjusted HR for mortality of 1.40 (1.27 to 1.55) (95). In another cohort 
study of 920,985 patients, not included in the meta-analysis, among those with an eGFR of 45 
to 59 ml/min/1.73 m2, the adjusted rates of mortality per 1000 person-years were 7.0 (6.4 to 
7.6), 11.9 (10.7 to 13.2), and 18.0 (15.6 to 20.9) for a urine ACR of < 3, 3 to 30, and > 30 
mg/mmol, respectively (90). In those with an eGFR of 15 to 29 ml/min/1.73 m2, the 
equivalent rates were 16.3 (13.0 to 25.0), 22.0 (18.5 to 26.0), and 24.6 (20.5 to 29.6), 
respectively (90). 
As would be expected, age is also strongly associated with the risk of mortality in 
patients with CKD. In a prospective cohort of nearly 1000 patients with CKD, compared to 
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patients aged < 45 years, those 45 to 64 and those ³ 65 had adjusted HRs for mortality of 2.8 
(1.7 to 4.8) and 5.2 (3.1 to 9.0), respectively (145). 
There are many other prognostic factors for mortality in CKD that have been reported 
in the literature, some examples of which are given in Table 1.9, and it will be noted that 
many of these are cardiovascular risk factors. 
Table 1.9. Examples of prognostic factors for mortality in CKD 
Prognostic factor Measure Reference Adjusted HR Study 
Blood pressure (mmHg) 
< 120/80 
120 to 139/ 
80 to 89 
1.42 (1.41 to 1.43) 
(146) 
140 to 159/ 
90 to 99 
0.95 (0.94 to 0.96) 
> 160/100 1.05 (1.03 to 1.07) 
≤ 130/ 
131 to 160/ 
1.22 (1.11 to 1.34) 
(147) 
> 160/ 1.06 (0.93 to 1.22) 
Body mass index (kg/m2) ≤ 20 > 20 2.0 (1.4 to 2.8) (145) 
Serum phosphate (mg/dl) 
per + 1  1.20 (1.05 to 1.37) (148) 
per + 1  1.18 (1.12 to 1.25) (149) 
HbA1c (%)* > 9 < 7 1.35 (1.20 to 1.53) (150) 
Plasma 1,25(OH)2 D (pg/ml) < 15 > 22 1.33 (1.01 to 1.74) (151) 
FGF-23 (RU/ml) > 946 ≤ 216 2.17 (1.56 to 3.08) (152) 
*in patients with DM. 
1.4.2.3. Prognostic models for mortality 
A prognostic model to predict the risk of mortality by five years in individuals with 
CKD was developed using data from 382 participants with CKD stages G3 to G5 (but not 
receiving KRT) of the CRIB study (105). Of 44 candidate predictors, four were included in 
the final model: age, smoking status, and the cardiac markers NT-pro-BNP and Troponin T 
(TnT). The following equation gives the predicted 5-year risk (%) of mortality: 
 




where age is in years, NT-pro-BNP is in pg/ml, smoker is 1 for current smokers and 0 for 
others, and ‘positive TnT’ is 1 for those with a TnT ≥ 0.01 ng/ml and 0 for those with a TnT < 
0.01 ng/ml. 
The model was externally validated in a separate cohort of 213 patients with CKD 
stages G3 to G5. The C statistic of 0.82 suggested the model has moderate predictive ability, 
and the model has not been used in routine clinical practice. 
As discussed above, the models developed in 2018 by Grams et al. may be used to 
predict the risk of death by two and four years in patients with CKD with a GFR < 30 
ml/min/1.73 m2 (109). Factors in the model that strongly predict death before experiencing 
kidney failure or a CVD event are older age and smoking. 
 
1.4.2.4. Interventions to reduce the risk of mortality 
A positive impact of nephrology care on mortality in patients with CKD has been 
inferred from multiple studies by comparison of early vs late (within six months of the need 
for dialysis) referral to nephrology. For example, a meta-analysis of 22 studies involving 
12,749 patients with CKD showed a higher mortality rate in patients who were referred late 
(153), and a subsequent retrospective study of 39,031 patients showed that having at least two 
visits to a nephrology clinic was associated with a lower risk of mortality (154). 
There are several therapeutic strategies employed to reduce the risk of death in 
patients with CKD, and they are principally aimed at reducing the risk of CVD events. The 
approach to reducing cardiovascular risk is as follows: 
• Statin therapy. The Study of Heart and Renal Protection (SHARP) trial randomised 
9270 patients with CKD (some on dialysis) and no known history of myocardial 
infarction or coronary revascularisation to either treatment with simvastatin plus 
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ezetimibe or placebo (155). In the subgroup of 6247 patients not on dialysis, those 
receiving simvastatin and ezetimibe had a significantly lower risk of major 
atherosclerotic events (risk ratio 0.78 [0.67 to 0.91]) (155). Subsequent meta-analyses 
have also shown that statin therapy reduces the risk of CVD events and death in non-
dialysis CKD (156-158), and the NICE guideline on lipid modification recommends 
statin therapy for the primary or secondary prevention of CVD in patients with CKD 
(159). 
• Control of hypertension. In a meta-analysis of 26 studies which included over 30,000 
patients with CKD, ACEi therapy, compared to placebo therapy, reduced the risk of a 
major CVD event (HR 0.81 [0.73 to 0.89]), with a similar but statistically non-
significant effect with calcium antagonists (HR 0.74 [0.53 to 1.03]) (160). Irrespective 
of antihypertensive drug class, a reduction in systolic BP was associated with a lower 
risk of a major CVD event (HR 0.83 [0.76 to 0.90] per 5 mmHg reduction) (160). The 
BP targets recommended by NICE are discussed in Section 1.4.1.3. 
• Aspirin in some patients. A Cochrane review of antiplatelets in CKD found that, 
compared to placebo, antiplatelets reduced the risk of myocardial infarction (risk ratio 
0.87 [0.76 to 0.99]) but not of stroke or death, and the risk of major bleeding was 
significantly increased (risk ratio 1.33 [1.10 to 1.65]) (161). The NICE CKD guideline 
suggests offering antiplatelet drugs to patients with CKD for secondary prevention of 
CVD, but being aware of the increased risk of bleeding (22). 
• Other measures employed are those recommended in the general population and 
include smoking cessation, achieving and maintaining healthy body weight, regular 
exercise, and glycaemic control in patients with DM. 
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It is also important that patients with CKD receive adequate treatment for established 
CVD, but many studies show that patients with CKD are less likely to receive proven 
therapies for incident CVD. For example, therapies such as percutaneous coronary 
intervention, ACEi, and beta-blockers are less likely to be offered to patients with CKD 
compared to patients without CKD (162-165). 
Although there is a focus on reducing cardiovascular risk, a holistic approach, 
including optimal management of co-morbid conditions and addressing other risks associated 
with mortality, is important. For example, patients with CKD have a higher risk of infection 
and infection-related death, and vaccination against influenza and pneumococcus may reduce 
these risks (166). Public Health England identifies CKD stages G3 to G5 as a clinical risk 
group that should be offered the influenza vaccination, and stages G4 to G5 as a group that 
should receive the pneumococcal immunisation (167). 
CKD care should be multidisciplinary and ideally coordinated in a multidisciplinary 
clinic. Multidisciplinary care is associated with improved outcomes for patients with CKD, 
including reduced mortality (168, 169). In addition to a nephrologist, a multidisciplinary 
clinic may include health professionals with skills in patient education, dialysis vascular 
access, renal anaemia, clinical psychology, a dietician, and a social worker.  
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1.5. The need for more prognosis research in CKD 
As described in previous sections of this chapter, the incidence and prevalence of 
CKD and deaths due to CKD are all increasing in the UK, as are common diseases that may 
be associated with CKD, such as DM, hypertension, and CVD. The increasing prevalence of 
CKD, the serious complications associated with it, and the financial costs, mean that CKD 
presents a significant and growing challenge for health services. 
Further high-quality prognosis research in CKD may, therefore, be regarded as a 
priority within the field of nephrology. The importance of further prognosis research in CKD 
is demonstrated not only by a large number of prospective CKD cohort studies that have been 
established in the UK and globally, but also by impressive international collaborative efforts, 
in particular, the CKD Prognosis Consortium (170). The CKD Prognosis Consortium was 
established in 2009 by KDIGO as a group of investigators representing cohorts from around 
the world who share data for meta-analyses to study prognosis in CKD. This work has 
resulted in high quality and generalisable estimates of the association between routine kidney 
measures, such as eGFR and urine ACR, and adverse clinical outcomes in CKD. 
Although eGFR and albuminuria are now well established prognostic factors in CKD, 
there is significant interest in identifying novel prognostic factors in CKD. This requires a 
different approach from the work done by the CKD Prognosis Consortium, which 
amalgamates data on routinely-collected variables that are available in multiple cohorts, 
because the investigation of novel prognostic factors is usually only feasible in one or a small 
number of studies initially. 
Some of the potential benefits of further prognostic research and the identification of 
novel independent prognostic factors in CKD include: 
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• Accurate estimates of the average prognosis in CKD may allow the modelling of the 
population burden of CKD and provide a measure of the effectiveness of healthcare 
for CKD; 
• Prognostic factors may be identified that predict treatment effects (e.g. high levels of 
albuminuria are associated with more benefit from RAASi); 
• The identification of factors that provide a measure of the response to a particular 
treatment; 
• The identification of prognostic factors that have a causal association with adverse 
outcomes would provide insight into the underlying pathophysiological mechanisms 
and identify potential therapeutic targets; 
• Improved prognostic models would allow more accurate risk prediction, which may 
benefit patients, and aid clinicians in the practice of stratified medicine. 
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1.6. Summary and research aims 
This introductory chapter has provided an overview of CKD and its importance with a 
particular focus on its prognostic implications. The case for more prognosis research in CKD 
has been made, and a useful framework for the conduct of prognosis research has been 
described. The work in this thesis aimed to assess four biomarkers in patients with CKD to 
determine whether they are independent prognostic factors and associated with the risk of 
kidney failure or death in CKD. The biological basis for assessing the specific biomarkers is 
discussed in each results chapter. They were selected based on pre-existing evidence that 
suggested either a demonstrable association in preliminary studies or evidence for a 
pathogenetic role in the progression of CKD. Hypotheses were prespecified and addressed 
using new data.  
1.6.1. Hypotheses 
The prespecified hypotheses that were tested for the work presented in this thesis 
comprised: 
1. Higher levels of serum polyclonal light chains are independently associated with a 
higher risk of kidney failure and death in patients with CKD. 
2. Higher levels of urinary free light chains are independently associated with a higher 
risk of kidney failure and death in patients with CKD. 
3. The presence of a non-malignant monoclonal gammopathy is independently 
associated with a higher risk of kidney failure and death in patients with CKD. 
4. Higher levels of serum endotrophin are independently associated with a higher risk of 
kidney failure and death in patients with CKD. 
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1.7. Thesis structure 
Chapter II provides an overview of the methods employed in this thesis, including the 
statistical approach. Methods specific to each analysis are included in the relevant chapter. 
Chapter III presents the assessment of serum polyclonal light chains as a prognostic 
factor in CKD, in the form of a meta-analysis incorporating data from four CKD cohorts 
(some published, and some new data). 
Chapter IV reports an evaluation of urinary free light chains as a prognostic factor in 
CKD using a prospective cohort study. 
Chapter V incorporates data from three CKD cohort studies to assess the prognostic 
significance of the presence of a non-malignant monoclonal gammopathy in patients with 
CKD. 
Chapter VI presents the evaluation of a marker of collagen type VI formation, serum 
endotrophin, as a prognostic factor in CKD, using a prospective cohort study. 
Chapter VII provides a summary of the results, draws conclusions from this research, 
and ends with a discussion of future research required.
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CHAPTER II: GENERAL METHODS 
This chapter provides an overview of the methods employed in the work presented in 
this thesis. Methods that are specific to a particular analysis are described in the relevant 
chapter. 
All analyses were performed on samples and data from prospective cohort studies of 
patients with CKD. The Renal Impairment in Secondary Care (RIISC) study was the basis for 
the work presented in this thesis and is described in detail in the following sections. Several 
chapters also include data from other studies, including the Renal Risk in Derby (RRID) and 





2.1. The Renal Impairment in Secondary Care study 
The RIISC study is a prospective cohort study of patients with CKD in secondary care 
that was established to assess prognosis and prognostic factors in patients with CKD. The 
study methodology was published in 2013 (171), and the study is registered in the 
ClinicalTrials.gov registry (identifier: NCT01722383). Details of the RIISC study follow with 
an emphasis on those aspects pertinent to the work presented in this thesis, and a brief 
description of the other aspects. 
2.1.1. Ethics 
The study protocol was approved by the South Birmingham Research Ethics 
Committee (REC) (reference 10/H1207/6) and University Hospitals Birmingham Research 
and Development department (reference RRK3917). The study was conducted in accordance 
with the Declaration of Helsinki. All participants provided written, informed, consent. 
2.1.2. Setting 
The study was conducted in nephrology clinics in two hospitals in Birmingham, UK: 
the Queen Elizabeth Hospital and Heartlands Hospital. 
2.1.3. Participants 
Adult patients with CKD who had been under follow-up in a general nephrology or 




• Inclusion criteria 
o eGFR < 30 ml/min/1.73 m2 or 
o eGFR 30 to 59 ml/min/1.73 m2 with at least one of: 
§ Urine ACR ³ 70 mg/mmol on three occasions 
§ eGFR decline of ³ 5 ml/min/1.73 m2 over a year 
§ eGFR decline of ³ 10 ml/min/1.73 m2 over five years 
• Exclusion criteria 
o Kidney replacement therapy (i.e. dialysis or kidney transplantation) 
o Immunosuppression for immune-mediated kidney disease 
2.1.4. Baseline study visit 
Recruitment occurred between October 2010 and December 2015, and eligible 
patients who consented to participate had their baseline study visit on the day of recruitment. 
Data collected during the baseline visit were recorded on a paper case report form (CRF) 
before being entered into an electronic study database. The data and samples collected during 
the baseline study visit are described below. 
 
2.1.4.1. Demographic and lifestyle factors 
A summary of the demographic and lifestyle variables that were collected and 
recorded is provided in Table 2.1. 
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Ethnicity White/Black/South Asian/other 
Education 
level 




1. Currently employed: yes/no/retired 
2. If employed or retired, job type: unskilled or manual/skilled or 
manual/clerical/managerial/professional 
Deprivation Index of Multiple Deprivation (IMD) 2010* (172), derived from 
participant’s postcode. IMD provides an overall measure of relative 




2. If current or previous: pack-years* 
Alcohol 
intake 
Units per week* 
*recorded as continuous variables. 
2.1.4.2. Health-related quality of life  
Health-related quality of life (HRQL) was assessed using the EuroQol EQ-5D-3L 
instrument, which has two components (173):  
1. Descriptive system: a categorical self-assessment (no problems/some 
problems/extreme problems) in five domains: 
a. mobility 
b. self-care 
c. usual activities 
d. pain/discomfort 
e. anxiety/depression 
2. Visual analogue scale: the participant rates their health on a continuous scale from 0 




In a review of patient-reported outcome measures for patients with CKD, evidence for 
the EQ-5D was found to be more favourable compared to two other measures as it 
demonstrates good discriminative properties and the response rates for completion are high 
(174). 
 
2.1.4.3. Clinical history 
Factors related to the participant’s clinical history were recorded as listed in Table 2.2. 




1. Complete PMH recorded as free text 
2. Yes/no for: DM, IHD, cerebrovascular disease, PAD, COPD, 
malignancy 
Cause of CKD Vascular/diabetes/glomerular/tubulointerstitial/cystic or 
congenital/other or unknown 




All current drugs and their doses 
PMH, past medical history. 
2.1.4.4. Physical assessment 
Variables recorded from the physical assessment that was performed at the baseline 
visit included anthropometric data (participants’ height [cm], weight [kg], body mass index 
[kg/m2], waist circumference [cm], hip circumference [cm], and thigh circumference [cm]) 
and blood pressure (BP). Blood pressure was recorded using the BpTRUä device (BpTRU 
Medical Devices, Coquitlam, BC, Canada), an automated BP measuring device that, after a 
five minute rest period, records six readings at one-minute intervals. The first reading is 
discarded, and the average of the subsequent five readings is recorded as the BP. The standard 
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operating procedure (SOP) for BP measurement using BpTRU is presented in Appendix 1. In 
patients with CKD, clinic BP measurements by BpTRU are lower than manual BP 
measurements (which may be higher due to the ‘white coat’ effect) and similar to the daytime 
mean and overall mean from a 24-hour ambulatory BP monitor (the gold standard) (175). 
Arterial stiffness was estimated by measuring carotid-to-femoral pulse wave velocity 
(PWV) using the Vicorder device (SMART Medical, Gloucestershire, UK), regarded as the 
gold-standard non-invasive technique for measurement of aortic stiffness (176). The SOP for 
PWV measurement using the Vicorder device is presented in Appendix 2. Increased arterial 
stiffness is associated with a higher risk of incident CVD and death in patients with CKD 
(177, 178). 
An estimate of tissue advanced glycation end products (AGEs) was also obtained 
using the AGE Reader device (Diagnoptics Technologies, Groningen, Netherlands), which 
measures skin autofluorescence, based on the fluorescent properties of certain AGEs 
accumulated in dermal tissue. The SOP is presented in Appendix 3. AGEs are a 
heterogeneous group of compounds formed by the reaction of free amino groups on proteins, 
lipids, and nucleic acids with reactive carbonyl groups on reducing sugars (179, 180). In 
CKD, increased oxidation or decreased detoxification of carbonyl compounds results in 
increased concentrations of small carbonyl precursors and thus, the accumulation of AGEs 
(181). AGEs are pro-inflammatory and associated with endothelial dysfunction and arterial 
stiffness, and higher levels may be associated with a higher risk of CVD (182). 
Finally, participants underwent a periodontal assessment. One of the primary 
hypotheses to be tested in RIISC was that chronic periodontitis in patients with CKD is 
associated with a higher risk of CKD progression and death. At the baseline visit, participants 
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underwent a periodontal assessment and plaque and saliva sampling, and the methodology 
and initial results from this have been published (183). 
 
2.1.4.5. Samples 
Samples of serum, plasma, and urine were collected at the baseline visit and all 
follow-up visits. For the routine clinical blood tests (full blood count, creatinine, eGFR, 
potassium, calcium, phosphate, albumin, parathyroid hormone, bicarbonate, glucose, HbA1c, 
and lipids) and urine ACR, samples of serum and urine were processed in the local hospital 
laboratory as per the current standard of care. 
Further, extra blood and urine were collected specifically for the investigation of novel 
prognostic factors. For this purpose, serum, plasma, and urine were processed immediately 
after collection and stored at -80 ̊C until analysis. The SOP for the processing of serum, 
plasma, and urine is given in Appendix 4. 




The assay methods used for each particular potential prognostic factor being assessed 
in this thesis are described within the relevant chapter. 
Of particular importance in all multivariable analyses were the creatinine-based eGFR 
and the urine ACR. Serum creatinine assays were performed on a Roche cobas® 8000 
modular analyser using the Jaffé method, calibrated to the isotope dilution mass spectrometry 
(IDMS) methodology, and eGFR was calculated using the CKD-EPI equation unless 
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otherwise stated. Urine ACR was measured using an immunoturbidimetric assay on a Roche 
Hitachi 702 analyser. 
2.1.5. Follow-up 
Participants were followed up with study visits at six months, 18 months, and 36 
months, and after that ‘remote’ follow-up for outcomes. Participants were followed up until 
kidney failure, death, or ten years from the baseline study visit, and study follow-up is 
ongoing. Patients who withdrew from the study did not attend further study visits but gave 
consent for the remote collection of kidney failure and death outcome events. 
 
2.1.5.1. Data and sample collection 
At all follow-up visits, data were collected on lifestyle factors (current smoking status 
and alcohol intake), HRQL, current medications and their doses, and the following patient-
reported outcomes sustained since the previous study visit: 
• New diagnoses and the date of diagnosis 
• Hospital admissions, with the reason for admission and dates 
• Cardiovascular events (myocardial infarction/angina/stroke/transient ischaemic 
attack/PAD) 
• Kidney failure 
All elements of the physical assessment as described for the baseline visit were 
repeated at every follow-up visit other than the periodontal assessment, which was performed 
only at baseline and 36 months. 
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Further samples of serum, plasma, urine, and saliva were collected, processed, and 
stored at every follow-up visit in the same manner as at the baseline visit. DNA samples were 
not retaken at follow-up visits. 
 
2.1.5.2. Outcomes 
The events of interest in this work were kidney failure and death. 
Kidney failure was defined as CKD with the requirement for KRT and was recorded 
as the time between the date of the baseline study visit and the date of dialysis treatment or 
kidney transplantation, whichever came first. In addition to patient-reported kidney failure 
events obtained at follow-up visits, the electronic database of each hospital’s renal unit, which 
records all patients being treated with KRT, was regularly searched to identify new kidney 
failure events. 
Deaths were defined as death from any cause and were identified through linkage with 
Lorenzo, an electronic health record, on which deaths are registered. The time between the 
date of the baseline study visit and the date of death was recorded. 
For all analyses of RIISC data in this thesis, kidney failure and death events up to 31 
December 2018 are included. Participants who had not experienced an endpoint by 31 
December 2018 were censored on this date. 
 
64 
2.2. Role in the RIISC study 
The RIISC study has been a collaborative effort, with many people involved in its 
design and conduct. This researcher’s contributions to the conduct of the study have included: 
• Screening potential participants for eligibility; 
• Consenting and recruiting eligible patients into the study; 
• Assessment of participants at baseline and follow-up study visits, collecting and 
recording the required data onto CRFs, and subsequent recording of data into the 
electronic study database; 
• Management of samples, including storage, organisation, and arranging external 
sample transfers for assay; 
• The writing and submission of major protocol amendments to the REC, including an 





Bias is defined as a systematic deviation in results from the truth. This is distinguished 
from random error which is a deviation in results from the truth caused by statistical 
fluctuations (in either direction) in the measured data (184). The primary sources of bias in 
prognosis research and how these have been addressed are described below: 
2.3.1. Selection bias 
The risk of selection bias is lower in prospective cohort studies such as RIISC 
compared to historical cohort studies, but biased results may still result from participation or 
attrition bias. These risks were minimised as follows. 
• Participation bias: 
o Study visits (both baseline and follow-up) were aligned to participants’ routine 
outpatient renal appointments such that the patient would receive their routine 
clinical review as part of the study visit and not need to come for a separate 
visit, reducing the risk of a low participation rate. 
o All eligible patients attending renal outpatient clinics were consecutively, 
rather than selectively, invited to participate in the study. 
o The eligibility criteria were clear and easy to apply, such that the risk of 
incorrectly inviting or excluding patients was low. 
• Attrition bias: 
o The risk of participants missing follow-up study visits was reduced by aligning 
them with their routine clinic visits. 
o Electronic health sources were used to remotely capture kidney failure and 
death outcome events, such that if participants missed a follow-up visit or 
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withdrew from the study, there was a very low risk of missing these outcome 
data. 
2.3.2. Information bias 
The risk of information bias was reduced by: 
• The outcome events (kidney failure and death) were clearly defined and not 
ambiguous or subjective. 
• The majority of outcome events were captured using reliable electronic data sources, 
as described above, rather than patient-reported outcomes. 
• A participant’s baseline characteristics in no way influenced the above methods of 
outcome event capture. 
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2.4. Sample size 
Issues concerning study sample size are described below. 
2.4.1. RIISC 
The aim was to recruit 1000 participants into RIISC as this would allow robust 
interpretation of the relationship between candidate prognostic factors and clinical outcomes, 
including subgroup analyses, e.g. by DM status. Recruitment was reviewed in December 
2015, by which time 931 patients had been recruited. Based on the high number of observed 
kidney failure and death events (the most important factor influencing power for time-to-
event analyses), the study ended recruitment with a final study population of 931 participants. 
2.4.2.  Other studies 
Where individual participant data were included from studies other than RIISC, such 
as RRID and SKS, all recruited participants eligible for that analysis and for whom data were 
available were included. 
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2.5. Statistical methods 
All statistical analyses were prespecified and not data-driven. Analyses deviated from 
the prespecified methods only where recommended in peer review. 
2.5.1. Preliminary data cleaning and assessment 
Data were assessed, cleaned, and prepared prior to each analysis. Duplicate cases were 
checked for and removed where identified, and implausible values for each variable were 
checked for by assessing the minimum and maximum values and distribution of each variable. 
Values were modified where there was a manifest error, e.g. height (cm) recorded as 1.66 was 
replaced with 166. Where there was still doubt about the plausibility of a value, the CRF was 
referred to, and the dataset corrected where possible. In six cases, both systolic and diastolic 
BP were recorded as 0 mmHg in the dataset and on the CRF, and these values were deleted 
and treated as missing data. 
Categorical variables were coded numerically, and labels assigned to each value. 
The distribution of each continuous variable was assessed with histograms to 
determine whether parametric or non-parametric statistical tests were appropriate and whether 
a transformation was required. 
2.5.2. Description of the study population 
For each analysis, the distributions of demographic characteristics (such as age, sex, 
and ethnicity), co-morbidities, established prognostic factors, and the prognostic factor being 
assessed are reported. These are presented in tabular form as the frequency and percentage for 
categorical variables, the mean and standard deviation (SD) for normally distributed 
continuous variables, and the median and interquartile range (IQR) for non-normally 
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distributed continuous variables. In the same table, the number of missing values for each 
variable are also presented. 
Follow-up time is summarised as the median and interquartile range, estimated by the 
reverse Kaplan-Meier method (185). Outcomes are reported as both the number of events and 
as an event rate (e.g. events per 100 person-years of follow-up). 
2.5.3.  Relationship of a prognostic factor with other variables 
The relationship of the prognostic factor being assessed with other baseline variables, 
including established prognostic factors such as eGFR and urine ACR, was evaluated both 
statistically and graphically, e.g. a scatter plot for the relationship between two continuous 
variables. 
Fisher’s exact test was used to assess for a significant relationship between two 
categorical variables. 
The relationship between two normally distributed continuous variables was assessed 
statistically by Pearson’s correlation coefficient (r), Spearman's rank correlation coefficient 
(ρ) where one variable was non-normally distributed, and Kendall's rank correlation 
coefficient (τ) where both variables were non-normally distributed. Correlation coefficients of 
0.2, 0.5, and 0.8 were considered weak, moderate, and strong, respectively (186). Fractional 
polynomial transformations were also used to assess for non-linear relationships. 
A statistical assessment of the relationship between a continuous variable and a binary 
categorical variable was by the t-test (for normally distributed continuous variables) or the 
Mann-Whitney U test (for non-normally distributed continuous variables). 
The relationship between a continuous variable and a categorical variable with three or 
more categories was assessed by analysis of variance (ANOVA, for normally distributed 
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continuous variables) or the Kruskall-Wallis test (for non-normally distributed continuous 
variables). 
2.5.4. Association between prognostic factor and outcomes 
Kaplan-Meier analyses and curves, and regression models based on time-to-event 
data, were used to assess the association between potential prognostic factors and clinical 
outcomes. 
Associations with the risk of death were assessed using Cox proportional hazards 
models (187), and are presented as a hazard ratio (HR) with a 95% confidence interval (CI). 
Log-log plots (ln(-ln(survival)) versus survival time) were assessed for each variable to ensure 
that the proportional-hazards assumption was not violated.  
Associations with the risk of kidney failure were primarily assessed using competing-
risks regression models, using the Fine and Gray method to model the subdistribution hazard 
(188). This method is appropriate for the analysis of time-to-event data in the presence of a 
competing risk, defined as an event that impedes the occurrence of the event of interest. When 
modelling time to kidney failure, death is a competing risk because patients who die cannot 
later proceed to develop kidney failure. The association between each variable and the risk of 
kidney failure is presented as a subhazard ratio (SHR) with a 95% CI. 
An alternative approach to subdistribution hazard models in the presence of competing 
risks is to fit cause-specific hazard models. These were fitted and presented as supplemental 
results in tabular form in the appendices. Any tabulated results that differ significantly from 




2.5.4.1. Regression model development 
First, univariable models were used to assess the association between the potential 
prognostic factor and the clinical outcome, i.e. without adjustment for additional variables. 
Univariable associations are also presented for all other baseline variables. 
Multivariable regression models were then built to account for confounding and to 
assess the association of the factor with clinical outcomes after adjustment for established 
prognostic factors. Included variables were prespecified and not selected based on univariable 
analyses or automated stepwise variable selection procedures, avoiding biases caused by data-
dependent model selection. 
Given the issues associated with multiple testing and overfitting of models, 
interactions between the prognostic factor of interest and the other model covariates were not 
routinely tested for. In the few analyses where clinically plausible interactions were tested for, 
they are explicitly stated. 
 
2.5.4.2. Continuous variables 
Continuous variables were kept as continuous in all regression models to avoid the 
loss of information inherent in categorisation. Where it was felt to be potentially informative, 
models with categorised continuous variables are presented as a supplementary to, and not in 
place of, the primary models which retain the variable’s continuous nature. 
Potential non-linear associations between continuous variables and outcome were 
assessed by checking for an improvement in model fit using fractional polynomials (FP). In 
such models, for continuous variable x, powers (p) were selected from a set of eight (-2, -1, -
0.5, 0 [ln], 0.5, 1, 2, 3) and the model with FP of degree 1 (FP1, where LM/ is substituted for 
Lx) or degree 2 (FP2, where L"M/4 + L'M/! 	is substituted for Lx) with the best fit was 
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selected (189). Given the additional complexity, FP2 models were only used if they provided 
a significantly better model fit compared to the best FP1 model. 
Where FP models provide a better fit, graphs of risk (HR or SHR) versus the variable 
on its original scale are presented to aid the understanding of the non-linear relationship with 
outcome. 
2.5.5. Analysis of data from multiple studies 
Where analyses were performed on individual participant data amalgamated from 
multiple cohorts, a one-stage meta-analytic approach was used. Clustering was accounted for 
by stratifying the regression model by cohort, in which the baseline hazard is allowed to vary 
by cohort while the estimated coefficient for each predictor variable is assumed to be equal 
across cohorts (i.e. a fixed-effects model) (190). 
2.5.6. Missing data 
The number of missing values for each variable are reported in each chapter. Although 
commonly performed, complete case analysis, i.e. including only the cases with complete 
data, reduces the sample size available for analysis, and is statistically inefficient, especially 
in multivariable analyses where missing values in each of several variables can result in a 
large number of patients being excluded. In work presented in this thesis, data were missing 
in multiple variables, and in order to account for missing data in a way that allowed all 
patients to be included in the analyses, missing data were handled by multiple imputation. 
Given that there were different types of variables with missing data, multiple 
imputation was performed using chained equations, in which each variable is imputed using 
its own imputation model (191). For continuous variables, on the basis of their skewed 
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distributions, predictive mean matching was used rather than linear regression alone, with 
imputed values drawn from the ten nearest neighbours as recommended by Morris et al. 
(192). All categorical variables with missing values had more than two categories, and 
therefore values were imputed using multinomial logistic regression (augmented to avoid 
perfect prediction as recommended by White et al. (193)). 
The imputation models included all covariates to be included in the final Cox or 
competing-risks multivariable regression models, an outcome variable (for analyses of death 
this was a binary variable, and for kidney failure a categorical variable indicating censored, 
kidney failure, or death), and the cumulative hazard function (approximated by the Nelson-
Aalen estimate (191)). Where multiple imputation was performed for individual-level data 
amalgamated from multiple cohorts, a categorical study variable was also included in the 
imputation models. 
It has been recommended that the number of imputations created should be at least 
equal to the percentage of incomplete cases (191). Therefore, for the analyses presented in 
this thesis, the number of imputations was determined by the percentage of incomplete cases 
rounded up to the nearest five (e.g. if 17% participants had missing values in one or more 
variables, 20 imputations would be created). 
Following imputation, analyses were performed on each imputed dataset, before the 
estimates of coefficients and their standard errors were combined using Rubin’s rules (194). 
2.5.7. Sensitivity analyses 
The results of analyses from multiple imputation were compared to results from 





Stata 15 (StataCorp, College Station, Texas, US) was used to perform all statistical 
analyses and to create all graphs. Where user-written commands were used, they are 




CHAPTER III: SERUM FREE LIGHT CHAINS 
The work presented in this chapter aimed to address the hypotheses that higher 
concentrations of serum free light chains are associated with a higher risk of kidney failure 
and death in patients with chronic kidney disease (CKD). 
This work has been published in the article ‘The Association of Serum Free Light 
Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney 
Disease: Systematic Review and Individual Patient Data Meta-analysis,’ in Mayo Clinic 
Proceedings in 2017 (195), and presented in poster format at the American Society of 






To clarify the associations between serum combined (κ + λ) free light chain (cFLC) 
concentration and risk of kidney failure and death in patients with chronic kidney disease 
(CKD), by conducting a systematic review and individual patient data meta-analyses. 
Patients and Methods 
On December 28, 2016, a search was conducted using four databases (MEDLINE, Embase, 
CINAHL, and PubMed) and conference proceedings for studies presenting independent 
analyses of associations between serum cFLC concentration and kidney failure or death in 
patients with CKD. Study quality was assessed in five domains: sample selection, 
measurement, attrition, reporting, and funding. 
Results 
Five prospective cohort studies were included, judged moderate to good quality. In 
multivariable meta-analyses, serum cFLC concentration was independently associated with 
the risk of kidney failure (three studies, 2092 participants, median 5.7 years follow-up), with a 
non-linear association suggesting increased risk up to 150 mg/l, beyond which the risk does 
not increase further. A higher serum cFLC concentration was also independently associated 
with a higher risk of death (five studies, 3851 participants, median 4.1 years follow-up), again 
with a non-linear association. 
Conclusion 
Higher concentrations of non-clonal serum FLCs are independently associated with a higher 
risk of death and kidney failure in patients with CKD. Future work is needed to explore the 
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There are prognostic factors measurable in the serum of patients with CKD that are 
associated with the risk of kidney failure and death, the strongest being measures of kidney 
function such as creatinine concentration and the eGFR derived from it. Beyond these 
markers of kidney function, there is a desire to identify independent serum prognostic factors 
that may add incremental value in risk prediction models and risk stratification. Serum factors 
that have a direct causal role in the adverse outcomes associated with CKD are perhaps more 
likely to be able to provide this information and may represent novel treatment targets. 
For the various reasons outlined in this chapter, free light chains (FLC) deserve further 
investigation in this regard. Patients with CKD are exposed to relatively high serum 
concentrations of FLCs, which have numerous biological effects that are potentially 
deleterious and plausibly linked to kidney damage and the risk of death. 
3.2.1. Structure and physiology of FLCs 
Immunoglobulin (Ig) molecules consist of four chains: two identical heavy chains 
from one of five classes (gamma, alpha, mu, epsilon, or delta) and two identical light chains 
from one of two classes (kappa [κ] or lambda [λ]). Each heavy and light chain has a constant 




Figure 3.1. Structure of an immunoglobulin molecule 
Each immunoglobulin molecule consists of two heavy chains (shown in purple) and two light 
chains (shown in green), and each chain consists of constant (C) and variable (V) regions. 
The Fab portions of the Ig molecule bind antigen and the Fc portion binds to Fc 
receptors on effector cells such as B cells, natural killer cells, macrophages, neutrophils, and 
mast cells. 
The Ig isotype is determined by the class of heavy chain (IgG, IgA, IgM, IgE, or IgD), 
and the designation of Ig molecules also includes the type of light chain with which the heavy 
chains are associated, e.g. IgG-κ, IgA-λ. 
Immunoglobulin molecules are synthesised by plasma cells and other cells of the B 
cell lineage. Within B cells, light chains are produced in excess of heavy chains, such that 
only approximately 60% of synthesised light chains are incorporated into complete Ig 
molecules, and the remaining 40% are released into the blood as unbound FLCs (196). 
Approximately 500 mg per day of FLCs are produced, and there are approximately twice as 
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many κ-producing plasma cells than λ-producing cells (196). The clearance of FLCs is mainly 
renal, as described below, although there is a small contribution from the reticuloendothelial 
system (197). 
In the blood, κ FLCs generally exist as monomers (~25 kDa) and λ FLCs as dimers 
(~50 kDa), and their size permits filtration at the glomerulus. After glomerular filtration, they 
enter the proximal tubule, from where they are endocytosed by proximal tubular cells 
(mediated by the cell surface receptors megalin and cubulin), before degradation within 
lysosomes into their constituent amino acids which are transported back into the circulation 
(198, 199). The renal handling of FLCs is illustrated in Figure 3.2. 
 
Figure 3.2. Renal handling of free light chains 
Free light chains undergo glomerular filtration before being endocytosed and catabolized in 
proximal tubular cells. From reference (199). 
Given the smaller size of monomeric κ FLCs compared to dimeric λ FLCs, κ FLCs 
have a higher filtration rate and rate of renal clearance and thus a shorter serum half-life. 
Therefore, despite an approximate 2:1 ratio of κ to λ FLC production, serum κ FLC 
concentration is usually lower than λ FLC concentration, with a median serum κ/λ FLC ratio 
 
 81 
of approximately 0.6 (reference range 0.26 to 1.65) (200). A ratio outside of this reference 
range may signify monoclonal FLC production. 
The proximal tubular pathway for FLC catabolism is thought to process all FLCs 
filtered at the glomerulus (197). Although between 1 and 10 mg of FLCs are excreted in the 
urine per day in healthy individuals, these are thought to be secreted in the urinary tract 
alongside IgA as part of the mucosal defence system rather than originating from glomerular 
filtration (197). 
3.2.2. Serum FLCs in CKD 
As GFR declines, so does the renal clearance of FLCs, such that the serum FLC 
concentration increases progressively with each stage of CKD, as is shown in Figure 3.3. 
 
Figure 3.3. Box plot of serum FLC concentration by CKD stage 
CKD stages refer to the G stage, with 3a and 3b combined. Grey boxes are κ FLC, and white 
boxes are λ FLC. Con = healthy control population. From reference (201). 
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As renal clearance declines, the clearance of FLCs becomes more dependent on the 
reticuloendothelial pathway. This pathway, unlike renal clearance, shows no size preference 
and clears both κ and λ FLCs at the same rate, so that the serum half-life of κ FLCs 
approaches that of λ FLCs. Thus, the relative FLC concentrations change to reflect more 
closely the higher rate of κ production, and the serum κ/λ FLC ratio progressively increases 
with CKD stage, as shown in Figure 3.4 (201). 
 
Figure 3.4. Serum κ\λ FLC ratio by stage of CKD 
CKD stages refer to the G stage, with 3a and 3b combined. Con =healthy control population. 
From reference (201). 
Because of this, some patients with CKD may have a serum κ/λ FLC ratio above the 
general population reference range, even in the absence of monoclonal FLC production (202). 
Therefore a ‘renal reference range’ for serum κ/λ FLC ratio of 0.37 to 3.10 has been proposed 
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for patients with CKD (201, 202). The renal reference range is more sensitive and specific for 
the diagnosis of monoclonal disorders in patients with CKD (202-204). 
Serum FLCs may be measured as κ and λ FLCs separately or combined (κ + λ) FLC 
(cFLC). The serum κ\λ FLC ratio allows the detection of clonality. A rise in cFLC with a κ\λ 
ratio within the reference range is consistent with a non-clonal process, i.e. reduced clearance 
as is seen in CKD or increased production as is seen in various diseases associated with B cell 
activation and immune stimulation, such as infections, inflammation and autoimmune disease 
(205, 206). However, an abnormal κ\λ ratio with an increase in the involved FLC (i.e. a high 
ratio with increased κ FLC concentration, or a low ratio with increased λ FLC concentration) 
is a marker of a monoclonal process (monoclonal gammopathy). 
3.2.3. Serum FLCs and prognosis 
Serum cFLC concentration has been shown to have prognostic significance, including 
an independent association with the risk of death. There have been several studies showing 
that a higher non-clonal serum FLC concentration is associated with a higher risk of mortality 
in the general population. In nearly 16,000 individuals aged 50 years or older without a 
monoclonal disorder and with a median follow up of 12.7 years, those with a serum FLC 
concentration above the highest decile had a higher risk of death (risk ratio 2.07 [95% CI 1.91 
to 2.24], after adjustment for age, sex, and serum creatinine) (207). The increased mortality 
was not restricted to any specific cause of death, with a higher risk of death observed in nearly 
all categories of the International Statistical Classification of Diseases. Another study in 
nearly 5000 individuals from the general population also showed a higher risk of death with a 
higher serum cFLC concentration, again without an association to any particular category of 
cause of death (208). 
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In addition to having prognostic significance in the general population, serum cFLC 
concentration has been shown to have an independent association with risk of death in various 
non-renal diseases, including heart failure (209, 210), rheumatoid arthritis (211), and COPD 
(212). 
As described in the previous section, CKD is associated with higher serum FLC 
concentrations. Given the independent association between serum cFLC concentration and 
risk of death observed in the general population and other non-renal diseases, it is plausible 
that serum cFLC have a role in the higher mortality risk associated with CKD. Several studies 
have examined the association between serum cFLC concentration and risk of death in 
cohorts of patients with CKD but have produced conflicting results. Thus, further work is 
required to answer this question. 
It is also possible that the higher serum FLC concentrations observed in CKD have a 
role in the risk of kidney failure. It is well established that high levels of monoclonal FLCs, 
present in diseases such as multiple myeloma, can cause kidney damage through various 
pathways but it is not known whether high levels of non-clonal FLCs are associated with 
kidney damage and the risk of kidney failure. Two studies have assessed this, but, again, the 
results are conflicting. 
It is therefore still unknown whether higher concentrations of non-clonal serum FLCs 
are associated with a higher risk of kidney failure or death in patients with CKD. A systematic 
review and meta-analysis of individual patient data was performed to address these questions, 




The following pre-specified hypotheses were addressed: 
1. Higher concentrations of non-clonal serum cFLC are associated with a higher risk of 
kidney failure in patients with CKD; 
2. Higher concentrations of non-clonal serum cFLC are associated with a higher risk of 




This meta-analysis was prospectively registered on PROSPERO, an international 
database of prospectively registered systematic reviews (registration number: 
CRD42015025195) (213). Several stages of the meta-analysis, such as the literature search, 
data extraction, and study assessment process, were performed independently by two 
researchers, allowing a comparison of independently obtained results with discussion and 
agreement before moving on to the next stage. Where the term ‘two researchers’ is used, it 
refers to the author of this thesis and Dr Simon Fraser (Clinical Lecturer in Public Health, 
Academic Unit of Primary Care and Population Sciences, Faculty of Medicine, University of 
Southampton). 
3.4.1. Eligibility criteria 
Two researchers independently performed a literature search to identify quantitative 
studies (not case reports or qualitative studies) which had to contain all of the following to be 
included: 
1. Participants with CKD. Participants were excluded at an individual level if they had 
received kidney replacement therapy (dialysis or a kidney transplant), or if they had a 
monoclonal gammopathy (e.g. multiple myeloma). 
2. A measure of serum FLC concentration (κ and λ individually or cFLC). 
3. Kidney failure or death as outcomes. 
4. An estimate of the association between serum FLC concentration and the above 
outcomes. 




3.4.2. Search strategy 
The search included MEDLINE, Embase, PubMed, CINAHL, the Cochrane library, 
the Centre for Reviews and Dissemination, the ClinicalTrials.gov register, the conference 
proceedings from three major nephrology conferences from 2012-2015 (UK Renal 
Association, European Renal Association/European Dialysis and Transplant Association, and 
the American Society of Nephrology Kidney Week), and the reference lists of identified 
eligible studies. The last search was performed on 28 December 2016. 
The search strategy incorporated free text and MeSH (Medical Subject Headings) 
terms for CKD and FLCs, and excluded studies with myeloma in the title. As an example, the 
search strategy for MEDLINE (1946-present) is presented in Table 3.1. 
Table 3.1. Search strategy for MEDLINE 
Stage Search terms 
1 (Chronic kidney disease* OR CKD* OR chronic renal failure* OR renal failure* 
OR renal insufficiency, chronic OR renal insufficiency*) as free text words (.mp) 
2 MeSH subject heading: exp Renal Insufficiency, Chronic/ 
3 1 OR 2 
4 (light chain* OR immunoglobulin* OR light-chain* OR Ig* OR kappa-
immunoglobulin* OR kappa immunoglobulin* OR lambda-immunoglobulin* OR 
lambda immunoglobulin*) as free text words (.mp) 
5 MeSH subject heading: exp Immunoglobulin Light Chains 
6 4 OR 5 
7 free.mp 
8 polyclonal.mp 
9 7 OR 8 
10 6 AND 9 
11 3 AND 10 
12 myeloma*.m_titl. 
13 11 NOT 12 
14 Limit to humans and remove duplicates 
15 Screening titles and abstracts 
The search strategy included MeSH (Medical Subject Headings) terms and free text. 
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Two researchers independently assessed each potentially eligible study, and any 
differences of opinion regarding eligibility were resolved by discussion. 
3.4.3. Data collection 
The corresponding author of each eligible study was contacted by email to request 
individual participant data (IPD) and anonymised IPD were obtained for all studies for the 
variables shown in Table 3.2. An assessment of the IPD integrity was performed as per 
Section 2.5.1. 
Table 3.2. Variables collected for all eligible studies 
Variable Notes 




DM Coded diagnosis: yes/no 
CVD Coded diagnosis: yes/no 
Systolic BP mmHg 
Urine ACR mg/mmol 
eGFR ml/min/1.73 m2 (MDRD) 
Serum albumin g/dl 
Serum calcium mmol/l 
Serum phosphate mmol/l 
Use of RAASi Yes/no 
Kidney failure 1.Yes/no 
2.Time-to-kidney failure (months) 
Death 1.Yes/no 
2.Time-to-death (months) 
Time to last follow-up Months, for censoring 
Variables included in the anonymised IPD collected for all eligible studies. RAASi = renin-
angiotensin-aldosterone system inhibitors. 
Of note, eGFR calculated by the four-variable MDRD equation was used in these 
analyses, as not all studies had eGFR calculated by the CKD-EPI equation. 
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3.4.4. Risk of bias assessment 
Two researchers independently assessed the risk of bias in each study using a tool 
similar to that recommended in the Cochrane Handbook, attributing a low, moderate or high 
risk of bias based on sample selection, measurement, attrition, reporting and funding (214). 
This process was informed by systematically extracting data from and reviewing each study 
using a standardized form based on the STROBE Statement checklist, including study date, 
location, primary aim, participant characteristics (number, CKD stage), setting (e.g. primary 
or secondary care), main outcome, sampling method and potential sampling bias, potential 
confounders, presence of sample size calculation, main results (measure and magnitude of 
effect), method of serum FLC analysis, missing data, loss to follow up, and evidence of 
reporting bias including funding source (215). Final study quality status was then agreed by 
discussion. 
3.4.5. Data synthesis 
IPD were amalgamated, and patient characteristics were summarized in tabular form, 
as per Section 2.5.2, including the number of missing values for each variable. Relationships 
between serum cFLC concentration and other baseline characteristics were assessed 
statistically as per Section 2.5.3, with graphs presented for non-linear relationships. 
The primary analyses were performed using a one-stage approach, i.e. the associations 
between serum cFLC concentration and kidney failure and death were estimated from all data 
in all studies simultaneously. This approach allows more modelling flexibility than the 
traditional two-stage approach, for example, fitting non-linear effects. All models were 
stratified by study, to account for clustering of patients within studies (Section 2.5.5). Fixed-
effects univariable and multivariable models were fitted, using subdistribution hazard models 
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for the analysis of time to kidney failure, handling death as a competing risk. Cause-specific 
hazard models were also fitted and are presented in Appendix 5. Cox proportional hazards 
regression was used for the analysis of time to death. All multivariable models were pre-
specified. 
To allow the plotting of forest plots and assessment of statistical heterogeneity by I2, a 
supplementary two-stage analysis was performed, in which estimates of the association 
between serum cFLC concentration and adverse outcomes were generated for each study 
separately, before combining these estimates using the fixed-effects inverse-variance method. 
Missing data were managed by multiple imputation, as per section 2.5.6. As 23% of 
cases had missing data in at least one variable, 25 imputations were used. 
3.4.6. Assays 
All included studies measured serum FLC concentration using the Freelite® 




3.5.1. Study selection and IPD obtained 
The numbers of studies screened, assessed for eligibility, and included, with reasons 
for exclusions, are shown in the flow diagram in Figure 3.5. 
 
Figure 3.5. Flow diagram of studies screened, assessed, and included 
 
Five studies were included, all of which were prospective cohort studies of patients 
with CKD (216-220). All five had presented an estimate of the association between serum 
FLC and the risk of death, and two presented an estimate of the association with kidney 
failure. IPD were sought and obtained from all five studies. 
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3.5.2. Study characteristics 
The characteristics of each included study, including the number of participants, basic 
demographic data, and follow-up time, are presented in Table 3.3. 















Assi at al. 
2015 (216) 
1695 2008-10 74 39 3 114.5 
Desjardins et 




2006-7 67 62 2-5 88.2 





1997-99 61 65 3-5 





al. 2014 (219) 
848 2006-7 60 54 1-5 63 
Ritchie et al. 
2015 (220) 
872 2004-10 66 62 3-5 41.4 
*Average follow-up is presented as the median, except for Haynes et al., which is presented as 
the mean. MGUS = monoclonal gammopathy of undetermined significance. 
All studies were conducted in the UK apart from the study by Desjardins et al. which 
was conducted in France, and all studies recruited patients from secondary care apart from 
that by Assi et al. which recruited from primary care. The study by Haynes et al. included 35 
participants with MGUS, and that by Desjardins et al. included 44 participants on dialysis. 
These participants were excluded from the meta-analyses.  
3.5.3. Data integrity 
The IPD obtained from each study were assessed as per Section 2.5.1, and there were 
no critical data issues identified. 
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3.5.4. Risk of bias within studies 
Four studies were judged to have a moderate overall risk of bias, and one study was 
judged to have a low overall risk of bias. This risk of bias assessment across five domains and 
an overall judgement are shown in Figure 3.6. 
 
Figure 3.6. Risk of bias within each study 
Risk of bias in each domain and overall was judged to be low (green), moderate (yellow), or 
high (red). 
3.5.5. Results of individual studies 
The main results reported for each study are presented in Table 3.4. Two studies 
reported the association with kidney failure. An independent association between serum cFLC 
concentration and kidney failure was observed Ritchie et al. but not by Haynes et al. All five 
studies reported the association with death. The results obtained by Assi et al., Hutchison et 
al., and Ritchie et al. suggest an independent association between serum cFLC concentration 
and death whereas those by Desjardins et al. and Haynes et al. do not. 
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This section reports the results obtained from the IPD meta-analysis. 
 
3.5.6.1. Baseline characteristics 
A summary of basic demographic characteristics, co-morbidities, serum cFLC 
concentration, and other standard prognostic variables from the amalgamated IPD is provided 
in Table 3.5, along with numbers of missing values. 
Table 3.5. Summary of baseline data 
Variable Median (IQR) or N(%) Missing data (N[%]) 
Age (years) 70 (60 to 77) 4 (0.1) 
Sex  4 (0.1) 
Male 1942 (50.5)  
Female 1905 (49.5)  
Ethnicity  108 (2.8) 
White 3452 (92.2)  
Other 291 (7.8)  
Co-morbidities   
DM 853 (22.3) 23 (0.6) 
CVD 1281 (33.5) 28 (0.7) 
Systolic BP (mmHg) 137 (124 to 151) 151 (3.9) 
Urine ACR (mg/mmol) 2.6 (0.3 to 23.1) 603 (15.7) 
eGFR (ml/min/1.73 m2) 43.3 (27.7 to 55.3) 19 (0.5) 
Serum albumin (g/dl) 42 (39 to 44) 49 (1.3) 
Serum calcium (mmol/l) 2.30 (2.22 to 2.39) 49 (1.3) 
Serum phosphate (mmol/l) 1.16 (1.02 to 1.32) 139 (3.6) 
RAASi 2343 (62.0) 69 (1.8) 
Serum cFLC (mg/l) 49.4 (33.7 to 80.0) 16 (0.4) 
Categorical factors are summarised as N with percentage, and continuous factors as the 
median with interquartile range. 
The median serum cFLC concentration was 49.4 (IQR 33.7 to 80.0) mg/l, and the 




Figure 3.7. Histogram of serum cFLC concentration 
Histogram illustrating the skewed distribution of serum cFLC concentration. 
3.5.6.2. Relationship between cFLC and other prognostic factors 
Statistical assessment of the relationships between serum cFLC concentration and 





















Table 3.6. Relationships between cFLC and other baseline factors 
Associations Kendall’s τ or Median (IQR) P 
Age -0.004 0.73 
Sex  <0.001 
Female 42.9 (29.7 to 66.9)  
Male 57.8 (39.7 to 90.1)  
Ethnicity  <0.001 
White 47.5 (33.1 to 75.1)  
Non-White 71.3 (44.5 to 121.8)  
DM  <0.001 
Yes 63.7 (43.1 to 97.8)  
No 46.2 (32.0 to 73.6)  
CVD  <0.001 
Yes 54.9 (38.1 to 89.5)  
No 46.7 (32.0 to 75.4)  
Systolic BP 0.122 <0.001 
Urine ACR 0.413 <0.001 
eGFR -0.546 <0.001 
Serum albumin -0.069 <0.001 
Serum calcium -0.136 <0.001 
Serum phosphate 0.193 <0.001 
RAASi  0.90 
Yes 49.4 (34.6 to 76.7)  
No 49.2 (32.2 to 84.6)  
The relationship between serum cFLC concentration and other continuous variables is 
presented as Kendall’s τ with associated P-value. Relationships with categorical variables 
are shown as the median for each category with a P-value from a Mann-Whitney U test. 
Serum cFLC concentrations were significantly higher in males, those of non-White 
ethnicity, and those with DM or CVD. There was a weak positive correlation with urine ACR 
and very weak positive correlations with systolic BP and serum phosphate. There was a 
moderate negative correlation with eGFR and very weak negative correlations with serum 
albumin and serum calcium. 
In a multivariable analysis, variables that had an independent relationship with serum 
cFLC concentration were sex, ethnicity, serum albumin, eGFR, and urine ACR. Male sex 
(males 59.8 [45.3 to 83.3] mg/l; females 42.2 [32.0 to 61.8] mg/l; P<0.001), non-White 
ethnicity (non-White 77.5 [59.6 to 111.5] mg/l; White 49.0 [36.2 to 71.0]; P<0.001), lower 
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serum albumin (Figure 3.8), lower eGFR (Figure 3.9), and higher urine ACR (Figure 3.10) 
were associated with a higher serum cFLC concentration.  
 
Figure 3.8. Relationship between serum albumin and serum cFLC concentration 
Scatter plot. The line represents the predicted serum cFLC concentration with a 95% CI from 




Figure 3.9. Relationship between eGFR and serum cFLC concentration 
Scatter plot. The line represents the predicted serum cFLC concentration with a 95% CI from 
an FP2 model with powers 0 and 1. 
 
Figure 3.10. Relationship between urine ACR and serum cFLC concentration 
Scatter plot. The line represents the predicted serum cFLC concentration with a 95% CI from 




















3.5.6.3. Kidney failure 
Although only two studies had reported progression to kidney failure (Haynes et al. 
and Ritchie et al.), a third study (Hutchison et al.) had also collected outcome data for kidney 
failure, and these data were included in the meta-analysis. 
Therefore, IPD for 2092 participants from three studies were included. During a 
median follow-up time of 5.7 years, 492 (23.5%) participants experienced kidney failure, with 
an overall kidney failure rate of 5.9 per 100 person-years. 
The univariable associations and the multivariable model for kidney failure are shown 
in Table 3.7. 




SHR 95% CI P SHR 95% CI P 
Age 1.00a 1.00 to 1.00 <0.001 1.00a 1.00 to 1.00 <0.001 
Male sex 0.78 0.65 to 0.93 0.007 0.92 0.76 to 1.11 0.37 
Non-White ethnicity 1.55 1.21 to 1.99 0.001 1.17 0.89 to 1.54 0.27 
DM 1.22 0.99 to 1.49 0.06 0.94 0.76 to 1.17 0.60 
CVD 0.83 0.69 to 1.01 0.07 0.98 0.80 to 1.21 0.86 
Systolic BP 1.15 1.05 to 1.27 0.004 1.11 1.00 to 1.24 0.048 
Urine ACR 15.18b 9.49 to 24.30 <0.001 1.39h 1.25 to 1.55 <0.001 
 0.12c 0.06 to 0.22 <0.001 1.01i 1.01 to 1.02 <0.001 
eGFR 0.00d 0.00 to 0.00 <0.001 0.00b 0.00 to 0.00 <0.001 
 127669e 8940 to 1823193 <0.001    
Serum albumin 0.99a 0.98 to 0.99 <0.001 1.18 1.05 to 1.31 0.004 
Serum calcium 0.47a 0.39 to 0.56 <0.001 0.86 0.78 to 0.96 0.005 
 1.77f 1.55 to 2.02 <0.001    
Serum phosphate 73.21d 38.85 to 137.96 <0.001 1.30 1.15 to 1.48 <0.001 
 0.58e 0.50 to 0.67 <0.001    
RAASi 1.28 1.06 to 1.54 0.011 1.06 0.86 to 1.31 0.58 
Serum cFLC 0.19g 0.16 to 0.23 <0.001 1.76h 1.33 to 2.31 <0.001 
    0.51i 0.38 to 0.69 <0.001 
For continuous variables with a linear association, SHR is per +1 SD. Two rows for a 
continuous variable indicate the SHR for each power of the degree-2 fractional polynomial 
transformation. Fractional polynomial transformations are denoted by: a = x3; b = x0.5; c = 
x0.5ln(x); d = x; e = x2; f = x3ln(x); g = x-1; h = ln(x); i = (ln(x))2. 
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On univariable analysis, a higher serum cFLC concentration was associated with a 
higher risk of kidney failure. The relationship was non-linear and is illustrated in Figure 3.11. 
 
Figure 3.11. Unadjusted SHR for kidney failure according to serum cFLC concentration 
Subhazard ratio with 95% CI, relative to 50 mg/l. 
Other variables associated with a higher risk of kidney failure on univariable analysis 
were younger age (non-linear, Figure 3.12), female sex, non-White ethnicity, higher systolic 
BP, higher urine ACR (non-linear, Figure 3.13), lower eGFR (non-linear, Figure 3.14), lower 
serum albumin (non-linear, Figure 3.15), lower serum calcium (non-linear, Figure 3.16), 
lower serum phosphate (non-linear, Figure 3.17), and the use of RAASi. Diagnoses of DM 



































Figure 3.12. Unadjusted SHR for kidney failure according to age 
SHR with 95% CI, relative to 70 years. 
 
Figure 3.13. Unadjusted SHR for kidney failure according to urine ACR 















































Figure 3.14. Unadjusted SHR for kidney failure according to eGFR 
SHR with 95% CI, relative to 45 ml/min/1.73 m2. 
 
Figure 3.15. Unadjusted SHR for kidney failure according to serum albumin 























































Figure 3.16. Unadjusted SHR for kidney failure according to serum calcium 
SHR with 95% CI, relative to 2.3 mmol/l. 
 
Figure 3.17. Unadjusted SHR for kidney failure according to serum phosphate 





























































In the multivariable model (Table 3.7), a higher serum cFLC concentration remained 
independently associated with an increased risk of kidney failure after adjustment for age, 
sex, ethnicity, DM, CVD, systolic BP, urine ACR, eGFR, serum albumin, serum calcium, 
serum phosphate, and use of RAASi. The association was non-linear, as shown in Figure 
3.18, with a graded increase in the risk of kidney failure up to a serum cFLC concentration of 
approximately 150 mg/l. Beyond 150 mg/l, the risk does not appear to increase further. 
 
Figure 3.18. Adjusted SHR for kidney failure according to serum cFLC concentration 
SHR with 95% CI, relative to 50 mg/l, from the multivariable model in Table 3.7. 
A forest plot showing the risk of kidney failure associated with a higher serum cFLC 































Figure 3.19. Forest plot for risk of kidney failure 
Risk of kidney failure is per +1 SD in serum cFLC concentration, adjusted for age, sex, 
ethnicity, DM, CVD, systolic BP, urine ACR, eGFR, serum albumin, serum calcium, serum 
phosphate, and use of RAASi. 
Other baseline factors associated with a higher risk of kidney failure in the 
multivariable model (Table 3.7) were younger age (non-linear, Figure 3.20), higher systolic 
BP, higher urine ACR (non-linear, Figure 3.21), lower eGFR (non-linear, Figure 3.22), higher 
serum albumin, lower serum calcium, and higher serum phosphate. Sex, ethnicity, DM, CVD, 




Figure 3.20. Adjusted SHR for kidney failure according to age 
SHR with 95% CI, relative to 70 years, from the multivariable model in Table 3.7. 
 
Figure 3.21. Adjusted SHR for kidney failure according to urine ACR 


















































Figure 3.22. Adjusted SHR for kidney failure according to eGFR 
SHR with 95% CI, relative to 45 ml/min/1.73 m2, from the multivariable model in Table 3.7. 
3.5.6.4. Death 
Data for 3851 participants from all five studies were included in the analyses for 
death, with a median follow-up time of 4.1 years. 628 (16.31%) participants died, with an 
overall death rate of 4.3 per 100 person-years. Mean survival was estimated to be 26.1 years. 
The univariable associations and the multivariable model for the risk of death are 



























HR 95% CI P HR 95% CI P 
Age 2.89 2.57 to 3.25 <0.001 2.28 2.01 to 2.60 <0.001 
Male sex 1.61 1.36 to 1.91 <0.001 1.31 1.10 to 1.57 0.003 
Non-White 
ethnicity 
0.68 0.47 to 0.97 0.033 0.79 0.55 to 1.15 0.22 
DM 1.63 1.38 to 1.94 <0.001 1.26 1.06 to 1.51 0.009 
CVD 2.77 2.35 to 3.26 <0.001 1.68 1.42 to 1.99 <0.001 
Systolic BP 0.00a 0.00 to 0.00 <0.001 0.99 0.91 to 1.07 0.74 
 74002b 216 to 2.53e+07 <0.001    
Urine ACR 1.05c 1.01 to 1.08 0.004 0.89 0.79 to 1.02 0.09 
eGFR 0.00d 0.00 to 0.01 <0.001 0.77 0.66 to 0.90 0.001 
Serum albumin 0.99e 0.98 to 0.99 <0.001 0.55f 0.00 to 92.34 0.82 
    2.12e+08g 2039 to 2.21e+13 0.001 
Serum calcium 0.84 0.78 to 0.92 <0.001 0.99 0.91 to 1.07 0.75 
Serum phosphate 1.22 1.13 to 1.32 <0.001 1.13 1.02 to 1.24 0.022 
RAASi 0.85 0.72 to 1.00 0.054 0.93 0.78 to 1.10 0.40 
Serum cFLC 3.82c 3.15 to 4.63 <0.001 5.83a 3.28 to 10.36 <0.001 
 0.97e 0.94 to 0.99 0.010 0.96e 0.93 to 0.99 0.009 
For continuous variables with a linear association, HR is per +1 SD. Two rows for a 
continuous variable indicate the HR for each power of the degree-2 fractional polynomial 
transformation. Fractional polynomial transformations are denoted by: a = x0.5; b = x0.5ln(x); 
c = ln(x); d = x2; e = x3; f = x-2; g = x-2ln(x). 
A higher serum cFLC concentration was associated with a higher risk of death on 




Figure 3.23. Unadjusted HR for death according to serum cFLC concentration 
Hazard ratio with 95% CI, relative to 50 mg/l. 
Other factors associated with a higher risk of death on univariable analysis were older 
age, male sex, White ethnicity, DM, CVD, higher systolic BP (non-linear, Figure 3.24), 
higher urine ACR (non-linear, Figure 3.25), lower eGFR (non-linear, Figure 3.26), lower 
serum albumin (non-linear, Figure 3.27), lower serum calcium, and higher serum phosphate. 



























Figure 3.24. Unadjusted HR for death according to systolic BP 
HR with 95% CI, relative to 135 mmHg. 
 
Figure 3.25. Unadjusted HR for death according to urine ACR 
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Figure 3.26. Unadjusted HR for death according to eGFR 
HR with 95% CI, relative to 45 ml/min/1.73 m2. 
 
Figure 3.27. Unadjusted HR for death according to serum albumin 












































In the multivariable model (Table 3.8), a higher serum cFLC concentration remained 
independently associated with a higher risk of death after adjustment for age, sex, ethnicity, 
DM, CVD, systolic BP, urine ACR, eGFR, serum albumin, serum calcium, serum phosphate, 
and the use of RAASi. Again, the association was non-linear and is shown in Figure 3.28. 
 
Figure 3.28. Adjusted HR for death according to serum cFLC concentration 
HR with 95% CI, relative to 50 mg/l, from the multivariable model in Table 3.8. 
A forest plot showing the risk of death associated with a higher serum cFLC 






















Figure 3.29. Forest plot for risk of death 
Risk of death per +1 SD in serum cFLC, adjusted for age, sex, ethnicity, DM, CVD, systolic 
BP, urine ACR, eGFR, serum albumin, serum calcium, serum phosphate, and use of RAASi. 
Other factors significantly associated with a higher risk of death in the multivariable 
model (Table 3.8), were older age, male sex, DM, CVD, lower eGFR, lower serum albumin 
(non-linear, Figure 3.30), and higher serum phosphate. Ethnicity, systolic BP, urine ACR, 




Figure 3.30. Adjusted HR for death according to serum albumin 



























This systematic review and meta-analysis of IPD examined the hypotheses that higher 
serum cFLC concentrations in patients with CKD are associated with a higher risk of kidney 
failure and death, and the results are consistent with these hypotheses. 
Five moderate-to-good quality prospective cohort studies were included that 
incorporated patients across the full spectrum of pre-dialysis CKD (216-220). There was an 
independent association between serum cFLC concentration and the risk of both kidney 
failure and death in analyses that included established prognostic factors. 
Analysis of the data showed that eGFR was a significant determinant of serum cFLC 
concentration, which increased as eGFR decreased, consistent with previously published 
results (201, 216-218, 220). Sex, ethnicity, serum albumin, and urine ACR were also shown 
to be independent determinants of serum cFLC concentration, relationships that have been 
demonstrated in these data in their original studies (216, 218, 220). 
 
3.6.1. Kidney failure 
Two studies had reported an estimate of the association between serum cFLC 
concentration and the risk of kidney failure (218, 220). However, these studies reported 
inconsistent results, and it remained unknown whether an independent association existed. By 
incorporating additional IPD from a third study and applying a uniform pre-specified analysis 
across the data from all cohorts, this meta-analysis provides the most persuasive evidence to 
date on serum cFLC concentration as a risk factor for kidney failure in CKD. 
The results of the meta-analysis show that a higher serum cFLC concentration is 
independently associated with a higher risk of kidney failure in patients with CKD after 
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adjustment for age, sex, ethnicity, DM, CVD, systolic BP, urine ACR, eGFR, serum albumin, 
serum calcium, serum phosphate, and use of RAASi. Further, the risk appears to increase with 
serum cFLC concentration up to a concentration of approximately 150 mg/l, beyond which 
the risk plateaus. 
The results of this meta-analysis do not prove that high serum cFLC concentrations 
have a causal role in the risk of kidney failure, and to date, there are no published studies that 
report a direct mechanism for non-clonal FLCs in kidney injury. However, there are 
biologically plausible mechanisms by which high concentrations of serum FLCs may 
exacerbate kidney damage in CKD, thus increasing the risk of progression to kidney failure. 
First, it is well established that monoclonal FLCs can cause direct kidney injury in 
multiple myeloma, B-cell lymphoproliferative disorders, or monoclonal gammopathy of renal 
significance. In these disorders, the FLCs can cause kidney disease through various pathways 
that can result in deposition diseases, cast formation, or tubular toxicity. The latter may be 
caused by the induction of pathways linked with inflammation, apoptosis, and fibroblastic 
differentiation (221-224). 
Second, in CKD, it has been shown that non-clonal FLCs can bind with uromodulin to 
form tubular casts, and the number of FLC-containing casts positively correlates with indices 
of chronic kidney damage and interstitial macrophage numbers, and inversely correlates with 
capillary density (225). It has been suggested that non-clonal FLCs in CKD might promote 
cast formation in the distal tubules, leading to interactions between uromodulin and 
macrophages and the promotion of fibrosis (225). Another study observed that in patients 
with CKD, there is a significant deposition of FLCs in the renal tubules, the degree of which 
correlates with the degree of renal impairment and interstitial fibrosis (226). 
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Third, FLCs are biologically active molecules, with enzymatic activity, binding of 
various intra- and extra-cellular proteins, and binding to various cells such as mesangial cells, 
B-cells, and mast cells (227). Again, although there is no direct evidence to show any of these 
biological activities of FLCs play a specific role in the risk of kidney failure, there are 
plausible mechanisms by which they might, such as the activation of mast cells which can 
contribute to the development of interstitial fibrosis (228). 
3.6.2. Death 
All five included studies presented an estimate of the association between serum FLCs 
and the risk of death. Three studies observed an independent association with death, while 
two studies did not. Therefore it remained unknown whether non-clonal serum FLC 
concentration is associated with mortality in patients with CKD. 
The meta-analysis of IPD from the five studies demonstrated that a higher serum 
cFLC concentration was associated with a higher risk of death after adjustment for age, sex, 
ethnicity, DM, CVD, systolic BP, urine ACR, eGFR, serum albumin, serum calcium, serum 
phosphate, and the use of RAASi. 
Higher serum cFLC concentrations may reflect changes in the non-renal determinants 
of its concentration, such as B-cell stimulation and activation and reticuloendothelial health, 
which may themselves be associated with the risk of death. However, there are plausible 
mechanisms through which FLCs themselves, through their multitude of biological activities, 
may have a causal role in the higher risk of death. Serum FLCs isolated from patients with 
kidney disease have been shown to abrogate essential functions of neutrophils, including 
chemotaxis (229, 230). They also inhibit neutrophil apoptosis which may interfere with the 
resolution of inflammation, thus perpetuating a chronic inflammatory state, which is 
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associated with adverse outcomes in patients with CKD (229-231). Further, FLCs activate 
mast cells which may accelerate both atherosclerosis and myocardial fibrosis, and indeed 
serum cFLC concentration has previously been shown to correlate with cardiovascular risk in 
both type 1 and type 2 DM (227, 232-234). 
The association between serum cFLC concentration and risk of death observed in this 
meta-analysis is consistent with general population studies identifying an association between 
elevated serum FLCs and mortality in individuals without CKD (207, 235). However, 
contrary to our findings in patients with pre-dialysis CKD, a study of patients with kidney 
failure being treated with haemodialysis found an inverse relationship between serum cFLC 
concentration and death, i.e. a higher serum cFLC concentration was associated with a lower 
risk of death (236). The authors of that study speculated that higher serum cFLC 
concentrations may reflect less uraemia-related bone marrow dysfunction and that increased 
serum FLC concentrations may be associated with improved defence against infection. 
Further work is needed in the haemodialysis population to validate that study’s findings. 
 
The renal clearance of FLCs and the association between serum cFLC concentration 
and kidney function was described in Section 3.2.2. The associations between serum cFLC 
concentration and adverse outcomes demonstrated in this meta-analysis may reflect a residual 
confounding effect of kidney function. However, there is good supportive evidence for a truly 
independent association between serum FLCs with adverse outcomes. First, the significant 
association between serum cFLC concentration and adverse outcomes remained after 
adjustment for creatinine-based eGFR. Although it has been suggested that other filtration 
markers such as cystatin C, beta-trace protein (BTP), and beta-2-microglobulin (B2M) may 
provide more accurate estimates of GFR, a patient-level meta-analysis showed limited 
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additional value for these markers for outcome assessment in analyses that included 
creatinine-based eGFR (237). 
Second, while serum cFLC concentration is in part determined by kidney function, 
other factors are important, such as B-cell and plasma cell stimulation and activation, and 
non-renal clearance through the reticuloendothelial system, which accounts for a greater 
proportion of clearance in CKD as kidney function declines (238). The degree of correlation 
with kidney function, and the large variability that remains in serum cFLC concentration after 
adjustment for kidney function, provides evidence for the significant contribution of these 
non-renal factors in the determination of serum cFLC concentration. 
Third, the association between serum cFLC concentration and death has been 
demonstrated in studies of the general population with normal kidney function and studies of 
non-renal disease, supporting the theory that FLCs have adverse effects via mechanisms other 
than through an association with kidney impairment (207, 209, 212, 235, 239). It remains 
possible that even in these groups without kidney disease, the serum cFLC concentration 
partially reflects the spectrum of kidney function. 
Finally, there are biologically plausible mechanisms for a relationship between serum 
FLCs and adverse outcomes, such as through their association with inflammation and 
reticuloendothelial system health. 
3.6.3. Strengths and limitations 
The strengths of this meta-analysis include a broad search strategy, the use of robust 
methods for study selection and quality assessment, and the inclusion of IPD from all eligible 
studies. Models were pre-specified and measures to reduce the risk of bias, including robust 
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statistical methods such as including non-linear associations and the use of multiple 
imputation to address missing data, were used. 
Limitations include a limited search of grey literature, such that studies may have been 
missed if they were only reported as conference abstracts. Further, data were not available for 
other markers of systemic inflammation, such as C-reactive protein, or other prognostic 
factors such as the cause of CKD. 
3.6.4. Future research 
Further research is needed to identify the biological basis for the associations between 
serum FLCs and adverse outcomes in CKD. If evidence emerges of a causal role in the risk of 
kidney failure and death, then FLCs as a treatment target may be explored. 
Further, the utility of serum cFLC concentration as a biomarker for enhanced risk 
prediction and risk stratification should be assessed. Serum FLC concentration, unlike many 
other biomarkers assessed as prognostic factors, are now routinely available for measurement 
in clinical practice. An initial assessment of the incremental value of serum cFLC 
concentration, when added to existing prognostic factors, could be performed in existing data. 
However, a robust assessment to produce generalisable results and a cost-benefit analysis 




The serum cFLC concentration in patients with CKD without monoclonal disease is 
an independent prognostic factor for the risks of kidney failure and death. The nature of the 
associations, in particular, whether there is a causal relationship, in which case FLCs may 
ultimately be assessed as treatment targets, requires further research. Further work is also 
required to assess the potential use of serum cFLC concentration in risk prediction and 
stratification in patients with CKD.
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CHAPTER IV: URINE FREE LIGHT CHAINS 
The work presented in this chapter aimed to address the hypotheses that higher 
concentrations of urine free light chains (FLC) are associated with a higher risk of kidney 
failure and death in patients with chronic kidney disease (CKD). It has previously been shown 
that serum FLC concentration correlates with urine FLC excretion and following on from the 
results of Chapter III, an assessment of urine FLC as an independent prognostic factor in 
CKD was conducted. 
This work has been published in the article ‘Association between urinary free light 
chains and progression to end stage renal disease in chronic kidney disease,’ in PLOS ONE in 





Urine free light chain (FLC) excretion correlates with serum FLC concentration, which is an 
independent prognostic factor in CKD. Further, urinary FLCs may reflect tubular exposure to 
potentially nephrotoxic FLCs. As assessment was made of the association between urine FLC 
and kidney failure and death in patients with CKD. Further, the incremental value of urine 
FLCs when added to an established model for the prediction of kidney failure was assessed. 
Materials and Methods 
Five hundred fifty-six patients with CKD and urine FLC measurements from a prospective 
cohort study were included, with a median follow-up time of 6.1 years. The association 
between urine kappa/creatinine (κCR) and lambda/creatinine (λCR) ratios and development of 
kidney failure was assessed by competing-risks regression (to account for the competing risk 
of death). The change in C-statistic and integrated discrimination improvement were used to 
assess the incremental value of adding urine κCR or λCR to the Kidney Failure Risk Equation 
(KFRE). Cox proportional hazards regression was performed to assess the association with 
death. 
Results 
One hundred ninety-one participants developed kidney failure, and 129 participants died. 
Higher urine κCR and λCR were associated with a higher risk of kidney failure, but the 
associations lost significance after adjustment for standard prognostic factors. Neither κCR 
nor λCR provided incremental value when added to the KFRE for estimating the risk of 
kidney failure at two years. Similarly, higher urine κCR and λCR were associated with a 
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higher risk of death on univariable analysis, but not after adjustment for standard prognostic 
factors for mortality. 
Conclusions 
Despite a correlation with serum FLCs, urine FLC excretion is not independently associated 
with the risk of kidney failure or death in patients with CKD. Further, they do not improve 




There are prognostic factors measurable in the urine of patients with CKD that are 
associated with the risk of kidney failure or death, the most significant by far being albumin. 
Urinary albumin is a powerful prognostic factor because, not only is it a marker of glomerular 
damage, but it may also itself be involved in the pathogenesis of progressive CKD, 
exacerbating kidney damage in the tubulointerstitium. 
The identification of urinary factors that provide prognostic information over and 
above that provided by standard prognostic factors, including urinary albumin, has the 
potential to bring numerous benefits to clinical practice, including improved risk stratification 
and the identification of targets for new therapies. The search for these urinary factors is more 
likely to be fruitful when focused on markers that are of a different size to albumin, undergo 
different renal handling, and which have a direct causal association with the adverse outcomes 
being assessed. 
Urine FLCs meet these criteria. FLC molecules are smaller than albumin and 
processed differently in the kidneys, such that urine FLC concentrations are likely to be a 
reflection of tubular, rather than glomerular, health. Further, urine FLCs are determined in 
part by serum FLC concentration which, as shown in Chapter III is an independent prognostic 
factor in CKD. Finally, FLCs are known to have direct pathogenetic properties in the kidney, 
and therefore urine FLCs merit study as potential prognostic factors in CKD, and in particular 
whether they provide prognostic information with regard to the risk of kidney failure beyond 
that provided by standard prognostic factors including urinary albumin. 
It is also possible that urinary FLCs may be associated with mortality risk. Besides a 
possible correlation with serum FLC, several urinary markers of tubular injury have 
previously been shown to be associated with mortality. 
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4.2.1. Urine FLCs 
An overview of FLC biology was presented in Section 3.2. Free light chains filtered at 
the glomerulus are endocytosed and catabolized by proximal tubular cells, such that in health 
no FLCs from glomerular filtration are excreted in the urine. A small quantity of FLCs is 
excreted in the urine but is thought to originate further down the urinary tract alongside 
secretory IgA for mucosal defence (197). 
The presence of significant FLC in the urine implies either concentrations in the 
proximal tubule greater than can be reabsorbed, usually due to excess monoclonal FLC 
production in plasma cell dyscrasias, or renal disease with glomerular hyperfiltration or 
tubular dysfunction (198). 
As with albumin and other urinary markers, the urinary excretion of FLCs may be 
expressed as a ratio with urine creatinine concentration to give a urine κ/creatinine ratio 
(κCR) and urine λ/creatinine ratio (λCR). This adjusts for variable urine concentration and 
would be expected to correlate with daily urine FLC excretion. 
4.2.2. Urine FLCs in CKD 
There is a negative correlation between urine FLC/creatinine ratios and eGFR, such 
that in patients with CKD, urine κCR and λCR progressively increases as GFR declines (201). 





Figure 4.1. Urine FLC excretion by stage of CKD 
Urine κCR (grey) and λCR (white) increase with worsening CKD G stage. From (201). 
The proportion of patients with abnormal urine FLC/creatinine ratios, relative to a 
reference range derived in a healthy population, increased with each CKD stage (36, 50, 74, 
89, and 100%, for CKD G stages 1 through 5, respectively; P < 0.001) (201). 
Further, the proportion of patients with abnormal urine FLC/creatinine ratios also 
increased with each higher category of albuminuria (45, 61, 89, and 93% for urine ACR < 2, 2 




Figure 4.2. Abnormal urine FLC/creatinine ratios according to urine ACR 
Abnormal defined as urine κCR > 4.0 or λCR > 0.45, taken as the upper limits of the 95% 
confidence intervals from a healthy population. From (201). 
It has also been demonstrated that there is a correlation between urinary κCR and λCR 
and their corresponding serum FLC concentrations (R = 0.55 and 0.57 respectively, P < 
0.001, controlling for urine ACR) (201). 
Several studies suggest that urinary FLCs may be more sensitive than albuminuria as a 
marker of early CKD. Two studies observed that urine κCR and λCR are raised before the 
development of increased albuminuria in patients with type 2 diabetes mellitus (DM) (241, 
242). Urine FLC concentrations have also been shown to correlate with disease activity in 
IgA nephropathy and lupus nephritis (243, 244).  
Urine FLCs have not been studied for their use in the diagnosis of CKD or prognosis. 
Given that early CKD is associated with higher urinary excretion of FLCs, urine FLCs may 
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have a role in the early detection of kidney disease. Further, FLC molecules have properties 
quite different from albumin, including their size, renal handling, and pathogenetic properties 
within the kidney, and their role as prognostic factors merits study. The work presented in this 
chapter aimed to address whether urinary FLC excretion in patients with CKD is 
independently associated with the risk of kidney failure or death and, further, whether they 




The following pre-specified hypotheses were addressed: 
1. Higher urine FLC/creatinine ratios are associated with a higher risk of kidney failure 
in patients with CKD; 
2. Higher urine FLC/creatinine ratios add incremental value to the Kidney Failure Risk 
Equation for the prediction of kidney failure by two years in patients with CKD; 
3. Higher urine FLC/creatinine ratios are associated with a higher risk of death in 





Data and samples from the Renal Impairment in Secondary Care (RIISC) Study, a 
prospective cohort study of patients with CKD, were used. The RIISC study is described in 
detail in Section 2.1. 
All eligibility criteria described in Section 2.1.3 applied, but for this analysis, 
participants with a monoclonal gammopathy were also excluded, defined as: 
• a known diagnosis of myeloma, MGUS, AL amyloidosis, or another monoclonal 
gammopathy of renal significance, or 
• a serum κ/λ FLC ratio outside of the renal reference range (0.37-3.1) with an increased 
concentration of the involved light chain. 
4.4.2. Urine FLCs 
Urine concentrations of κ and λ FLCs were measured by turbidimetry on a Roche 
Modular P analyser using the Freelite® immunoassay (The Binding Site Group Ltd, 
Birmingham, UK). Urine κ and λ concentrations were divided by urine creatinine 
concentration, measured using a Roche Hitachi 702 analyser, to obtain urine κCR and λCR (in 
mg/mmol). 
4.4.3. Other variables 
The measurement of serum creatinine concentration and urine ACR and the 
calculation of eGFR by the CKD-EPI equation were all performed as stated in Section 2.1.4.6. 




Patients were recruited between October 2010 and December 2015, and data up to 
December 2018 were collected for the following outcomes: 
• Kidney failure, defined as the initiation of kidney replacement therapy 
(dialysis or kidney transplantation) 
• Death, from any cause. 
4.4.5. Statistical methods 
The distributions of baseline characteristics, including urine κCR and λCR, are 
presented in tabular form with the number of missing values reported for each variable. 
Histograms are plotted to show the distribution of urine κCR and λCR. 
The relationships between urine κCR and λCR and other baseline variables were 
assessed statistically. Relationships with continuous variables are expressed as Pearson’s r 
(after log transformation of both variables) with its corresponding P, and fractional 
polynomials were used to assess for non-linear relationships and presented graphically. For 
categorical variables, median and interquartile ranges are shown with between-group 
differences assessed using the Mann-Whitney U or Kruskal-Wallis tests.  
Univariable and multivariable regression models were fitted to show the association 
between urine κCR and λCR and other variables with adverse outcomes. Subdistribution 
hazard models were used to assess the association with kidney failure (handling death as a 
competing risk) and presented as a subhazard ratio (SHR) with a 95% confidence interval 
(CI). Cause-specific hazard models were also fitted and are presented in Appendix 6. Cox 
proportional hazards regression was used to assess associations with death and are presented 
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as a hazard ratio (HR) with 95% CI. Multivariable models were prespecified and non-linear 
associations were assessed, as per Section 2.5.4.2. 
Missing data were handled by multiple imputation as per Section 2.5.6. For the kidney 
failure model, 19% of participants had missing data in at least one variable, and therefore 20 
imputations were used. For the death model, 11% of participants had missing data, and 
therefore 15 imputations were used. 
 
4.4.5.1. Risk stratification 
To examine whether urine κCR or λCR provide incremental value in risk 
stratification, the four-variable Kidney Failure Risk Equation (KFRE) (106) (Section 1.4.1.2) 
was used as the baseline model for comparison. The KFRE estimates an individuals’ risk of 
kidney failure at two and five years. Binary logistic regression models were fitted for the 
outcome of kidney failure at two years. The baseline model contained only the KFRE-
calculated two-year risk of kidney failure, calculated as: 
1	– 	0.9832!("#.%%#&	×	()*+/&#	–	..#/0)	2	#.%30.	×	(4)5+	–	#.603%)	–	#.660.	×	(+789/6	–	..%%%)	2	#.36&#	×	(5:*;<9	–	6.&/.)) 
(the four-variable, non-North America, two-year risk equation from eAppendix 2 of (107); 
ACR was converted to mg/g before being entered into the model by dividing by 0.113). 
Urine κCR and λCR (separately) were added to the baseline KFRE model and the 
models compared. Overall model performance was estimated by pseudo R2, discrimination 
was assessed by the C-statistic, and calibration by the Hosmer-Lemeshow goodness-of-fit 
test. The incremental value of adding urine κCR or λCR to the baseline model was assessed 
by the change in C-statistic and by the reclassification measure Integrated Discrimination 
Index (IDI). The IDI is a measure of the extent to which adding a new marker to a model 
correctly revises upward the predicted risk of individuals who experience an event and 
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Urinary FLCs were measured in 636 participants of the RIISC study. Forty-one 
participants were excluded because they had evidence of a monoclonal gammopathy (21 with 
a serum κ/λ FLC ratio outside the renal reference range, 15 with MGUS, and 5 with multiple 
myeloma). Further, 39 patients had urine FLC or creatinine concentrations above or below the 
limits of detection and were excluded because urine κCR and λCR could not be calculated. 
Therefore, 556 participants were included for analysis. Median follow-up time was 6.1 years, 
and there were 191 kidney failure events and 129 deaths. 
4.5.1. Baseline characteristics 
The baseline characteristics of the study population are shown in Table 4.1.  
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Table 4.1. Baseline characteristics of the study population 
Characteristic Median (IQR) or N (%) Data completeness (%) 
Age (years) 64 (51 to 76) 100 
Male gender 351 (63.1) 100 
Ethnicity  100 
White 380 (68.3)  
South Asian 117 (21.0)  
Black 56 (10.1)  
Other 3 (0.5)  
Co-morbidities  100 
DM 196 (35.3)  
IHD 120 (21.6)  
Cerebrovascular disease 53 (9.5)  
PAD 53 (9.5)  
COPD 57 (10.3)  
Malignancy 71 (12.8)  
Cause of CKD  90 
Ischaemic/hypertensive 145 (28.9)  
Glomerulonephritis 72 (14.3)  
Diabetic kidney disease 65 (12.9)  
Polycystic kidney disease 29 (5.8)  
Interstitial nephropathy 29 (5.8)  
Reflux nephropathy 12 (2.4)  
Other/uncertain 150 (29.9)  
eGFR (ml/min/1.73 m2) 24.9 (19.3 to 34.1) 98 
Urine ACR (mg/mmol) 28.1 (5.7 to 103.5) 92 
Blood pressure (mmHg)   
Systolic 128 (116 to 144) 99 
Diastolic 76 (68 to 85) 99 
Serum κ (mg/l) 44.9 (29.4 to 67.0) 99 
Serum λ (mg/l) 32.5 (23.4 to 47.0) 99 
Urine κCR (mg/mmol) 14.6 (7.1 to 27.7) 100 
Urine λCR (mg/mmol) 2.1 (1.0 to 5.1) 100 
Categorical variables summarised as the number and %, and continuous variables as the 
median and interquartile range. 
Median urine κCR was 14.6 (IQR 7.1 to 27.7) mg/mmol and median λCR was 2.1 




Figure 4.3. Histograms of urine κCR and λCR 
Histograms illustrating the skewed distributions of urine κCR and λCR. 
4.5.2. Relationships with other baseline variables 
The relationships of urine κCR and λCR with other baseline variables are shown in 
Table 4.2. For comparison, the relationships of urine ACR are also given. 
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Table 4.2. Relationships of urine κCR, λCR, and ACR with other baseline variables 
Variable Urine κCR Urine λCR Urine ACR Median (IQR) or r P Median (IQR) or r P Median (IQR) or r P 
Age 0.109 0.010 0.012 0.77 -0.321 <0.001 
Gender  0.028  0.007  0.038 
Male 16.2 (7.4 to 29.3)  2.3 (1.1 to 5.2)  32.5 (7.3 to 111.3)  
Female 12.3 (6.3 to 26.5)  1.9 (0.7 to 4.3)  20.0 (4.4 to 83.2)  
Ethnicity  0.007  0.001  <0.001 
White 13.1 (7.1 to 24.5)  1.9 (1.0 to 4.3)  16.9 (4.2 to 76.4)  
South Asian 20.0 (8.4 to 37.2)  3.4 (1.5 to 7.9)  78.2 (22.8 to 156.6)  
Black 12.9 (4.0 to 28.9)  1.8 (0.6 to 5.2)  39.0 (9.5 to 88.7)  
Other 12.7 (8.3 to 39.9)  2.0 (1.9 to 7.4)  237.3 (187.1 to 302.4)  
Co-morbidities       
Diabetes Mellitus  <0.001  0.001  0.28 
Yes 18.7 (8.1 to 34.9)  2.9 (1.2 to 6.4)  23.8 (4.2 to 86.2)  
No 12.6 (6.6 to 24.3)  1.8 (0.9 to 4.3)  29.3 (6.9 to 108.7)  
Cardiovascular disease  0.37  0.89  0.048 
Yes 16.3 (7.1 to 30.3)  2.2 (1.0 to 5.2)  22.6 (3.7 to 82.6)  
No 14.3 (7.1 to 27.3)  2.0 (1.0 to 5.0)  29.1 (6.9 to 117.0)  
Malignancy  0.46  0.35  0.015 
Yes 16.0 (7.5 to 25.9)  1.8 (1.1 to 3.6)  12.0 (2.9 to 83.0)  
No 14.3 (7.0 to 27.8)  2.2 (1.0 to 5.1)  29.9 (6.5 to 106.6)  
Cause of CKD  <0.001  <0.001  <0.001 
Ischaemic/hypertensive 13.6 (7.3 to 27.7)  2.1 (1.0 to 4.7)  12.4 (2.6 to 56.0)  
Glomerulonephritis 8.2 (4.9 to 17.2)  1.4 (0.8 to 2.7)  70.5 (30.4 to 159.3)  
Diabetic kidney disease 20.9 (10.4 to 51.8)  4.7 (1.6 to 8.1)  64.9 (23.0 to 237.3)  
Polycystic kidney disease 12.0 (5.5 to 19.0)  1.5 (0.5 to 3.1)  10.2 (6.1 to 18.7)  
Interstitial nephropathy 15.0 (8.1 to 27.3)  3.1 (1.1 to 5.0)  10.4 (3.6 to 35.0)  
Reflux nephropathy 8.2 (3.7 to 22.8)  1.8 (0.6 to 3.9)  87.8 (29.3 to 141.0)  
Other/uncertain 16.1 (7.4 to 31.0)  2.3 (1.0 to 5.7)  32.9 (6.9 to 113.5)  
eGFR -0.387 <0.001 -0.340 <0.001 0.100 0.027 
Urine ACR 0.400 <0.001 0.516 <0.001 N/A  
Systolic BP 0.184 <0.001 0.179 <0.001 0.227 <0.001 
Diastolic BP 0.079 0.06 0.111 0.009 0.231 <0.001 
Serum κ 0.513 <0.001 0.479 <0.001 0.175 <0.001 
Serum λ 0.494 <0.001 0.563 <0.001 0.221 <0.001 
Urine κCR N/A  0.925 <0.001 0.400 <0.001 
Urine λCR 0.925 <0.001 N/A  0.516 <0.001 
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Urine FLC/creatinine ratios were higher in males, those of South Asian ethnicity, and 
those with DM or diabetic kidney disease, and lower in those with glomerulonephritis. Their 
strongest correlations, other than with each other, were moderate positive correlations with 
their counterpart serum FLC. There were weak-to-moderate positive correlations with urine 
ACR, very weak positive correlations with systolic BP, and weak negative correlations with 
eGFR. 
In a multivariable analysis, factors independently associated with urine FLC/creatinine 
ratios were their counterpart serum FLC concentration (Figure 4.4), urine ACR (Figure 4.5), 
and a renal diagnosis of glomerulonephritis (associated with a 9.3 [5.5 to 13.0] mg/mmol 
lower urine κCR, P < 0.001, and a 1.3 [0.3 to 2.2] mg/mmol lower urine λCR, P = 0.007). 
 
Figure 4.4. Relationship between urine κCR and λCR and their counterpart serum FLC 
Both relationships are non-linear. The data were best fit using FP2 models with powers 0 and 




Figure 4.5. Relationship between urine κCR and λCR and urine ACR 
The relationship with κCR was fit using an FP2 model with powers 0 and 1. The relationship 
with λCR is linear. 
4.5.3. Kidney failure 
During the median follow-up time of 6.1 years, 191 (34.4%) participants progressed to 
kidney failure, with an overall event rate of 8.1 per 100 person-years. The univariable 
associations between urine κCR and λCR and other baseline factors with the risk of kidney 
failure are shown in Table 4.3. 
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Table 4.3. Univariable associations between baseline factors and kidney failure 
Variable SHR 95% CI P 
Age 1.00a 1.00 to 1.00 <0.001 
Male gender 0.93 0.70 to 1.25 0.64 
Ethnicity    
White Ref   
South Asian 1.72 1.24 to 2.38 0.001 
Black 1.78 1.16 to 2.72 0.008 
Other 0.00 0.00 to 0.00 <0.001 
Co-morbidities    
DM 0.94 0.69 to 1.27 0.67 
IHD 0.68 0.47 to 1.00 0.05 
Cerebrovascular disease 1.07 0.66 to 1.73 0.79 
PAD 0.72 0.41 to 1.27 0.26 
COPD 0.44 0.23 to 0.85 0.014 
Malignancy 0.44 0.25 to 0.78 0.005 
Cause of CKD    
Ischaemic/hypertensive Ref   
Glomerulonephritis 1.14 0.69 to 1.89 0.61 
Diabetic kidney disease 1.87 1.14 to 3.07 0.014 
Polycystic kidney disease 3.71 2.39 to 5.75 <0.001 
Interstitial nephropathy 0.81 0.36 to 1.80 0.60 
Reflux nephropathy 1.07 0.41 to 2.77 0.89 
Other/uncertain 1.12 0.73 to 1.71 0.60 
eGFR 0.42 0.31 to 0.56 <0.001 
Urine ACR 1.48b 1.34 to 1.64 <0.001 
Systolic BP 1.22 1.06 to 1.40 0.005 
Diastolic BP 1.27 1.10 to 1.47 0.001 
MAP 1.30 1.13 to 1.51 <0.001 
Serum κ 2.64b 2.07 to 3.37 <0.001 
Serum λ 0.23c 0.16 to 0.34 <0.001 
Serum κ + λ 3.09b 2.37 to 4.03 <0.001 
Urine κCR 1.80b 1.53 to 2.11 <0.001 
Urine λCR 1.72b 1.51 to 1.95 <0.001 
For continuous variables with a linear association, SHR is per +1 SD. Non-linear fractional 
polynomial transformations are denoted by: a = x3; b = ln(x); c = x-0.5. 
On univariable analysis, higher urine κCR and λCR concentrations were both 
associated with a higher risk of kidney failure. The relationships are non-linear and are 




Figure 4.6. Unadjusted SHR for kidney failure according to urine κCR and λCR 
Subhazard ratio with 95% CI, relative to 15 mg/mmol for urine κCR and 2 mg/mmol for urine 
λCR. 
Other variables associated with a higher risk of kidney failure on univariable analysis 
were younger age (non-linear, Figure 4.7), non-White ethnicity, CKD due to polycystic 
kidney disease or diabetic kidney disease, lower eGFR, higher urine ACR (non-linear, Figure 
4.8), higher BP, and higher serum FLCs (non-linear, Figure 4.9). Having COPD or 




Figure 4.7. Unadjusted SHR for kidney failure according to age 
SHR with 95% CI, relative to 65 years. 
 
Figure 4.8. Unadjusted SHR for kidney failure according to urine ACR 

























































Figure 4.9. Unadjusted SHR for kidney failure according to serum FLCs 
Subhazard ratio with 95% CI (κ relative to 45 mg/l, λ relative to 35 mg/l, cFLC relative to 
100 mg/l). 
The multivariable models for urine κCR and λCR (separately) are shown in Table 4.4. 
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Table 4.4. Multivariable models for the risk of kidney failure 
Variable Urine κCR Urine λCR SHR 95% CI P SHR 95% CI P 
Age 0.41 0.33 to 0.51 <0.001 0.41 0.33 to 0.50 <0.001 
Male sex 1.42 1.01 to 2.01 0.046 1.42 1.01 to 2.00 0.045 
Ethnicity       
White Ref   Ref   
South Asian 0.98 0.67 to 1.44 0.92 0.95 0.65 to 1.39 0.79 
Black 1.63 1.00 to 2.66 0.05 1.60 0.98 to 2.62 0.06 
Other 0.00 . . 0.00 . . 
Cause of CKD       
Ischaemic/hypertensive Ref   Ref   
Diabetic kidney disease 0.95 0.55 to 1.63 0.84 0.94 0.55 to 1.61 0.82 
Glomerulonephritis 0.80 0.45 to 1.44 0.46 0.80 0.45 to 1.44 0.46 
Polycystic kidney disease 7.02 3.84 to 12.9 <0.001 7.19 3.90 to 13.2 <0.001 
Interstitial nephropathy 0.44 0.17 to 1.12 0.09 0.44 0.17 to 1.11 0.08 
Reflux nephropathy 0.31 0.10 to 0.93 0.037 0.31 0.10 to 0.94 0.038 
Other/uncertain 0.84 0.52 to 1.34 0.46 0.82 0.51 to 1.31 0.40 
MAP 0.86 0.72 to 1.03 0.09 0.86 0.72 to 1.02 0.09 
eGFR 0.97a 0.96 to 0.98 <0.001 0.97a 0.96 to 0.98 <0.001 
 66.0b 24.5 to 178 <0.001 64.9b 24.4 to 173 <0.001 
Urine ACR 5.53c 3.48 to 8.77 <0.001 5.48c 3.48 to 8.62 <0.001 
 0.99d 0.99 to 1.00 <0.001 0.99d 0.99 to 1.00 <0.001 
Urine κCR 1.08 0.90 to 1.31 0.41  
Urine λCR  1.15 0.96 to 1.38 0.13 
For continuous variables with a linear association, SHR is per +1 SD. The two rows for 
eGFR and urine ACR indicate the SHR for each power of the degree-2 fractional polynomial 
transformation. Fractional polynomial transformations are denoted by: a = x-2; b = x-0.5; c = 
x0.5; d = x3. 
After adjustment for age, sex, ethnicity, cause of CKD, MAP, eGFR, and urine ACR, 
neither urine κCR (SHR 1.08 [0.90 to 1.31] per +1 SD) or urine λCR (SHR 1.15 [0.96 to 
1.38] per +1 SD) had independent associations with the risk of kidney failure. 
Baseline factors that were associated with a higher risk of kidney failure in the 
multivariable models were younger age, male sex, CKD caused by polycystic kidney disease, 
lower eGFR (non-linear, Figure 4.10), and higher urine ACR (non-linear, Figure 4.11). CKD 




Figure 4.10. Adjusted SHR for kidney failure according to eGFR 
SHR with 95% CI, relative to 25 ml/min/1.73 m2, from the multivariable models in Table 4.4. 
 
Figure 4.11. Adjusted SHR for kidney failure according to urine ACR 
SHR with 95% CI, relative to 30 mg/mmol, from the multivariable models in Table 4.4. 
When these analyses were repeated in participants with a urine ACR < 30 mg/mmol 
(N=265), the results were similar, i.e. higher urine κCR and urine λCR were associated with a 





4.5.3.1. Risk stratification 
After excluding those who died without kidney failure within two years (N=39), 517 
participants had data on the outcome of kidney failure by two years. Of these, 62 (12.0%) had 
experienced kidney failure within two years from baseline. The logistic regression models for 
the prediction of kidney failure by two years, with measures of model performance and the 
incremental value of adding urine κCR or λCR to the KFRE, are shown in Table 4.5. 
Table 4.5. Logistic regression models for the prediction of kidney failure at two years 
Statistic Model KFRE KFRE + urine κCR KFRE + urine λCR 
Odds ratio (95% CI)    
KFRE 1.10 (1.08 to 1.13) 1.10 (1.08 to 1.13) 1.10 (1.08 to 1.13) 
κCR or λCR  1.04 (0.73 to 1.49) 1.05 (0.73 to 1.52) 
Pseudo R2 0.345 0.345 0.345 
Hosmer-Lemeshow (P) 6.71 (0.57) 5.23 (0.73) 5.22 (0.73) 
C-statistic 0.891 0.891 0.890 
Δ C-statistic  0.00 (-0.01 to 0.01) 0.00 (-0.01 to 0.01) 
IDI  0.00 (-0.01 to 0.02) 0.00 (-0.01 to 0.01) 
The odds ratios for urine κCR and λCR are per +1 SD. 
The baseline model, containing only KFRE, had a strong predictive ability for kidney 
failure at two years (C-statistic 0.891) and was well calibrated (Hosmer-Lemeshow statistic 
6.71, P=0.57). Urine κCR or urine λCR were not significantly associated with kidney failure 
in the models containing KFRE, and their addition to KFRE provided no improvement in 
model performance. Neither model showed any change in the C-statistic, suggesting no 
improvement in model discrimination between those who did and did not develop kidney 




During the median follow-up time of 6.1 years, 129 (23.2%) participants died, and the 
overall death rate was 5.5 per 100 person-years. The univariable associations between urine 
κCR and λCR and other baseline factors with the risk of death are shown in Table 4.6. 
Table 4.6. Univariable associations between baseline factors and risk death 
Variable Hazard ratio 95% CI P 
Age 3.34 2.56 to 4.35 <0.001 
Male gender 1.13 0.78 to 1.62 0.52 
Ethnicity    
White Ref   
South Asian 0.65 0.40 to 1.08 0.10 
Black 0.75 0.39 to 1.43 0.38 
Other 1.03 0.14 to 1.37 0.98 
Co-morbidities    
DM 1.48 1.04 to 2.10 0.028 
IHD 2.14 1.49 to 3.07 <0.001 
Cerebrovascular disease 1.75 1.06 to 2.89 0.027 
PAD 2.46 1.58 to 3.81 <0.001 
COPD 1.39 0.84 to 2.28 0.20 
Malignancy 2.05 1.35 to 3.11 0.001 
Smoking status    
Never Ref   
Previous 1.68 1.16 to 2.44 0.006 
Current 0.99 0.52 to 1.86 0.97 
eGFR 0.34 0.24 to 0.48 <0.001 
Urine ACR 1.00 0.80 to 1.24 0.99 
Systolic BP 1.25 1.05 to 1.48 0.011 
Diastolic BP 0.64 0.53 to 0.76 <0.001 
MAP 0.85 0.71 to 1.02 0.08 
Urine κCR 1.23 1.03 to 1.44 0.021 
Urine λCR 1.19 1.01 to 1.40 0.042 
Associations for continuous variables were all linear, and the HR is per +1 SD. 
On univariable analysis, higher urine κCR and λCR concentrations were both 
associated with a higher risk of death (urine κCR: HR 1.23 [1.03 to 1.44] per +1 SD; urine 
λCR: HR 1.19 [1.01 to 1.40] per + 1SD). 
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Other variables associated with a higher risk of death on univariable analysis were 
older age, a diagnosis of DM, IHD, cerebrovascular disease, PAD, or malignancy, being a 
previous smoker, lower eGFR, higher systolic BP, and lower diastolic BP. 
The multivariable models for urine κCR and λCR (separately) are shown in Table 4.7. 
Table 4.7. Multivariable models for the risk of death 
Variable Urine κCR Urine λCR HR 95% CI P HR 95% CI P 
Age 2.93 2.10 to 4.08 <0.001 2.96 2.12 to 4.14 <0.001 
Male sex 1.00 0.66 to 1.52 1.00 0.97 0.64 to 1.46 0.87 
Ethnicity       
White Ref   Ref   
South Asian 1.23 0.71 to 2.14 0.45 1.21 0.70 to 2.10 0.49 
Black 1.02 0.51 to 2.02 0.96 1.03 0.52 to 2.04 0.93 
Other 1.73 0.20 to 14.7 0.62 1.46 0.17 to 12.3 0.73 
Co-morbidities       
DM 1.11 0.75 to 1.63 0.61 1.09 0.74 to 1.60 0.67 
IHD 1.23 0.82 to 1.82 0.32 1.19 0.81 to 1.77 0.38 
CVD 1.13 0.67 to 1.90 0.66 1.14 0.68 to 1.92 0.61 
PVD 1.64 1.00 to 2.69 0.048 1.64 1.00 to 2.69 0.048 
COPD 1.25 0.74 to 2.12 0.41 1.29 0.76 to 2.18 0.34 
Malignancy 1.88 1.18 to 2.98 0.007 1.80 1.14 to 2.84 0.011 
Smoking status       
Never smoked Ref   Ref   
Previous smoker 1.00 0.66 to 1.51 0.99 0.97 0.64 to 1.48 0.90 
Current Smoker 1.37 0.67 to 2.81 0.39 1.35 0.66 to 2.78 0.41 
eGFR 0.51 0.34 to 0.76 0.001 0.53 0.36 to 0.80 0.002 
Urine ACR 1.49 1.21 to 1.84 <0.001 1.44 1.16 to 1.78 0.001 
Systolic BP 1.02 0.85 to 1.23 0.80 1.02 0.85 to 1.23 0.84 
Urine κCR 0.91 0.73 to 1.13 0.41  
Urine λCR  1.01 0.81 to 1.28 0.90 
All relationships between continuous variables and death were linear. 
After adjustment for age, sex, ethnicity, co-morbidities, smoking status, eGFR, urine 
ACR, and systolic BP, neither urine κCR (HR 0.91 [0.73 to 1.13] per +1 SD) or urine λCR 
(HR 1.01 [0.81 to 1.28] per +1 SD) had independent associations with the risk of death. 
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Baseline factors that were associated with a higher risk of death in the multivariable 





The work presented in this chapter examined the hypotheses that higher urine 
FLC/creatinine ratios would be associated with a higher risk of kidney failure in patients with 
CKD and improve risk stratification when added to a current prognostic model based on 
standard prognostic factors. Further, it addressed the hypothesis that higher urinary 
FLC/creatinine ratios are associated with a higher risk of death in CKD. However, the results 
were not consistent with these hypotheses and suggested that urine FLC/creatinine ratios are 
not independent prognostic factors for kidney failure or death in patients with CKD. 
The most important determinant of urine FLC/creatinine ratios was their counterpart 
serum FLC concentration. This correlation in patients with CKD has been reported previously 
(201). There are no published data on these correlations in healthy individuals. However, one 
would expect either no correlation or a very weak one because the capacity of the proximal 
tubules to catabolise FLCs is such that no filtered FLCs reach the urine, and therefore the 
urine FLC concentration should not reflect the serum concentration. The moderate 
correlations observed in this CKD study population are likely to reflect tubular disease, with 
impairment of FLC endocytosis and catabolism in the proximal tubule, or, as nephrons are 
lost in CKD, hyperfiltration of the remaining functional glomeruli and increased FLC delivery 
that exceeds the capacity of the proximal tubule to reabsorb and metabolise them. These 
mechanisms lead to the urinary escape of FLCs, which more closely reflects serum 
concentration. 
Urine FLC/creatinine ratios were also positively correlated with urine ACR. In CKD, 
glomerular damage (associated with increased albuminuria and possibly with increased 
filtration of FLCs) often coexists with tubulointerstitial fibrosis (and thus possibly reduced 
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tubular FLC reabsorption). The correlation between urinary albumin and FLC is, therefore, 
not unexpected. 
The finding of differences in urine FLC/creatinine ratios by cause of CKD has also 
been previously reported (201). In this cohort, those with glomerulonephritis had significantly 
lower urine FLC/creatinine ratios, consistent with the results of a previous study (201). The 
reason for this is not apparent, although as previously described, unlike urine ACR, higher 
urine FLC/creatinine ratios are likely to be more reflective of tubular rather than glomerular 
pathology. 
4.6.1. Kidney failure 
It was postulated that urine FLC/creatinine ratios may reflect kidney damage in a 
different way to urine ACR, being more reflective of tubular damage and that they may also 
reflect tubular exposure to FLCs where they may have deleterious effects. Thus, it was 
hypothesised that urine FLC/creatinine ratios would provide prognostic information on the 
risk of kidney failure in patients with CKD. Urine κCR and λCR were associated with the risk 
of kidney failure, but after adjustment for standard prognostic factors, the associations were 
significantly attenuated and became non-significant. 
 The lack of an independent association may reflect their lack of specificity for renal 
damage. As described, urine κCR and λCR correlated most strongly with their counterpart 
serum FLC, which may be determined by factors other than kidney function/damage, such as 
systemic inflammation and reticuloendothelial function. Further, urine κCR and λCR may 
also be influenced by mucosal secretion of FLCs in the urinary tract rather than solely 
reflecting renal loss. 
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Adding urine κCR or λCR to the KFRE, an established model for the estimation of the 
two-year risk of kidney failure, did not improve model performance in this cohort. Given the 
lack of an independent association with the risk of kidney failure identified in the previous 
step, it was not expected that urine κCR or λCR would improve risk stratification. However, 
these analyses were pre-specified and were conducted as had been planned before the 
assessment of multivariable associations. 
4.6.2. Death 
It was hypothesised that urine FLC/creatinine are independent prognostic factors for 
the risk of death in patients with CKD, but the results are not consistent with this hypothesis. 
Although urine κCR and λCR were associated with the risk of death, neither had a significant 
association after adjusting for standard prognostic factors for mortality in CKD. This is 
despite a significant correlation with serum FLC concentration, itself a marker of the risk of 
death as established in Chapter III.   
Previous studies have identified several urinary markers of tubular damage that are 
independently associated with mortality (247-249). Markers of tubular injury reflect kidney 
disease and tubular dysfunction, which may be associated with death through pathways 
involving mineral metabolism, erythropoiesis, acid-base regulation, and urinary concentrating 
ability (249). They may also reflect systemic deleterious processes, as kidney injury or 
fibrosis may parallel similar processes in other organs such as the heart and lungs (249). 
Despite their reflection of kidney damage and tubular dysfunction, urine FLCs were not 
independently associated with the risk of death in patients with CKD. 
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4.6.3. Strengths and limitations 
This work was performed in a well-characterised cohort of patients with prospective 
follow-up and a significant number of outcome events, and a rigorous approach to statistical 
modelling that incorporated standard prognostic factors. However, it was an observational 
study, without mechanistic data, and performed in a single cohort of individuals with 
advanced CKD that limits generalisability. 
4.6.4. Future research 
While no independent association was found with the risk of kidney failure or death in 
this cohort, further study in a larger cohort of patients may be justified. Further, the use of 
urine FLCs in detecting tubular dysfunction and in the diagnosis of CKD, especially in early 
disease, may be explored. 
This study population had relatively advanced CKD (median eGFR 25 ml/min/1.75 
m2, median urine ACR 28 mg/mmol), and the results may not be generalisable to all patients 
with CKD. Given the previous findings that increased urine FLC levels are detectable before 
the development of increased albuminuria, the use of urinary FLCs to stratify risk in early 




Neither urine κCR or urine λCR are independently associated with the risk of kidney 
failure or death in patients with CKD, and they do not improve upon the KFRE for predicting 
this risk of kidney failure by two years. Future work may explore the role of urine FLCs in the 
diagnosis and prognosis of early CKD.
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CHAPTER V: MONOCLONAL GAMMOPATHY 
The work presented in this chapter aimed to address the hypotheses that the presence 
of a monoclonal gammopathy (MG) is associated with a higher risk of kidney failure and 
death in patients with chronic kidney disease (CKD). 
Chapter III demonstrated that increased serum concentrations of non-clonal free light 
chains (FLC) are associated with a higher risk of kidney failure and death in patients with 
CKD. Further, it is well known that patients with monoclonal diseases, such as multiple 
myeloma, are at risk of kidney damage, kidney failure, and death. The association between 
non-malignant MG and adverse outcomes in patients with CKD was, therefore, assessed. 
At the time of thesis submission, this work has been accepted for publication in PLOS 





Malignant monoclonal gammopathy (MG) and increased non-clonal serum FLC 
concentration are both associated with an increased risk of kidney failure and death in 
patients with CKD. The association between the presence of a non-malignant MG and the 
risk of kidney failure or death in individuals with CKD was assessed. 
Methods 
Data were used from three prospective cohorts of individuals with CKD (not on dialysis or 
with a kidney transplant): 1. Renal Impairment in Secondary Care (RIISC, Queen Elizabeth 
and Heartlands Hospitals, Birmingham, UK, N=878), 2. Salford Kidney Study (SKS, Salford 
Royal Hospital, Salford, UK, N=861), 3. Renal Risk in Derby (RRID, Derby, UK, N=1739). 
Participants were excluded if they had multiple myeloma or any other B cell 
lymphoproliferative disorder with end-organ damage. 
Results 
All non-malignant MG was identified in the baseline serum of participants of RIISC only. 
Further, light-chain (LC) MG was identified and studied in participants of all three studies.  
One hundred two (11.6%) of the 878 RIISC participants had an MG. During a median 
follow-up time of 6.2 years, there were 324 kidney failure events and 202 deaths. The 
presence of MG was not independently associated with risk of kidney failure (adjusted SHR 
1.16 [95% CI 0.80 to 1.69]) or death (adjusted HR 1.37 [95% CI 0.93 to 2.00]). 
Fifty-five (1.6%) of the 3478 participants from all three studies had LC-MG. During the 
median follow-up time of 5.2 years, 564 participants progressed to kidney failure, and 803 
died. As with all MG, LC-MG was not independently associated with the risk of kidney 




The prevalence of MG was higher in this CKD cohort than that reported in the general 
population. However, the presence of an MG was not independently associated with a higher 




The monoclonal gammopathies (MG) are a group of disorders characterized by the 
proliferation of a single clone of plasma cells that produces a monoclonal immunoglobulin 
(termed a paraprotein) in an amount that can be detected by serum or urine immunofixation, 
or by the serum FLC assay (250). The paraprotein can consist of either an intact 
immunoglobulin or just FLCs. 
Monoclonal gammopathies are common, with a paraprotein detectable in the serum of 
approximately 1% of the population overall (251). The MGs are associated with a spectrum 
of diseases, from asymptomatic non-malignant disorders through to life-threatening 
malignant disease, as described in the following paragraphs. 
5.2.1. Malignant monoclonal gammopathies 
In some MGs, the clonal process producing the paraprotein is malignant with 
neoplastic disease infiltrating bone, lymph nodes, liver, spleen, or other organs. Examples of 
malignant MGs are multiple myeloma and Waldenström’s macroglobulinemia. Overall 
median survival in multiple myeloma is approximately five years (252). Further, nearly 50% 
of patients with multiple myeloma develop kidney disease, with approximately 10% 
requiring dialysis, and the presence of kidney disease is associated with worse survival (253, 
254). 
5.2.2. Non-malignant monoclonal gammopathies 
In most MGs, the clonal expansion of plasma cells is small and limited, and there is 
no evidence of neoplastic disease. Most individuals with an MG fall into this category and 
have no symptoms and no demonstrable organ damage. This is termed monoclonal 
gammopathy of undetermined significance (MGUS). MGUS is common, affecting around 
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3% of those aged over 50 years (255), although the prevalence has been reported to be higher 
in patients with CKD (218, 220). MGUS requires monitoring but no specific treatment. 
However, non-malignant MGs can occasionally be associated with disease due to the 
adverse properties of the secreted paraprotein itself (monoclonal gammopathy of clinical 
significance, MGCS) (256). For example, there may be tissue deposition of the paraprotein or 
the paraprotein may have autoantibody activity. Monoclonal gammopathy of renal 
significance (MGRS) represents a group of disorders in which a paraprotein secreted by a 
non-malignant B cell or plasma cell clone causes kidney damage (257). In MGRS, specific 
targeted therapy is indicated to preserve kidney function. 
5.2.3. Kidney disease in monoclonal gammopathies 
Paraproteins can directly cause kidney injury in both malignant MGs, such as multiple 
myeloma, and in non-malignant MGs (MGRS). There are various mechanisms by which 
paraproteins cause kidney disease, which tends to be mediated by FLCs, including 
intratubular cast formation, direct tubular toxicity, or paraprotein deposition within different 
compartments of the kidney. 
When large amounts of monoclonal FLCs are produced such that the capacity of the 
proximal tubule to endocytose them is exceeded, FLC binding with uromodulin leads to 
precipitation and cast formation within the tubules. The casts may cause tubular obstruction, 
rupture, and interstitial inflammation (254, 258). 
FLCs may also cause direct tubular toxicity, especially in the proximal tubule. 
Intracellular accumulation of endocytosed monoclonal FLCs is associated with the formation 
of reactive oxygen species such as hydrogen peroxide, and the initiation of apoptotic, pro-
inflammatory and fibrotic pathways (259-261). 
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Paraproteins may also be associated with deposition diseases, characterized by 
deposits of light chain or heavy chain fragments in various kidney compartments. Examples 
are light chain deposition disease, AL amyloidosis (where the light chain fragments form 
amyloid fibrils that deposit in the kidney), and heavy chain deposition disease (where heavy 
chains, with or without light chains, are deposited in the kidney). 
Patients with established kidney disease due to myeloma or MGRS have a risk of 
kidney failure, requiring dialysis, that varies by the particular form of MGRS. It is common 
to detect a paraprotein in patients with CKD, in part because the prevalence of both MGUS 
and CKD increase with age. The clinician needs to consider whether the finding of a 
paraprotein reflects incidental MGUS, or whether the paraprotein has a causal role in the 
kidney disease (MGRS, or a malignant MG such as multiple myeloma). Often, the 
probability of MGRS is felt to be low (for example, if the patient has another clear cause for 
kidney disease), and a kidney biopsy, which would exclude MGRS definitively, is not 
performed. The renal prognosis for a patient with (presumed) MGUS is not known. There has 
been only one small study, by Haynes et al., that assessed the risk of kidney failure associated 
with MGUS in patients with CKD (218). In the cohort of 364 patients with CKD, the 35 
(9.6%) patients with MGUS had a higher rate of kidney failure, but not after adjustment for 
age, sex, and eGFR. Further research is needed in cohorts with more patients and events to 
examine this association. 
5.2.4. Non-malignant MG and survival 
Although MGUS is defined by the absence of organ damage, several general 
population studies have shown that the presence of MGUS is associated with shorter survival 
(262, 263). This is in part related to malignant transformation of the MGUS to multiple 
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myeloma or other plasma-cell or lymphoid disorder, which occurs at a rate of approximately 
1% per year (262). 
The effect of MGUS on survival in patients with CKD is not known. Given the 
already increased risk of death in CKD, particularly from cardiovascular disease, it is not 
clear that an MGUS would be associated with a similar effect on survival to that seen in the 
general population. Indeed, in the study by Haynes et al., the presence of MGUS was not 
associated with a higher risk of death in patients with CKD (218). No other published studies 
have examined the association between MGUS and risk of death in patients with CKD. 
The detection of a non-malignant MG (often assumed to be MGUS) in a patient with 
CKD is common, but despite the known potential pathogenetic properties of paraproteins and 
the higher rate of death seen in the general population, there has been little study of the 
prognostic significance of non-malignant MG in patients with CKD. The work presented in 
this chapter assessed whether the presence of a non-malignant MG is associated with a higher 




The following pre-specified hypotheses were addressed: 
1. the presence of a non-malignant MG is independently associated with a higher risk of 
kidney failure in patients with CKD; 
2. the presence of a non-malignant MG is independently associated with a higher risk of 





Patients from three prospective UK cohorts of individuals with CKD who had not 
received kidney replacement therapy (KRT, i.e. dialysis or kidney transplant) were included: 
the Renal Impairment in Secondary Care (RIISC) study, the Salford Kidney Study (SKS, 
previously termed Chronic Renal Insufficiency Standards Implementation Study [CRISIS]), 
and the Renal Risk in Derby (RRID) study. 
Each study had research ethics committee (REC) approval (RIISC: West Midlands 
South Birmingham REC, ref 10/H1207/6; SKS: North West GM South REC; ref 
15/NW/0818; RRID: East Midlands Nottingham 1 REC). All participants in all three studies 
provided written informed consent, and all studies were conducted in accordance with the 
Declaration of Helsinki. 
The RIISC study has been described in Section 2.1, and details of the SKS and RRID 
studies cohorts have been published (180, 264). The study inclusion and exclusion criteria are 
summarised in Table 5.1, but for this analysis, participants were also excluded at an 





Table 5.1. Number of participants included and characteristics of each cohort study 





RIISC 878 Secondary care 
1. eGFR < 30 or 
2. eGFR 30-59 with 
a. eGFR decline* or 
b. Urine ACR > 70 
1. Previous dialysis or kidney 
transplant 
2. Immunosuppression for 
immune-mediated kidney disease 
2010 to 2015 End of 2018 74 (64 to 83) 
SKS 861 Secondary care eGFR >10 to <60 
1. Previous dialysis or kidney 
transplant 2002 to 2010 End of 2017 139 (110 to 161) 
RRID 1739 Primary care eGFR 30-59 1. Expected survival < 1 year 2. Previous solid organ transplant 2008 to 2010 End of 2015 61 (60 to 63) 
*eGFR decline defined as > 5 ml/min/1.73 m2 per year, or > 10 ml/min/1.73 m2 over 5 years.
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5.4.2. Definition of monoclonal gammopathy 
Although the majority of included participants who were identified to have an MG 
will have had MGUS, the more general term non-malignant MG is used throughout to reflect 
the fact that only a minority of participants had kidney biopsies to exclude MGRS 
definitively. Two forms of non-malignant MG were assessed: 
1. Any non-malignant MG (assessed in the RIISC cohort only), defined as: 
a. A monoclonal protein on serum protein electrophoresis (SPEP) 
confirmed by serum immunofixation or 
b. A serum k/l FLC ratio < 0.37 or > 3.10 with an increased level of the 
involved light chain; 
2. Light-chain (LC) MG (assessed in all three cohorts) defined as a serum k/l FLC ratio 
< 0.37 or > 3.10 with an increased level of the involved light chain. 
 
In the RIISC cohort, SPEP and immunofixation (using standard laboratory 
procedures) and serum FLC concentrations were measured, allowing the detection of any 
non-malignant MG. In the SKS and RRID cohorts, only serum FLC concentration was 
measured, and therefore only LC-MG could be detected in these two cohorts. 
The Freeliteâ assay (The Binding Site Group Ltd, Birmingham, UK) was used to 
measure k and l FLC concentration in all three cohorts. The serum k/l FLC ratio ‘renal 
reference range’ of 0.37 to 3.10 was used, as has been recommended in patients with kidney 
impairment to account for the associated change in FLC clearance (201, 202).  
5.4.3. Study design 
Patients were recruited prospectively in all three cohorts, and data and biological 
samples collected at baseline visits were used for this analysis. Years of recruitment, end of 
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follow-up, and median follow-up time for each study are given in Table 5.1. Time-to-event 
data were collected for kidney failure (defined as the initiation of KRT) and death from any 
cause. 
Individual participant data were available for the following variables: age, sex, 
ethnicity (White, Black, South Asian, or other), smoking status (current smoker, previous 
smoker, never smoked), co-morbidities (DM, IHD, cerebrovascular disease, PAD, COPD, 
and malignancy), cause of CKD (vascular, diabetes, glomerular, tubulointerstitial, cystic or 
congenital, or other or unknown), mean arterial pressure (MAP), eGFR (calculated using the 
four-variable MDRD formula), and urine ACR. 
No formal sample size calculations were carried out for these analyses which were 
performed using the available specimen collections and data sets. 
5.4.4. Statistical analysis 
Missing data were assumed to be missing at random and multiple imputation using 
chained equations was performed as per Section 2.5.6.  
Continuous variables all had skewed distributions as assessed by histograms. The 
relationships between MG or LC-MG status with other categorical baseline variables were 
assessed using Fisher's exact test, and relationships with continuous variables were assessed 
using the Wilcoxon rank-sum test. 
The prognostic significance of an MG or LC-MG for risk of kidney failure was 
estimated using subdistribution hazard models (accounting for the competing risk of death) 
and expressed as a subhazard ratio (SHR) with a 95% confidence interval (CI). Cause-
specific hazard models were also fitted and are presented in Appendix 7. The associations 
with risk of death were estimated using Cox proportional hazards models and expressed as a 
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hazard ratio (HR) with a 95% CI. Log-log plots were assessed for each variable to ensure that 
the proportional-hazards assumption was not violated. 
The analyses of LC-MG included amalgamated data from all three cohorts, and 
clustering was accounted for by the use of stratified models as per Section 2.5.5. 
All variables included in multivariable models were pre-specified. Fractional 
polynomials were used to explore the presence of non-linear relationships between 
continuous predictors and each outcome, and where they provided a better model fit, plots of 




Assessment of the association between any non-malignant MG and adverse outcomes 
included only RIISC data and is presented first, followed by analyses for LC-MG, which 
included data from all three cohorts. 
5.5.1. Any non-malignant MG 
Eight hundred seventy-eight participants from the RIISC cohort were included, and 
102 (11.6%) of these had an MG. Types of MG were as follows: 63 (61.8%) were IgG, 8 
(7.8%) were IgM, 5 (4.9%) were IgA, 1 (1.0%) was biclonal (IgG and IgM), and 25 (24.5%) 
were LC-MG. Median follow-up time was 6.2 years. Study population characteristics and the 




Table 5.2. Baseline characteristics by MG status 
Variable All MG +ve MG -ve Completeness 
of data (%) 
N (%) 878 102 (11.6) 776 (88.4) 100 
Age (years) 64.6 (51.7 to 76.0) 73.8 (59.8 to 81.4) 63.7 (50.2 to 75.5) 100 
Sex (male) 542 (61.7) 66 (64.7) 476 (61.3) 100 
Ethnicity    100 
White 598 (68.1) 68 (66.7) 530 (68.3)  
South Asian 188 (21.4) 24 (23.5) 164 (21.1)  
Black 84 (9.6) 9 (8.9) 75 (9.7)  
Other 8 (0.9) 1 (1.0) 7 (0.9)  
Co-morbidities    100 
DM 341 (38.8) 48 (47.1) 293 (37.8)  
IHD 208 (23.7) 30 (29.4) 178 (22.9)  
Cerebrovascular disease 102 (11.6) 15 (14.7) 87 (11.2)  
PAD 93 (10.6) 14 (13.7) 79 (10.2)  
COPD 89 (10.1) 8 (7.8) 81 (10.4)  
Malignancy 128 (14.6) 22 (21.6) 106 (13.7)  
Smoking status    98.2 
Never 416 (48.3) 47 (47.0) 369 (48.4)  
Previous 333 (38.6) 40 (40.0) 293 (38.5)  
Current 113 (13.1) 13 (13.0) 100 (13.1)  
Cause of CKD    91.2 
Vascular 230 (28.7) 34 (36.2) 196 (27.7)  
Diabetes 125 (15.6) 20 (21.3) 105 (14.9)  
Glomerular 109 (13.6) 7 (7.4) 102 (14.4)  
Tubulointerstitial 89 (11.1) 6 (6.4) 83 (11.7)  
Cystic or congenital 66 (8.2) 4 (4.3) 62 (8.8)  
Other or unknown 182 (22.7) 23 (24.5) 159 (22.5)  
MAP (mmHg) 93 (85 to 102) 92 (83 to 103) 93 (86 to 102) 97.6 
eGFR (ml/min/1.73 m2) 31 (23 to 42) 28 (22 to 42) 31 (23 to 42) 96.8 
Urine ACR (mg/mmol) 33.4 (6.3 to 130.0) 32.7 (5.6 to 161.2) 33.4 (6.5 to 122.7) 94.0 
Categorical variables are shown as a frequency (percentage) and continuous variables as the 
median (interquartile range). 
Compared to those without an MG, those with an MG were on average older 
(P<0.001) and a higher proportion had a history of malignancy (P=0.037). For all other 
baseline variables, there were no statistically significant differences between those with and 




5.5.1.1. Kidney failure 
Three hundred twenty-seven (37.2%) participants progressed to kidney failure, with 
rates per 100 person-years of 10.5 and 9.3 for those with and without MG, respectively. The 
univariable associations between baseline variables and the risk of kidney failure are shown 




Table 5.3. Association between baseline variables and risk of kidney failure and death 
Variable 
Kidney failure Death 
Univariable Multivariable Univariable Multivariable 
SHR 95% CI P SHR 95% CI P HR 95% CI P HR 95% CI P 
MG+ 0.97 0.68 to 1.38 0.85 1.16 0.80 to 1.69 0.43 2.13 1.49 to 3.02 <0.001 1.37 0.93 to 2.00 0.11 
Age 1.00a 1.00 to 1.00 <0.001 1.00a 0.99 to 1.00 <0.001 3.36 2.73 to 4.12 <0.001 2.83 2.21 to 3.64 <0.001 
Male sex 0.99 0.79 to 1.23 0.92 0.55 0.44 to 0.69 <0.001 1.27 0.95 to 1.69 0.11 0.88 0.62 to 1.24 0.46 
Ethnicity             
White Ref   Ref   Ref   Ref   
South Asian 2.02 1.58 to 2.57 <0.001 1.29 0.98 to 1.69 0.07 0.51 0.33 to 0.78 0.002 0.91 0.58 to 1.42 0.67 
Black 1.98 1.42 to 2.76 <0.001 1.77 1.32 to 2.38 <0.001 0.80 0.48 to 1.33 0.39 1.13 0.67 to 1.90 0.65 
Other 2.64 1.07 to 6.55 0.036 1.82 0.91 to 3.62 0.09 0.56 0.08 to 3.86 0.56 0.66 0.16 to 2.72 0.57 
Co-morbidities             
DM 0.92 0.73 to 1.15 0.46    1.64 1.25 to 2.16 <0.001 1.27 0.94 to 1.72 0.12 
IHD 0.85 0.65 to 1.11 0.22    2.44 1.83 to 3.24 <0.001 1.44 1.05 to 1.96 0.022 
Cerebrovascular disease 0.77 0.53 to 1.13 0.18    1.97 1.38 to 2.81 <0.001 1.27 0.87 to 1.85 0.21 
PAD 0.86 0.59 to 1.27 0.45    2.21 1.57 to 3.11 <0.001 1.27 0.85 to 1.91 0.24 
COPD 0.45 0.28 to 0.72 0.001    1.46 0.99 to 2.16 0.06 1.14 0.74 to 1.77 0.55 
Malignancy 0.51 0.35 to 0.76 0.001    2.16 1.56 to 2.99 <0.001 1.56 1.10 to 2.22 0.013 
Smoking status             
Never Ref      Ref   Ref   
Previous 0.69 0.54 to 0.88 0.003    1.73 1.28 to 2.34 <0.001 1.06 0.76 to 1.49 0.74 
Current 1.07 0.78 to 1.47 0.71    1.14 0.71 to 1.84 0.58 1.25 0.70 to 2.24 0.45 
Cause of CKD             
Vascular Ref   Ref   Ref      
Diabetes 1.92 1.33 to 2.78 0.001 1.05 0.69 to 1.60 0.81 0.81 0.52 to 1.26 0.35    
Glomerular 1.19 0.81 to 1.76 0.38 1.00 0.66 to 1.51 1.00 0.22 0.11 to 0.41 <0.001    
Tubulointerstitial 0.89 0.57 to 1.38 0.59 0.63 0.37 to 1.06 0.08 0.31 0.16 to 0.59 <0.001    
Cystic or congenital 2.85 2.01 to 4.04 <0.001 3.99 2.74 to 5.83 <0.001 0.26 0.10 to 0.63 0.003    
Other or unknown 1.24 0.89 to 1.73 0.21 1.21 0.85 to 1.73 0.28 0.82 0.57 to 1.17 0.27    
MAP 1.39 1.25 to 1.54 <0.001 0.93 0.83 to 1.06 0.28 0.79 0.68 to 0.93 0.005    
eGFR 1.18b 1.14 to 1.22 <0.001 0.94b 0.93 to 0.96 <0.001 0.45 0.36 to 0.56 <0.001 0.67 0.53 to 0.86 0.002 
 1.06c 1.05 to 1.07 <0.001 3.26e 2.73 to 3.91 <0.001       
Urine ACR 1.48d 1.37 to 1.59 <0.001 3.30f 2.61 to 4.17 <0.001 0.78g 0.63 to 0.96 0.018 1.24 1.07 to 1.45 0.005 
    1.00a 1.00 to 1.00 <0.001 1.01a 1.00 to 1.01 <0.001    
Continuous variables are linear per +1 SD unless indicated. Two rows for a continuous variable indicate the SHR or HR for each power from 
an FP2 model. Fractional polynomial transformations are indicated by: a = x3; b = x-2; c =x-2ln(x); d = ln(x); e = x-1; f = x0.5; g = x.
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On univariable analysis, the presence of an MG did not have a significant association 
with the risk of kidney failure (SHR 0.97 [95% CI 0.68 to 1.38], P=0.85; Figure 5.1). 
 
Figure 5.1. Cumulative incidence of kidney failure by MG status 
Black line = MG+ with interrupted black lines representing the 95% CI; grey line = MG- 
with interrupted grey lines representing the 95% CI. 
Age, eGFR and urine ACR had non-linear relationships with the risk of kidney failure 




Figure 5.2. Unadjusted SHR for kidney failure, according age, eGFR and urine ACR 
SHR represents risk relative to 60 years for age, 30 ml/min/1.73 m2 for eGFR, and 30 
mg/mmol for urine ACR. 
The multivariable model for kidney failure is shown in Table 5.3. After adjustment 
for age, sex, ethnicity, cause of CKD, MAP, eGFR, and urine ACR, the presence of an MG 
was not significantly associated with risk of kidney failure (SHR 1.16 [95% CI 0.80 to 1.69], 
P=0.43). 
Younger age (non-linear, Figure 5.3), female sex, Black ethnicity, a cystic or 
congenital cause of CKD, lower eGFR (non-linear, Figure 5.3), and higher urine ACR (non-





Figure 5.3. Adjusted SHR for kidney failure according to age, eGFR, and urine ACR 
SHR relative to 60 years for age, 30 ml/min/1.73 m2 for eGFR, and 30 mg/mmol for urine 
ACR, from the multivariable model in Table 5.3. 
5.5.1.2. Death 
Two hundred two (23.0%) participants died. The death rates per 100 person-years 
were 10.8 and 5.3 for those with and without MG, respectively. The univariable associations 
with death are shown in Table 5.3. The presence of an MG was associated with a higher risk 




Figure 5.4. Kaplan-Meier survival curves by MG status 
 
However, as shown in the multivariable model in Table 5.3, after adjusting for age, 
sex, ethnicity, co-morbidities, smoking status, eGFR and urine ACR, the presence of an MG 
no longer had a statistically significant association with death (HR 1.37 [95% CI 0.93 to 
2.00], P=0.11). 
Older age, a history of IHD or malignancy, lower eGFR and higher urine ACR were 
associated with a higher risk of death in the multivariable model. 
5.5.2. Non-malignant LC-MG 
Three thousand four hundred seventy-eight participants from the three cohorts were 
included, and 55 (1.6%) of these had an LC-MG. Median follow-up time was 5.2 years. 
Table 5.4 shows the study population characteristics and the relationship between LC-MG 




Table 5.4. Baseline characteristics by LC-MG status 
Variable All LC-MG +ve LC-MG -ve Data completeness (%) 
N (%) 3478 55 (1.6) 3423 (98.4)  
Age (years) 71.0 (61.2 to 78.0) 
77.8 (71.0 to 
82.0) 
71.0 (61.1 to 
78.0) 100 
Sex (male) 1760 (50.6) 38 (69.1) 1722 (50.3) 100 
Ethnicity    100 
White 3126 (89.9) 44 (80.0) 3082 (90.0)  
South Asian 237 (6.8) 5 (9.1) 232 (6.8)  
Black 96 (2.8) 6 (10.9) 90 (2.6)  
Other 19 (0.6) 0 (0.0) 19 (0.6)  
Co-morbidities    100 
DM 914 (26.3) 16 (29.1) 898 (26.2)  
IHD 1347 (38.7) 10 (18.2) 1337 (39.1)  
Cerebrovascular 395 (11.4) 3 (5.5) 392 (11.5)  
PAD 879 (25.3) 5 (9.1) 874 (25.5)  
Smoking status    99.5 
Never 1486 (43.0) 26 (47.3) 1460 (42.9)  
Previous 1667 (48.2) 28 (50.9) 1639 (48.1)  
Current 307 (8.9) 1 (1.8) 306 (9.0)  
MAP (mmHg) 93 (86 to 102) 92 (85 to 99) 93 (86 to 102) 99.3 
eGFR (ml/min/1.73 
m2) 
42.3 (26.2 to 
54.4) 
40.4 (24.3 to 
54.2) 




3.4 (0.3 to 
27.3) 
4.7 (0.4 to 
76.6) 
3.4 (0.2 to 
26.7) 95.5 
Categorical variables are shown as a frequency (percentage) and continuous variables as the 
median (interquartile range). 
Compared to those without an LC-MG, those with an LC-MG were on average older 
(P<0.001), a higher proportion were male (P=0.006) and of Black ethnicity (P=0.004), and a 
lower proportion had a history of IHD (P=0.001) or PAD (P=0.004). There were no 
statistically significant differences between those with and those without LC-MG for all other 
baseline variables. 
 
5.5.2.1. Kidney failure 
Five hundred sixty-four (16.2%) patients progressed to kidney failure, with rates per 
100 person-years of 4.9 and 3.2 for those with and without an LC-MG, respectively. The 
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univariable associations between baseline variables and the risk of kidney failure are shown 




Table 5.5. Association between baseline variables and risk of kidney failure and death 
Variable 
Kidney failure Death 
Univariable Multivariable Univariable Multivariable 
SHR 95% CI P SHR 95% CI P HR 95% CI P HR 95% CI P 
LC-MG+ 1.07 0.58 to 1.96 0.82 1.42 0.78 to 2.57 0.26 2.51 1.59 to 3.96 <0.001 1.49 0.93 to 2.39 0.10 
Age 1.01a 1.00 to 1.02 0.20 1.00a 1.00 to 1.00 <0.001 2.88 2.60 to 3.19 <0.001 2.76 2.48 to 3.08 <0.001 
 1.00b 0.99 to 1.00 0.050          
Male sex 0.95 0.81 to 1.12 0.53 1.14 0.96 to 1.37 0.13 1.59 1.37 to 1.84 <0.001 1.27 1.09 to 1.49 0.002 
Ethnicity             
White Ref   Ref   Ref   Ref   
South Asian 1.94 1.56 to 2.41 <0.001 1.15 0.89 to 1.48 0.30 0.67 0.47 to 0.94 0.022 1.11 0.79 to 1.56 0.56 
Black 1.84 1.35 to 2.49 <0.001 1.71 1.29 to 2.27 <0.001 0.77 0.48 to 1.25 0.30 1.10 0.70 to 1.73 0.69 
Other 2.80 1.34 to 5.86 0.006 1.42 0.55 to 3.62 0.47 0.48 0.12 to 1.94 0.30 0.79 0.29 to 2.14 0.64 
Co-morbidities             
DM 0.92 0.77 to 1.09 0.31    1.71 1.48 to 1.97 <0.001 1.42 1.22 to 1.65 <0.001 
IHD 1.03 0.85 to 1.24 0.78    1.64 1.35 to 1.99 <0.001 1.31 1.10 to 1.56 0.002 
Cerebrovascular 0.84 0.64 to 1.10 0.20    1.97 1.65 to 2.36 <0.001 1.39 1.15 to 1.69 0.001 
PAD 1.10 0.88 to 1.36 0.41    0.93 0.70 to 1.22 0.58 0.93 0.76 to 1.14 0.49 
Smoking status             
Never Ref      Ref   Ref   
Previous 0.72 0.60 to 0.86 <0.001    1.71 1.47 to 2.00 <0.001 1.26 1.07 to 1.48 0.005 
Current 1.14 0.91 to 1.44 0.26    1.34 1.04 to 1.74 0.026 1.56 1.16 to 2.09 0.003 
MAP 1.33 1.23 to 1.44 <0.001 1.07 0.97 to 1.18 0.16 0.00h 0.00 to 0.00 <0.001    
       71.39i 6.10 to 835.26 0.001    
eGFR 1.17c 1.15 to 1.20 <0.001 0.96c 0.95 to 0.97 <0.001 0.00f 0.00 to 0.01 <0.001 0.65 0.58 to 0.74 <0.001 
 1.06d 1.05 to 1.06 <0.001 2.4g 2.10 to 2.80 <0.001       
Urine ACR 10.97e 7.20 to 16.70 <0.001 3.58e 2.62 to 4.90 <0.001 1.68e 1.18 to 2.40 0.005 1.15h 1.09 to 1.22 <0.001 
 0.80f 0.68 to 0.95 0.008    0.40j 0.29 to 0.55 <0.001 1.01i 1.00 to 1.01 <0.001 
Continuous variables are linear per +1 SD unless indicated. Two rows for a continuous variable indicate the SHR or HR for each power from 
an FP2 model. Fractional polynomial transformations are indicated by: a = x3; b = x3ln(x); c = x-2; d = x-2ln(x); e = x0.5; f = x2; g = x-1; h = 
ln(x); i = (ln(x))2; j = x0.5ln(x).
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The presence of an LC-MG did not have a significant association with the risk of 
kidney failure in univariable analysis (SHR 1.07 [95% CI 0.58 to 1.96], P=0.82; Figure 5.5).  
 
Figure 5.5. Cumulative incidence of kidney failure by LC-MG status 
Black line = LC-MG+; grey line = LC-MG-. 
Age, eGFR, and urine ACR had non-linear associations with risk of kidney failure in 































Figure 5.6. Unadjusted SHR for kidney failure according to age, eGFR, and urine ACR 
SHR relative to 70 years for age, 40 ml/min/1.73 m2 for eGFR, and 3 mg/mmol for urine ACR. 
The multivariable model for kidney failure is shown in Table 5.5. After adjusting for 
age, sex, ethnicity, cause of CKD, MAP, eGFR, and urine ACR, the presence of an LC-MG 
did not have a statistically significant association with risk of kidney failure (SHR 1.42 [95% 
CI 0.78 to 2.57], P=0.26). 
In this multivariable model, younger age (non-linear, Figure 5.7), Black ethnicity, 
lower eGFR (non-linear, Figure 5.7), and higher urine ACR (non-linear, Figure 5.7) were 
associated with a higher risk of kidney failure. 
  
Figure 5.7. Adjusted SHR for kidney failure according to age, eGFR, and urine ACR 
SHR relative to 70 years for age, 40 ml/min/1.73 m2 for eGFR, and 3 mg/mmol for urine ACR, 




Eight hundred three (23.1%) participants died. Death rates were 9.3 and 4.5 per 100 
person-years for those with and without an LC-MG, respectively. The univariable 
associations between baseline factors and death are shown in Table 5.5. LC-MG was 
associated with a higher risk of death (HR 2.51 [95% CI 1.59 to 3.96], P<0.001) and Figure 
5.8 shows Kaplan-Meier survival curves by LC-MG status. 
 
Figure 5.8. Kaplan-Meier survival curves by LC-MG status 
 
The univariable analyses showed that MAP, eGFR, and urine ACR had non-linear 




Figure 5.9. Unadjusted HR for death according to MAP, eGFR, and urine ACR 
HR with 95% CI relative to 90 mmHg for MAP, 40 ml/min/1.73 m2 for eGFR, and 3 mg/mmol 
for urine ACR. 
In the multivariable model (Table 5.5), after adjustment for age, sex, ethnicity, co-
morbidities, smoking status, eGFR, and urine ACR, an LC-MG did not have a statistically 
significant association with death (HR 1.49 [95% CI 0.93 to 2.39], P=0.10). 
In this multivariable model, older age, male sex, a history of DM, IHD, or 
cerebrovascular disease, being a previous or current smoker, lower eGFR, and higher urine 




Figure 5.10. Adjusted HR for death according to urine ACR 




It was hypothesised that, in patients with CKD, the presence of a non-malignant MG 
would be associated with a higher risk of kidney failure and death, based on the known 
pathogenetic properties of paraproteins in the kidney, and on the knowledge that MGUS is 
associated with reduced survival in the general population. Only one other study, by Haynes 
et al. (218), has assessed the relationship between MG and clinical outcomes in patients with 
CKD. That study had far fewer participants (382, of whom 35 had MGUS) and event rates 
than the work presented here and therefore there is likely to be less bias in the estimates 
presented in this chapter. While patients with CKD are already at a higher risk of kidney 
failure and death compared to the general population, the results of this work suggest that the 
presence of a non-malignant MG does not add to these risks. 
The prevalence of non-malignant MG in this CKD population was significantly higher 
than the reported estimates of prevalence for the general population (255). This was also the 
case in the study by Haynes et al. (218), and it appears attributable to an increased prevalence 
of both intact Ig MG and LC-MG. The prevalence of total MGUS in the Olmsted County 
cohort in individuals aged 70 to 79 was 5.9%, and the prevalence of LC-MGUS was 1.1% 
(265); in this study, the crude prevalence was 11.6% for total MGUS (median age 73.8 years) 
and 1.6% for LC-MGUS (median age 77.8 years).  
5.6.1. Kidney failure 
The presence of a non-malignant MG was not associated with a higher risk of kidney 
failure in this study. This is consistent with the results of the study by Haynes et al. (218). 
This may be reassuring for patients with CKD and a non-malignant MG and their clinicians. 
Paraproteins are known to have potentially pathogenetic properties that can directly cause 
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kidney damage in MGRS and malignant MGs. If a significant association with kidney failure 
had been detected, it might have suggested that there are undiagnosed cases of MGRS. It is 
common to detect a paraprotein during the assessment of a patient with CKD, and in many 
patients, a kidney biopsy is foregone, and a presumed diagnosis of MGUS is made. 
Consensus guidelines have recently been published and recommend that a kidney biopsy be 
performed in those with MG and unexplained kidney disease, those with known risk factors 
for CKD but an atypical clinical course, and those with kidney disease and MG aged younger 
50 years (266). 
5.6.2. Death 
The results of this study and the study by Haynes et al. (218) suggest that the shorter 
survival associated with MGUS in the general population is not seen in patients with CKD. It 
is possible that neither study was large enough to detect a small increase in the risk of death, 
or that follow-up was not long enough to detect an increase in mortality due to malignant 
transformation which occurs at a rate of approximately 1% per year. However, it may be that 
the already significantly increased rate of death in individuals with CKD, particularly due to 
CVD, renders any risk associated with an MG negligible. 
5.6.3. Strengths and limitations 
A significant strength of this study was the inclusion of participants from multiple 
cohorts from both primary and secondary care and that it is the largest cohort to date of 
patients with MGUS and CKD. 
A significant limitation was the absence of SPEP and immunofixation data from the 
SKS and RRID cohorts. In these two cohorts, only LC-MG could be detected, and many 
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patients with an intact Ig MG would not have been identified. However, in the RIISC study, 
where SPEP and immunofixation were performed on serum from all participants, the presence 
of any non-malignant MG was not associated with a higher risk of kidney failure or death. 
Further, other clinically important outcomes associated with MGUS in the general 
population were not assessed, such as cardiovascular events, infections, or the evolution of an 
MG to multiple myeloma or other paraprotein-related diseases. 
Finally, CKD progression by the change in eGFR with time was not assessed, which 
would likely be a more sensitive marker for MG-associated kidney damage than the outcome 
of kidney failure. 
5.6.4. Future research 
Further research is required concerning the prognostic implications of non-malignant 
MG in patients with CKD, particularly for outcomes other than kidney failure and death, such 




In conclusion, the prevalence of non-malignant MG appears to be higher in patients 
with CKD than in the general population, but these patients and their healthcare providers 




CHAPTER VI: SERUM ENDOTROPHIN 
The work presented in this chapter aimed to address the hypotheses that a higher 
serum concentration of endotrophin is associated with a higher risk of kidney failure and 
death in patients with chronic kidney disease (CKD). 
Endotrophin is a fragment of collagen type VI, cleaved off after microfibril formation, 
and its concentration in the serum has been used as a marker of collagen type VI expression. 
As it is known that CKD is associated with a greater fibrotic burden in the kidney and 
cardiovascular system, it was hypothesised that serum endotrophin concentration, as a marker 
of this fibrotic load, would be associated with adverse outcomes in patients with CKD. 
This work has been published in the article ‘Serum endotrophin, a type VI collagen 
cleavage product, is associated with increased mortality in chronic kidney disease,’ in PLOS 
ONE in 2017 (267), and was presented in poster format at the American Society of 





Patients with CKD are thought to have dysregulation of extracellular matrix formation with 
accelerated systemic and renal fibrosis. The relationship between serum endotrophin 
concentration, a marker of collagen type VI formation, and the risk of kidney failure and 
death in a cohort of patients with CKD was assessed. 
Methods 
Serum endotrophin concentration was measured in 500 patients from the RIISC study, a 
prospective cohort study of patients with CKD. Patients were followed up until kidney failure 
or death. The association between serum endotrophin and kidney failure was assessed by 
competing risks regression (handling death as a competing event), and the association with 
death was assessed by Cox proportional hazards regression. 
Results 
Median follow-up time was 37 months, and there were 104 kidney failure events and 66 
deaths. Serum endotrophin concentration was not significantly associated with the risk of 
kidney failure (adjusted SHR 1.04 [0.85 to 1.27] per +1 SD) but did have an independent 
association with the risk of death (adjusted HR 1.59 [1.24 to 2.04] per +1 SD). 
Conclusions 
Serum endotrophin concentration is not independently associated with the risk of kidney 
failure in patients with CKD but is independently associated with mortality. This may reflect 
increased cardiovascular fibrosis, but further work is required for validation and exploration 




Kidney fibrosis is the common final pathological manifestation of CKD, irrespective 
of the original cause of kidney disease, as described in Section 1.2.6, and its strong 
association with renal prognosis has been shown in many studies (268, 269). As described 
below, CKD is also associated with increased cardiovascular fibrosis. Endotrophin is a marker 
of collagen type VI deposition, and its use as a potential non-invasive marker of fibrosis and 
as a prognostic factor in patients with CKD merits further study. 
6.2.1. Collagen type VI 
Collagen type VI forms a network of beaded microfilaments in the ECM of most 
connective tissues, where it interacts with other ECM molecules and provides structural 
support for cells. In addition to a mechanical role, collagen type VI has cytoprotective 
functions such as the inhibition of apoptosis and oxidative damage, and the regulation of cell 
differentiation and autophagy (270-272). It is an important protein within the healthy kidney, 
being one of the most abundant proteins of the glomerular ECM, localised within the 
glomerular basement membrane and the mesangial matrix (273), and it also forms part of the 
reticular structure of the renal interstitium (274).  
Nearly all forms of CKD are associated with renal collagen deposition and fibrosis. 
The deposition of collagen type VI is markedly increased in the fibrotic lesions seen in the 
glomerulus and interstitium in patients with CKD (275-277). The degree of tubulointerstitial 
fibrosis is strongly associated with long-term renal prognosis. The degree of interstitial 
collagen type VI expression, specifically, has been shown to be associated with the risk of 
kidney failure in patients with membranous nephropathy (278). 
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In addition to kidney fibrosis, patients with CKD have increased collagen deposition 
and fibrosis in other organs. Diffuse myocardial fibrosis has been demonstrated even in early 
CKD (279, 280) and, as in the kidney, collagen type VI forms part of the healthy myocardial 
ECM and increased deposition is demonstrated in myocardial fibrosis (281-285). Further, 
increased collagen deposition and fibrosis of arterial walls is observed in patients with CKD, 
which, in addition to arterial wall calcification, is associated with increased arterial stiffness 
(286-288). 
Collagen type VI is composed of three chains: α1, α2, and α3 (289). Each chain 
contains a short collagenous region between domains at the N and C termini, as shown in 
Figure 6.1 (289, 290). 
 
Figure 6.1. Organisation of domains in the α1, α2 and α3 chains of collagen type VI 
The collagenous region is shown in black, with domains at the N and C termini. Note the C5 
domain of α3 (purple), termed endotrophin. From (290). 
Intracellularly, collagen type VI monomers form dimers and then tetramers before 
secretion into the ECM. The secreted tetramers then associate end-to-end to form beaded 




Figure 6.2. The assembly of collagen type VI microfibrils from the three α chains 
The formation of monomers, dimers, and tetramers occurs intracellularly, while microfibril 
assembly occurs in the extracellular space. From (290). 
The C5 domain of the α3 chain, termed endotrophin (shown in purple in Figure 6.1), 
plays a crucial role in microfibril assembly, but following microfibril formation is 
immediately cleaved off, and its measurement has thus been used as a marker for collagen 
type VI expression (289, 291, 292). 
6.2.2. Endotrophin 
Because endotrophin is cleaved off mature collagen type VI microfibrils shortly after 
their assembly, serum endotrophin concentration has been measured as a surrogate marker of 
collagen type VI formation. 
In addition to playing a vital role in collagen type VI microfibril formation, released 
endotrophin has important biological effects in its own right. It appears to be particularly 
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abundant in adipose tissues, where it has pro-fibrotic effects and is pro-inflammatory, acting 
as a potent chemoattractant to macrophages (293).  
To date, few published studies have assessed the prognostic significance of serum 
endotrophin levels. Given that CKD is associated with increased kidney collagen type VI 
deposition and endotrophin expression (294) and that plasma endotrophin levels correlate 
strongly with kidney transplant dysfunction (295) and failure (Nordic Bioscience, 
unpublished data), it was hypothesised that serum endotrophin concentration would correlate 
with kidney damage in CKD, and thus be associated with the risk of kidney failure. 
Further, given the association between CKD and organ fibrosis, particularly 
cardiovascular fibrosis, and the potentially deleterious systemic effects of endotrophin, it was 







The work presented in this chapter aimed to address the following pre-specified hypotheses: 
1. Higher serum endotrophin concentration is associated with a higher risk of kidney 
failure in patients with CKD; 
2. Higher serum endotrophin concentration is associated with a higher risk of death in 





For sample availability reasons, data and samples from the six-month follow-up visit, 
rather than baseline visit, for the first 500 patients recruited into the Renal Impairment in 
Secondary Care (RIISC) Study were used. The RIISC study is described in detail in Section 
2.1. All eligibility criteria, as described in Section 2.1.3, applied. 
6.4.2. Assay 
Serum endotrophin concentration was measured using the ‘Pro-C6’ competitive 
ELISA (Nordic Bioscience, Herlev, Denmark) (296). 
6.4.3. Follow-up 
The six-month visits occurred between April 2011 and September 2014. Time-to-
event data were calculated from the date of the participant’s six-month visit, and outcomes up 
to 31 December 2018 were included for the following: 
• Kidney failure, defined as the initiation of kidney replacement therapy 
(dialysis or kidney transplantation) 
• Death, from any cause. 
6.4.4. Statistical methods 
The distributions of baseline characteristics, including serum endotrophin 
concentration, are presented in tabular form with the number of missing values reported for 




The relationships between serum endotrophin concentration and other baseline 
variables were assessed statistically. Given the possibility that serum endotrophin 
concentration may reflect cardiovascular fibrosis, the association with pulse wave velocity 
(PWV), a measure of arterial stiffness (see Section 2.1.4.4), was assessed. Relationships with 
continuous variables are expressed as Kendall’s τ with its corresponding P, and fractional 
polynomials were used to assess for non-linear relationships and presented graphically. For 
categorical variables, median and interquartile ranges are shown with between-group 
differences assessed using the Mann-Whitney U or Kruskal-Wallis tests. 
Univariable and multivariable regression models were fitted to show the association 
between serum endotrophin and other variables with outcomes. Subdistribution hazard 
models were used to assess the association with kidney failure (handling death as a competing 
risk) and presented as a subhazard ratio (SHR) with a 95% confidence interval (CI). Cause-
specific hazard models were also fitted and are presented in Appendix 8. Cox proportional 
hazards regression was used to assess associations with death and are presented as a hazard 
ratio (HR) with 95% CI. Multivariable models were prespecified and non-linear associations 
were assessed, as per Section 2.5.4.2. 
Missing data were handled by multiple imputation as per Section 2.5.6. For the kidney 
failure analyses, 13% of participants had missing data in at least one variable, and therefore 
15 imputations were used. For the death analyses, 3% of participants had missing data, and 






The 500 participants had a median follow-up time of 6.4 years, during which there 
were 170 kidney failure events and 109 deaths. 
6.5.1. Study population characteristics 
The characteristics of the study population at the six-month visit (the time point at 
which serum endotrophin was measured) are shown in Table 6.1. 
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Table 6.1. Characteristics of the study population 
Variable Median (IQR) or N(%) Data completeness (%) 
Age 64 (50 to 76) 100 
Sex (male) 308 (61.6) 100 
Ethnicity  100 
White 361 (72.2)  
South Asian 90 (18.0)  
Black 44 (8.8)  
Other 5 (1.0)  
Cause of CKD  89.6 
Vascular 130 (29.0)  
Diabetes 48 (10.7)  
Glomerular 82 (18.3)  
Cystic and congenital 38 (8.5)  
Tubulointerstitial 52 (11.6)  
Other/uncertain 98 (21.9)  
Co-morbidities  100 
Cerebrovascular disease 54 (10.8)  
COPD 60 (12.0)  
DM 183 (36.6)  
IHD 112 (22.4)  
Malignancy 72 (14.4)  
PAD 51 (10.2)  
Smoking status  100 
Never 218 (43.6)  
Previous 215 (43.0)  
Current 67 (13.4)  
Systolic BP (mmHg) 124 (114 to 139) 100 
Diastolic BP (mmHg) 75 (67 to 83) 100 
MAP (mmHg) 91 (84 to 99) 100 
PWV (m/s) 9.7 (8.4 to 11.3) 82.2 
eGFR (ml/min/1.73 m2) 27 (19 to 35) 99.4 
Urine ACR (mg/mmol) 32.4 (6.1 to 128.3) 97.6 
Serum endotrophin (ng/ml) 23.1 (16.8 to 30.1) 99.6 
From the six-month visit. 
Median serum endotrophin concentration was 23.1 ng/ml (IQR 16.8 to 30.1), and its 




Figure 6.1. Histogram of serum endotrophin concentration 
The histogram illustrates the skewed distribution of serum endotrophin concentration. 
6.5.2. Relationships between endotrophin and other variables 
















Table 6.2. Relationship between serum endotrophin and other variables 
Variable Kendall’s τ or Median (IQR) P 
Age 0.174 <0.001 
Sex  0.028 
Female 24.6 (18.2 to 31.4)  
Male 22.0 (16.2 to 29.4)  
Ethnicity  0.23 
White 23.1 (16.7 to 29.8)  
South Asian 24.3 (18.5 to 31.9)  
Black 21.5 (15.2 to 29.4)  
Other 21.8 (11.5 to 27.9)  
Cause of CKD  <0.001 
Vascular 25.3 (20.3 to 31.9)  
Diabetes 31.7 (23.3 to 38.0)  
Glomerular 17.1 (12.6 to 24.8)  
Cystic and congenital 19.9 (14.8 to 26.7)  
Tubulointerstitial 22.2 (18.2 to 29.6)  
Other/uncertain 23.4 (16.5 to 28.4)  
Co-morbidities   
Cerebrovascular disease  0.29 
Yes 23.2 (17.3 to 31.6)  
No 23.1 (16.6 to 29.8)  
COPD  0.84 
Yes 23.1 (17.0 to 30.6)  
No 23.1 (16.7 to 29.9)  
Diabetes mellitus  <0.001 
Yes 26.1 (18.6 to 32.9)  
No 21.4 (16.2 to 28.0)  
Ischaemic heart disease  0.017 
Yes 25.0 (19.0 to 31.1)  
No 22.2 (16.5 to 29.4)  
Malignancy  0.97 
Yes 22.9 (16.9 to 29.2)  
No 23.1 (16.7 to 30.2)  
Peripheral artery disease  0.38 
Yes 24.0 (19.4 to 29.4)  
No 23.0 (16.5 to 30.2)  
Smoking status  0.18 
Never 23.3 (16.8 to 30.9)  
Previous 23.3 (18.0 to 29.4)  
Current 21.1 (15.5 to 28.8)  
Systolic BP 0.135 <0.001 
Diastolic BP -0.129 <0.001 
MAP 0.002 0.96 
PWV 0.099 0.003 
eGFR -0.537 <0.001 
Urine ACR 0.061 0.045 
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Serum endotrophin concentration was higher in females, those with DM or diabetic 
kidney disease, and those with IHD. Any other relationships, including that with PWV, were 
very weak, except for the relationship with eGFR. 
In a multivariable analysis, the only variables with significant independent 
associations with serum endotrophin concentration were sex (2.1 [0.5 to 3.8] ng/ml higher in 
females, P=0.013), cause of CKD (7.2 [4.6 to 9.9] ng/ml higher in diabetic kidney disease, 
P<0.001), and eGFR, which had a non-linear relationship as shown in Figure 6.2. 
 
Figure 6.2. Relationship between eGFR and serum endotrophin concentration 
The non-linear relationship is best fit with the fractional polynomial transformation of eGFR 
x-0.5. 
6.5.3. Kidney failure 
During the median follow-up time of 6.4 years, 170 (34.0%) participants progressed to 
























associations between serum endotrophin concentration and other baseline factors with the risk 
of kidney failure are shown in Table 6.3. 
Table 6.3. Univariable and multivariable associations with kidney failure 
Variable 
Univariable Multivariable 
SHR 95% CI P SHR 95% CI P 
Age 1.00a 1.00 to 1.00 <0.001 0.993 0.99 to 1.00 <0.001 
Sex (male) 0.86 0.63 to 1.16 0.32 1.09 0.78 to 1.53 0.62 
Ethnicity       
White Ref   Ref   
South Asian 1.90 1.34 to 2.68 <0.001 1.25 0.84 to 1.86 0.28 
Black 1.52 0.92 to 2.52 0.10 1.30 0.75 to 2.23 0.35 
Other 1.31 0.38 to 4.58 0.67 1.07 0.25 to 4.50 0.93 
Cause of CKD       
Vascular Ref   Ref   
Diabetes 2.00 1.12 to 3.57 0.020 1.01 0.56 to 1.82 0.98 
Glomerular 1.36 0.81 to 2.28 0.24 0.82 0.46 to 1.45 0.49 
Cystic and congenital 3.07 1.89 to 4.98 <0.001 3.19 1.80 to 5.64 <0.001 
Tubulointerstitial 1.11 0.62 to 1.98 0.72 0.81 0.43 to 1.55 0.53 
Other/uncertain 1.33 0.83 to 2.15 0.24 1.01 0.61 to 1.66 0.97 
Co-morbidities       
Cerebrovascular disease 0.76 0.45 to 1.30 0.32    
COPD 0.41 0.21 to 0.77 0.006    
DM 0.75 0.54 to 1.04 0.09    
IHD 0.83 0.57 to 1.22 0.35    
Malignancy 0.48 0.28 to 0.83 0.008    
PAD 0.62 0.34 to 1.13 0.12    
Smoking status       
Never Ref      
Previous 0.77 0.56 to 1.07 0.12    
Current 0.85 0.53 to 1.37 0.51    
MAP 1.35 1.17 to 1.56 <0.001 1.04 0.87 to 1.24 0.64 
eGFR 5.17b 3.72 to 7.19 <0.001 13.03b 7.67 to 22.16 <0.001 
Urine ACR 1.47c 1.33 to 1.62 <0.001 3.19d 2.22 to 4.59 <0.001 
    1.00a 0.99 to 1.00 0.014 
Serum endotrophin 0.01b 0.00 to 0.03 <0.001 1.04 0.85 to 1.27 0.69 
SHR for continuous variables are per +1 SD, unless fractional polynomial transformation 
provided better model fit, which are denoted by: a = x3; b = x-0.5; c = ln(x); d = x0.5. 
On univariable analysis, a higher serum endotrophin concentration was associated 




Figure 6.3. Unadjusted SHR for kidney failure according to serum endotrophin 
SHR with 95% CI, relative to 25 ng/ml. 
Other variables associated with a higher risk of kidney failure on univariable analysis 
were younger age (non-linear, Figure 6.4), South Asian ethnicity, CKD due to diabetes or a 
cystic or congenital disease, higher MAP (non-linear, Figure 6.5), lower eGFR (non-linear, 
Figure 6.6), and higher urine ACR (non-linear, Figure 6.7). Diagnoses of COPD or 































Figure 6.4. Unadjusted SHR for kidney failure according to age 
SHR with 95% CI, relative to 65 years. 
 
Figure 6.5. Unadjusted SHR for kidney failure according to MAP 
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Figure 6.6. Unadjusted SHR for kidney failure according to eGFR 
SHR with 95% CI, relative to 30 ml/min/1.73 m2. 
 
Figure 6.7. Unadjusted SHR for kidney failure according to urine ACR 
























































The multivariable model for kidney failure is shown in Table 6.3. After adjusting for 
age, sex, ethnicity, cause of CKD, MAP, eGFR, and urine ACR, serum endotrophin 
concentration was no longer associated with the risk of kidney failure (SHR 1.04 [0.85 to 
1.27] per +1 SD). 
Factors associated with a higher risk of kidney failure in the multivariable model were 
younger age (non-linear, Figure 6.8), a cystic or congenital cause of CKD, lower eGFR (non-
linear, Figure 6.9), and higher urine ACR (non-linear, Figure 6.10). 
 
Figure 6.8. Adjusted SHR for kidney failure according to age 


























Figure 6.9. Adjusted SHR for kidney failure according to eGFR 
SHR with 95% CI, relative to 30 ml/min/1.73 m2 from the multivariable model in Table 6.3. 
 
Figure 6.10. Adjusted SHR for kidney failure according to urine ACR 



















































During the median follow-up time of 6.4 years, 109 (21.8%) participants died, and the 
overall death rate was 4.7 per 100 person-years. The univariable associations between serum 
endotrophin concentration and other variables with the risk of death are shown in Table 6.4. 
Table 6.4. Univariable and multivariable associations with death 
Variable 
Univariable Multivariable 
HR 95% CI P HR 95% CI P 
Age 3.63 2.71 to 4.86 <0.001 3.51 2.47 to 4.98 <0.001 
Sex (male) 1.11 0.75 to 1.64 0.60 1.06 0.67 to 1.66 0.81 
Ethnicity       
White Ref   Ref   
South Asian 0.82 0.48 to 1.43 0.49 1.28 0.68 to 2.38 0.44 
Black 0.78 0.38 to 1.60 0.49 1.21 0.56 to 2.64 0.63 
Other 0.84 0.12 to 6.07 0.87 0.82 0.10 to 6.63 0.86 
Cause of CKD       
Vascular Ref      
Diabetes 0.94 0.51 to 1.77 0.86    
Glomerular 0.21 0.09 to 0.46 <0.001    
Cystic and congenital 0.26 0.08 to 0.84 0.024    
Tubulointerstitial 0.30 0.13 to 0.70 0.006    
Other/uncertain 0.58 0.34 to 0.98 0.041    
Co-morbidities       
Cerebrovascular disease 1.88 1.15 to 3.09 0.012 1.20 0.69 to 2.09 0.52 
COPD 1.36 0.82 to 2.26 0.23 1.29 0.76 to 2.20 0.35 
DM 2.05 1.40 to 2.99 <0.001 1.33 0.87 to 2.02 0.19 
IHD 2.52 1.71 to 3.71 <0.001 1.46 0.96 to 2.22 0.08 
Malignancy 1.32 0.82 to 2.13 0.26 1.03 0.62 to 1.70 0.91 
PAD 2.40 1.50 to 3.83 <0.001 1.32 0.79 to 2.22 0.29 
Smoking status       
Never Ref   Ref   
Previous 1.53 1.02 to 2.29 0.041 1.15 0.71 to 1.85 0.57 
Current 0.94 0.49 to 1.80 0.85 1.44 0.68 to 3.04 0.34 
MAP 5.e+224a 7.e+107 to . <0.001 1.17 0.95 to 1.44 0.14 
 0.00b 0.00 to 0.00 <0.001    
eGFR 0.34 0.23 to 0.50 <0.001 0.77 0.50 to 1.19 0.24 
Urine ACR 0.97 0.76 to 1.24 0.83 1.39 1.08 to 1.78 0.009 
Serum endotrophin 0.01a 0.00 to 0.03 <0.001 1.59 1.24 to 2.04 <0.001 
HR for continuous variables are per +1 SD, unless fractional polynomial transformation 
provided better model fit, which are denoted by: a = x-2; b = x-0.5. 
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On univariable analysis, a higher serum endotrophin concentration was associated 
with a higher risk of death. The association was non-linear, as shown in Figure 6.11. 
 
Figure 6.11. Unadjusted HR for death according to serum endotrophin concentration 
HR with 95% CI, relative to 25 ng/ml. 
Other factors associated with a higher risk of death on univariable analysis were older 
age, a history of cerebrovascular disease, DM, IHD, or PAD, being a previous smoker, a 
MAP < 78 or > 108 mmHg (Figure 6.12), and lower eGFR. Having a non-vascular or non-


























Figure 6.12. Unadjusted HR for death according to MAP 
HR with 95% CI, relative to 90 mmHg. 
After adjusting for age, sex, ethnicity, co-morbidities, smoking status, MAP, eGFR, 
and urine ACR, a higher serum endotrophin concentration remained significantly associated 
with a higher risk of death (HR 1.59 [1.24 to 2.04] per +1 SD). 
Other factors associated with a higher risk of death in the multivariable model were 
older age and higher urine ACR. It is particularly notable that eGFR is not associated with 
death in this model. When serum endotrophin concentration is removed from the 
multivariable model, eGFR becomes significantly associated with mortality (HR 0.53 [0.35 to 
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Tissue fibrosis and remodelling have been implicated in both CKD progression and 
the increased risk of death associated with CKD. The work presented in this chapter 
demonstrates an independent association between serum endotrophin concentration, a marker 
of collagen type VI formation, and mortality in a cohort study of participants with CKD. 
As has previously been demonstrated in kidney transplant recipients (295), there was 
an inverse relationship between eGFR and serum endotrophin concentration, for which there 
are several possible explanations. First, the correlation may reflect a reduction in renal 
clearance of endotrophin as kidney function declines. Although the estimated molecular 
weight of endotrophin is approximately 10 to 15 kDa (297), the renal clearance of 
endotrophin is not known. Second, it may reflect the increased abundance of fibrotic tissue, 
and therefore collagen type VI and endotrophin generation, in patients with CKD: renal 
fibrosis may be a contributing source of endotrophin, but the elevated serum levels are also 
likely to reflect a greater systemic fibrotic burden in patients with more advanced CKD. 
These data do not allow a determination of the relative contributions of these potential 
explanations for the relationship described. 
6.6.1. Kidney failure 
Based on the hypothesis that serum endotrophin concentration may reflect increased 
kidney endotrophin expression, which has been shown to co-localise with collagen type VI in 
kidney fibrosis (294), and thus kidney damage, the association between serum endotrophin 
concentration and the risk of kidney failure in patients with CKD was explored. Although 
there was a higher risk of kidney failure associated with a higher endotrophin concentration, 
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after adjustment for eGFR and other standard prognostic factors, there was no independent 
association. 
It is likely that serum endotrophin level is highly influenced by systemic, particularly 
cardiovascular, fibrosis, and therefore not specific enough as a marker of kidney fibrosis. 
Urine endotrophin-creatinine ratio, meanwhile, has been shown to be an independent 
predictor of CKD progression, suggesting that urine endotrophin is a more specific marker of 
kidney fibrosis than serum endotrophin (294). The search for non-invasive, particularly 
urinary, markers of kidney fibrosis is an active area of nephrology research, as discussed in 
the final chapter. 
6.6.2. Death 
The results in this chapter suggest an independent association between serum 
endotrophin concentration and the risk of death in patients with CKD. After adjustment for 
eGFR and other standard prognostic factors, a higher serum endotrophin concentration was 
independently associated with a higher risk of death (HR 1.59 [1.24 to 2.04] per +1 SD, 
P<0.001). Furthermore, the association between serum endotrophin concentration and risk of 
death appears to be stronger than for eGFR, which is one of the most important prognostic 
factors for mortality in CKD. 
Despite the lack of an association between PWV, a marker of arterial stiffness, and 
serum endotrophin concentration, the association between endotrophin and mortality may still 
represent the effect of systemic, particularly cardiovascular, collagen type VI deposition and 
fibrosis. Previous studies have demonstrated increased diffuse myocardial fibrosis in patients 
with CKD (279, 280) and collagen type VI deposition has been demonstrated in myocardial 
fibrosis (281-285). Further, increased collagen deposition and fibrosis of the vascular wall is 
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observed in patients with CKD (286-288). The presence of collagen type VI has also been 
demonstrated in atherosclerotic lesions (298). Serum endotrophin concentration may reflect 
cardiovascular collagen type VI expression, thus a surrogate marker for cardiac and arterial 
fibrosis or atherosclerosis, and mortality risk. In patients with DM, serum endotrophin 
concentration correlates with markers of atherosclerosis severity and with the risk of 
cardiovascular events (299). 
Collagen type VI itself has also been shown to have various deleterious effects. For 
example, it has a significant role in platelet adhesion, which is intimately involved in 
atherosclerosis and microvascular pathology. Collagen type VI binds platelets both directly 
and via von Willebrand factor (vWF), and of the multiple subendothelial collagens to which 
vWF binds, collagen type VI appears to be especially important (300-302). Collagen type VI 
may also have deleterious effects on the myocardium. Collagen type VI deletion in knockout 
mice is associated with improved cardiac function, structure and remodelling after myocardial 
infarction (303). 
Endotrophin has also been demonstrated to have various adverse biological effects. 
For example, it has been shown to activate cardiac fibroblasts from healthy adult donors and 
induces fibrogenesis (304). It also plays a pivotal role in shaping a metabolically unfavourable 
microenvironment within adipose tissue, where it triggers fibrosis and inflammation and 
ultimately results in systemic elevation of pro-inflammatory cytokines, insulin resistance, and 
the metabolic syndrome (293). Further, endotrophin has been shown to play a role in 
promoting tumour growth and metastasis (270, 271, 305). 
The underlying nature of the relationship between serum endotrophin concentration 
and risk of death requires further work. 
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6.6.3. Strengths and limitations 
The strengths of this work include the utilisation of a large prospective CKD cohort 
with detailed bio-clinical phenotyping incorporating multiple prognostic factors for adverse 
outcomes. The limitations include it being single-centre, with no validation cohort, and the 
lack of experimental data to explore the mechanisms underlying the association between 
serum endotrophin and mortality. In particular, markers of cardiovascular fibrosis other than 
PWV, urinary endotrophin excretion, and causes of death, would have helped significantly to 
explain the associations described. 
6.6.4. Future research 
The independent association between serum endotrophin concentration and risk of 
death requires validation in a separate cohort of patients with CKD. Ideally, additional data, 
particularly on cardiovascular health and fibrosis, such as cardiac magnetic resonance 
imaging, cardiovascular events, and cause of death, would be collected to further the 
understanding of the nature of the relationship. Following validation, its role in risk prediction 




In conclusion, serum endotrophin concentration is not independently associated with 
the risk of kidney failure in patients with CKD but is independently associated with the risk of 
death after adjustment for standard prognostic factors. Further work is required to validate this 
finding and to understand the nature of the association.
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CHAPTER VII: GENERAL DISCUSSION 
7.1. Introduction 
Chronic kidney disease (CKD) has an estimated prevalence of approximately 10% in 
adults in the UK, and the prevalence is increasing. It is associated with an increased risk of 
serious adverse health outcomes, including kidney failure and death. However, the prognosis 
for an individual patient with CKD will fall on a spectrum, from asymptomatic disease with 
no progression and a lifespan equivalent to that expected in the healthy population, to rapid 
progression with kidney failure or early cardiovascular death. 
Identifying the likely prognosis for an individual patient with CKD provides important 
information for both the patient and their clinicians, helping guide management decisions in 
the individual patient’s care. Prognostic factors help to stratify risk and may be combined in 
prognostic models to predict an individual’s risk of adverse outcomes such as kidney failure. 
There are established prognostic factors in CKD that are associated with the risk of 
adverse outcomes, including age, cause of CKD, eGFR, and urine ACR. Risk prediction 
models, such as the Kidney Failure Risk Equation, are increasingly being employed in routine 
clinical practice to guide decision-making. For example, decisions around whether a patient 
needs follow-up in secondary care nephrology rather than primary care, or whether a patient 
should begin preparation for kidney replacement therapy can be aided by accurate prognostic 
information. An upcoming revision of the NICE CKD guideline is likely to recommend the 
use of the KFRE in routine care of patients with CKD. An assessment of the impact of 
introducing the model into clinical practice on clinical outcomes and the cost-effectiveness of 
care will be an essential consideration.  
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The identification of new factors that provide added prognostic information above and 
beyond that provided by established prognostic factors has the potential to improve risk 
stratification and risk prediction, and the potential to identify targets for new treatments, and 
thus improve the care of patients with CKD. 
In work presented in this thesis, four potential prognostic factors in CKD were 
examined for independent associations with the risk of kidney failure or death, as summarised 
in the following paragraphs.  
7.2. Serum free light chains 
Five studies had published estimates of the association between serum cFLC 
concentration and the risks of kidney failure or death in patients with CKD, but their results 
were inconsistent. A meta-analysis of individual participant data was conducted, 
incorporating additional data not previously reported, to examine these associations. 
A higher serum cFLC concentration was independently associated with a higher risk 
of kidney failure. For the first time, it was shown that the relationship between serum cFLC 
concentration and risk of kidney failure is non-linear, with an increasing risk up to a serum 
cFLC concentration of approximately 150 mg/l, above which the risk plateaus. Given the 
known nephrotoxic effects of FLCs, such as their ability to cause tubular toxicity or form 
casts, the association may be causal, although this cannot be proven from these data and 
requires further research. 
Serum cFLC concentration was also independently associated with the risk of death. 
Again, the relationship is non-linear, with a relatively smaller increase in risk at higher levels 
of cFLC concentration. The association may reflect confounding, such as inflammatory 
processes not measured in these data, but a causal association is possible given the potentially 
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deleterious effects of FLCs. Future work that incorporates measures of inflammation, such as 
C-reactive protein and cytokines, is required to explore the nature of the association further. 
Serum FLCs are routinely measured in clinical practice in the assessment of 
monoclonal disorders, but there is currently no role for the routine assessment of non-clonal 
serum FLC concentrations. Now that the association with kidney failure has been established, 
the potential incremental value of adding serum cFLC concentration to prognostic models for 
the prediction of kidney failure, such as the KFRE, should be assessed. Further, prognostic 
models may be developed and assessed that incorporate serum cFLC concentration for the 
prediction of risk of death in patients with CKD. 
Should evidence of a causal role in the association between serum FLCs and the risk 
of adverse outcomes be established, an assessment may be made of their potential as a 
treatment target. For example, rituximab, a monoclonal antibody targeted against CD20 
expressed on most B cells, leads to B cell depletion and a reduction in serum cFLC 
concentration when used in conditions such as systemic lupus erythematosus and rheumatoid 
arthritis (306, 307). 
7.3. Urine free light chains 
Urine FLC excretion in patients with CKD is in part determined by serum FLC 
concentration. Given the results of Chapter III, and the supposition that urine FLC excretion 
may reflect kidney exposure to potentially nephrotoxic FLCs, an assessment was made of the 
association between urine FLCs and the risk of kidney failure and death in a prospective 
cohort of patients with CKD. 
A significant correlation between serum FLC concentration and urine FLC/creatinine 
concentrations was confirmed. However, urine FLC/creatinine concentrations were not 
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independently associated with the risk of kidney failure or death and did not provide any 
improvement when added to the KFRE for the prediction of kidney failure at two years. 
The detection of monoclonal urine FLCs (Bence Jones protein) is still used in clinical 
practice in the assessment for monoclonal disorders, but there is no evidence to date that the 
measurement of urine non-clonal FLCs is clinically useful. Given previous work showing that 
urine FLC excretion increases early in CKD before the development of increased 
albuminuria, however, the use of urine FLCs for the early diagnosis of CKD may be explored.   
7.4. Monoclonal gammopathy 
The presence of a malignant monoclonal gammopathy (MG) may be causally 
associated with kidney failure, and with death. Chapter III showed a higher serum 
concentration of non-clonal FLCs is also associated with a higher risk of kidney failure and 
death in patients with CKD. However, there has been little study of the prognostic 
significance of non-malignant MG in patients with CKD. 
One study, by Haynes et al., found no independent association between the presence 
of an MGUS and the risk of kidney failure (218). Further, unlike in the general population, 
MGUS was not associated with worse survival (218). However, this was a relatively small 
study, and given the common finding of a non-malignant MG in patients with CKD, an 
assessment was made using data from three cohort studies of the association between non-
malignant MG and kidney failure and death in CKD. 
As observed in other CKD cohorts, the prevalence of an MG was higher than the 
prevalence in the general population. However, the presence of an MG was not independently 
associated with the risk of kidney failure or death. These results are consistent with the 
findings of Haynes et al. (218). 
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This information is of significant importance in clinical practice. It is common to 
detect a non-malignant MG in patients with CKD and based on these results these patients 
and their clinicians may be reassured that the MG does not add to their risk of kidney failure 
or death. However, the association between the presence of an MG and other important 
outcomes, such as cardiovascular events or malignant transformation, were not studied and 
may be studied in future research. 
7.5. Serum endotrophin 
Finally, the prognostic significance of serum endotrophin concentration in patients 
with CKD was assessed. CKD is associated not only with kidney fibrosis but also with 
accelerated cardiac and arterial fibrosis. It was hypothesized that the serum concentration of 
endotrophin, a marker of collagen type VI deposition, may reflect this fibrotic burden and be 
associated with the risk of adverse outcomes.  
While there was no independent association between serum endotrophin concentration 
and the risk of kidney failure, a higher serum endotrophin concentration was independently 
associated with a higher risk of death. Of particular interest was the finding that this 
association was stronger than the association between eGFR and risk of death in this cohort. 
This finding requires validation in a separate cohort of patients with CKD, ideally with 
additional cardiovascular phenotyping and data on causes of death to explore the association 
between endotrophin and death. Blood pressure and PWV were assessed in this cohort and 
did not have strong relationships with endotrophin. Should the significant association between 
endotrophin and mortality be validated, its role in the risk prediction for mortality in patients 
with CKD may be assessed. 
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Despite a lack of association between serum endotrophin and the risk of kidney 
failure, recent work has demonstrated an association between urinary endotrophin excretion 
and CKD progression, perhaps suggesting that urine endotrophin is a more specific and 
reliable marker of kidney fibrosis than serum concentration (294). 
7.6. Strengths and limitations 
The work in this thesis has all been performed using data and samples from 
prospective cohort studies of patients with CKD, and methods were employed to reduce the 
risk of bias, such as remote outcome event capture to supplement patient-reported events and 
robust pre-specified statistical analyses. 
However, the data are observational. The association between each prognostic factor 
and kidney failure and death were estimated, but the underlying nature of the associations and 
in particular whether they were causal relationships, could only be speculated upon. The lack 
of mechanistic data, such as that from kidney biopsy specimens, is a significant limitation and 
is common to most observational CKD cohort studies. The availability of kidney biopsy 
tissue in the recently-established NURTuRE (the National Unified Renal Translational 
Research Enterprise)-CKD prospective study, described below, is one of its particular 
advantages. 
7.7. Cause-specific hazard models 
In addition to the primary analyses for kidney failure in each chapter in which the 
subdistribution hazard was modelled, cause-specific hazards were also modelled and 
presented in Appendices 5 to 8. It has been suggested that subdistribution hazard models are 
preferable to estimate the future risk of an outcome and prognosis (308). In contrast, cause-
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specific hazard models allow an estimation of the association between a factor on the hazard, 
e.g. of kidney failure, and are preferable when considering whether a factor has a causal 
association with the outcome (308). 
There were no significant differences between the results of the subdistribution hazard 
models and the cause-specific hazard models with regard to the novel prognostic factors being 
assessed. In both types of modelling, a higher serum cFLC concentration was associated with 
a higher risk of kidney failure, but urine FLC/creatinine ratios, monoclonal gammopathy, and 
serum endotrophin concentration were not. 
The higher risk of kidney failure associated with a higher serum cFLC concentration 
in the cause-specific hazard models would be consistent with but does not prove, a causal 
association. Interestingly, the graph in Appendix 5 suggests that the hazard associated with a 
higher serum cFLC concentration continues to increase even above 150 mg/l, despite there 
not being a further increase in incidence above this concentration (based on the 
subdistribution hazard model), likely due to the higher risk of the competing event of death 
associated with high concentrations of serum cFLC. The potential pathogenetic properties of 
FLCs seen in monoclonal disorders such as multiple myeloma and MGRS, and the other 
plausible mechanisms by which FLCs might be nephrotoxic, as discussed in Chapter III, lend 
weight to the hypothesis of a causal relationship. However, further research is needed to 
explore the nature of the association. 
7.8. Future research 
Several findings from work presented in this thesis may form the basis of further 
research. First, serum cFLC concentration has been shown, using data from five prospective 
CKD cohort studies, to be independently associated with the risk of kidney failure and death. 
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The role of serum FLC concentration in risk prediction may now be examined. This would 
preferably involve assessing the incremental value of serum FLC concentration when added 
to pre-existing models predicting the risk of kidney failure and death in patients with CKD, 
rather than the development of new models. A preliminary assessment could be undertaken 
using the existing data. 
Further laboratory-based research may also be undertaken to examine the nature of the 
underlying association, for example by assessing the effect on cells of the kidney, heart, and 
vasculature to exposure to high concentrations of FLCs. Should evidence for a causal role be 
demonstrated, the use of treatments targeted against FLCs or FLC-producing B cells may be 
explored. 
The finding of an independent association between serum endotrophin concentration 
and the risk of death in patients with CKD first requires validation in a separate cohort of 
patients. If the association is replicated, an assessment should be made of its role in risk 
prediction, and further exploration of the nature of the association may be accomplished 
through detailed cardiovascular phenotyping and associations with incident cardiovascular 
disease and causes of death. Endotrophin measurement is not currently available in routine 
clinical practice, and further work is required to assess whether it may have a future role in 
the management of patients with CKD. 
In the UK, the NURTuRE-CKD study, which recently completed recruitment, has 
collected and stored serum, urine, DNA and kidney biopsy tissue from over 3000 patients 
with CKD from 18 NHS trusts, with linked clinical and outcome data. With the accrual of 
patient follow-up and outcome events, this biobank will provide the basis for the further 
development of risk prediction in CKD and the identification of further prognostic factors. 
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Further, international collaborations, such as the CKD Prognosis Consortium and 
iNET-CKD (International Network of Chronic Kidney Disease cohort studies), the 
availability of big data updated in real-time, developments in -omics research, and novel 
methods of prognosis research such as machine learning, may all have a role in the future 









To obtain blood pressure readings on patients in the RIISC study which are consistent with the study protocol. 
 
All participants will have their blood pressure recorded at all time-points 
 
Preparation and Method  
Patients will have rested in a quiet room for 5 minutes prior to taking a measurement. 
Patients will have the monitor sited at the same level as their heart with their back and arm supported in a relaxed 
position. Both feet should be flat on the floor. 
They will be asked not to talk while the recording is taking place. 
Align the artery indicator on the cuff with the patient’s brachial artery. Wrap the cuff around the arm and check 
that the white index marking on the edge of the cuff falls within the white range markings on the inside surface of 
the cuff.  
If the index does not fall within the range markers, replace the cuff with a smaller or larger size. 
Ensure the cuff is tight but allow two fingers to be inserted between cuff and arm. 
 
Taking a BP measurement. 
Turn on machine or press the Clear button to clear memory between patients. 
Attach cuff to upper arm of patient 
Use the cycle button to select an automatic series of measurements (indicated by a character from 1-5 in the Cycle 
display.) 
Press the BP start button to begin the measurement. (Wait 5 seconds after turning on the BpTRU before pressing 
the start button.) 
Press the Stop button at any time to stop the measurement and deflate the cuff or to pause between measurements. 
 
Results 
A tone will sound at the completion of six measurements. 











This SOP describes procedures to ensure the correct use of the Vicorder Equipment for the RIISC study to obtain 
measurements which are consistent with the study protocol. 
 
All participants will have their pulse wave velocity and pulse wave analysis measured at all time-points 
 
Method  
Vicorder readings will be recorded at all study time points: baseline, 6 months, 18 months, 3 years, 5 years and 10 
years. 
 
Take 3 readings; if there is a more than 10% deviance from expected normal of 7m/s; continue to take readings 
until there are two within 10% of one another. If the first three readings are above 12m/s then take another three 
readings.  
 
Note which leg and arm used for readings and enter data. Use same arm and leg throughout study at all time 
points. If at any time point this is different, record reason for change. 
 
Ensure room temperature kept between 22 and 24 degree Celsius: use temperature log sheet to record. 
 









The purpose of this SOP is to ensure the correct use of the AGE reader Equipment for the RIISC study 
The AGE Reader CU™ is a proprietary device that can non-invasively assess the tissue accumulation 
of Advanced Glycation End products (AGEs) and obtain measurements that are consistent with the study 
protocol. 
 
All participants will have their AGEs measured at all time-points 
 
Intended Use 
Measurements should be done on the dominant arm on healthy undamaged skin 
without birthmarks or excessive hair growth, tattoos or scars. Self tanning agents must not be used for at least 2 
days. If patient has used self tanning agents document and inform the patient not to use next time 2 days before 
the appointment. Sun-blockers and other skin care products should be removed before measurement. 
 
Pigmented skin 
The device and its software have been validated in patients with Fitzpatrick class 1-4 skin colour. For 
measurements on patients with Fitzpatrick class 5-6 (dark brown or black), users should check with the 
manufacturer or distributor for the correct software version in order to avoid unreliable results. If a measurement 
is performed on a skin type that is too dark to give a reliable result, the AGE Reader CU will give a warning. 
 
UV-Radiation 
Using the guidelines of the ICNIRP it is concluded that during AGE Reader CU measurements, as intended, even 
when repeated up to a 100 times on the same skin site within an 8-hour period, the local radiation exposure on the 
skin of the patients, and to the eyes of patients and operators remain considerably below the maximum allowed 
values for that period. Radiation exposure to the eyes normally does not occur. Exposure of the eyes longer than 
60 seconds per 8-hour period should be avoided (ie do not look directly into the UV light) 
 
Procedure and method  










The purpose of this SOP is to ensure standardised operating procedures, when collecting blood and urine samples 
for the purpose of this study. 
 
Blood, urine and saliva samples will be collected from all participants at all time-points 
    
Introduction/Method 
1. Collect blood samples using vacutainers (order of draw: 2 x red, 1 x EDTA, 1 x Paxgene) 
2. Tubes should be completely filled by the vacuum in order to obtain the correct ratio of blood to additive. Over and 
under filing alters the ration and changes results.  
3. Thoroughly mix by inverting the tube 8-10 times 
4. Leave serum (2 x red top) to clot for 1 hour at room temperature 
5. Spin at 2500rpm for 10 minutes at 4°C 
6. Spin the EDTA samples immediately at 2500rpm for 10 minutes at 4°C 
7. Urine collected as midstream clean catch. Where possible ask the patient to provide a fresh sample. Urine samples 
collected more than 2 hours ago should be discarded. 
8. Spin at 3000rpm for 15 minutes at 4°C 





RESULTS FROM CAUSE-SPECIFIC HAZARD MODELS (CHAPTER III) 
Univariable and multivariable cause-specific hazards of kidney failure using data from Chapter III. 
Results in bold differ from the subdistribution hazard model. 
 
Variable Univariable Multivariable HR 95% CI P HR 95% CI P 
Age 0.86 0.78 to 0.94 0.001 0.79 0.71 to 0.88 <0.001 
Male sex 0.81 0.68 to 0.97 0.021 0.86 0.71 to 1.05 0.14 
Non-White ethnicity 1.48 1.15 to 1.91 0.002 1.05 0.79 to 1.39 0.76 
DM 1.31 1.07 to 1.60 0.010 1.11 0.89 to 1.37 0.35 
CVD 0.93 0.77 to 1.13 0.46 1.01 0.82 to 1.25 0.91 
Systolic BP 1.17 1.06 to 1.28 0.001 1.11 1.00 to 1.24 0.043 
Urine ACR 16.3a 10.2 to 26.0 <0.001 1.40g 1.26 to 1.55 <0.001 
 0.12b 0.06 to 0.24 <0.001 1.01h 1.01 to 1.02 <0.001 
eGFR 0.00c 0.00 to 0.00 <0.001 0.00a 0.00 to 0.00 <0.001 
 606168d 52199 to 7.0e+06 <0.001 32.5e 5.50 to 192 <0.001 
Serum albumin 0.98e 0.98 to 0.99 <0.001 1.14 1.02 to 1.27 0.018 
Serum calcium 0.44e 0.37 to 0.52 <0.001 0.87 0.80 to 0.95 0.001 
 1.84f 1.62 to 2.10 <0.001    
Serum phosphate 115c 59.9 to 221 <0.001 1.24 1.12 to 1.37 <0.001 
 0.54d 0.47 to 0.63 <0.001    
RAASi 1.23 1.01 to 1.48 0.035 1.03 0.83 to 1.28 0.78 
Serum cFLC 198g 66.6 to 590 <0.001 32.0g 9.01 to 113 <0.001 
 0.00a 0.00 to 0.01 <0.001 0.01a 0.00 to 0.05 <0.001 
For continuous variables with a linear association, HR is per +1 SD. Two rows for a 
continuous variable indicate the HR for each power of the degree-2 fractional polynomial 
transformation. Fractional polynomial transformations are denoted by: a = x0.5; b = x0.5ln(x); 




Adjusted HR with 95% CI for kidney failure according to serum cFLC concentration (relative 
to 50 mg/l), from the multivariable cause-specific hazard model shown in the above table, to 






















RESULTS FROM CAUSE-SPECIFIC HAZARD MODELS (CHAPTER IV) 
Univariable and multivariable cause-specific hazards of kidney failure using data from Chapter IV. 
Results in bold differ from the subdistribution hazard model. 
 
Variable 
Univariable Multivariable (κCR) Multivariable (λCR) 
HR 95% CI P HR 95% CI P HR 95% CI P 
Age 0.74 0.65 to 0.84 <0.001 0.50 0.41 to 0.61 <0.001 0.50 0.40 to 0.61 <0.001 
Male gender 0.95 0.71 to 1.28 0.75 1.31 0.94 to 1.84 0.11 1.31 0.94 to 1.83 0.12 
Ethnicity          
White Ref   Ref   Ref   
South Asian 1.67 1.20 to 2.31 0.002 0.94 0.64 to 1.40 0.77 0.92 0.62 to 1.36 0.67 
Black 1.70 1.11 to 2.60 0.015 1.71 1.03 to 2.82 0.037 1.68 1.01 to 2.77 0.044 
Other 0.00 0.00 to . 1.00 0.00 . . 0.00 . . 
Co-morbidities          
DM 0.98 0.73 to 1.32 0.90       
IHD 0.81 0.55 to 1.18 0.27       
Cerebrovascular disease 1.16 0.72 to 1.86 0.55       
PAD 0.82 0.47 to 1.41 0.46       
COPD 0.47 0.25 to 0.89 0.020       
Malignancy 0.53 0.30 to 0.93 0.027       
Cause of CKD          
Ischaemic/hypertensive Ref   Ref   Ref   
Glomerulonephritis 0.93 0.57 to 1.54 0.79 0.84 0.47 to 1.51 0.57 0.84 0.47 to 1.50 0.56 
Diabetic kidney disease 1.88 1.16 to 3.04 0.010 0.88 0.50 to 1.54 0.64 0.88 0.50 to 1.54 0.65 
Polycystic kidney disease 3.06 1.83 to 5.12 <0.001 7.13 3.77 to 13.5 <0.001 7.23 3.77 to 13.9 <0.001 
Interstitial nephropathy 0.66 0.30 to 1.48 0.32 0.37 0.14 to 1.02 0.06 0.37 0.13 to 1.01 0.05 
Reflux nephropathy 0.83 0.29 to 2.32 0.72 0.35 0.12 to 1.06 0.06 0.36 0.12 to 1.07 0.07 
Other/uncertain 1.02 0.67 to 1.55 0.93 0.84 0.52 to 1.34 0.46 0.81 0.51 to 1.30 0.38 
eGFR 0.97a 0.95 to 0.98 <0.001 0.97a 0.96 to 0.98 <0.001 0.97a 0.96 to 0.98 <0.001 
 2.08b 1.70 to 2.53 <0.001 77.7d 30.2 to 200 <0.001 75.0d 29.0 to 194 <0.001 
Urine ACR 1.51c 1.36 to 1.67 <0.001 6.91e 4.26 to 11.2 <0.001 6.74e 4.15 to 11.0 <0.001 
    0.99f 0.99 to 1.00 <0.001 0.99f 0.99 to 1.00 <0.001 
Systolic BP 1.25 1.09 to 1.43 0.002       
Diastolic BP 1.20 1.04 to 1.39 0.012       
MAP 1.27 1.10 to 1.46 0.001 0.86 0.72 to 1.03 0.10 0.86 0.73 to 1.03 0.10 
Serum κ 3.42c 2.66 to 4.40 <0.001       
Serum λ 4.25c 3.19 to 5.65 <0.001       
Serum κ + λ 4.18c 3.17 to 5.50 <0.001       
Urine κCR 1.94c 1.65 to 2.29 <0.001 1.05 0.89 to 1.25 0.54    
Urine λCR 1.83c 1.60 to 2.10 <0.001    1.12 0.96 to 1.31 0.16 
For continuous variables with a linear association, HR is per +1 SD. Non-linear fractional 





RESULTS FROM CAUSE-SPECIFIC HAZARD MODELS (CHAPTER V) 
Univariable and multivariable cause-specific hazards of kidney failure using data from Chapter V. The 
first table incorporates data from the RIISC study only, and the second table incorporates data from all 
three studies. Results in bold differ from the subdistribution hazard model. 
 
Variable Univariable Multivariable HR 95% CI P HR 95% CI P 
MG+ 1.13 0.80 to 1.59 0.50 1.19 0.82 to 1.74 0.36 
Age 1.00a 1.00 to 1.00 <0.001 0.60 0.52 to 0.70 <0.001 
Male sex 1.04 0.83 to 1.29 0.76 0.48 0.37 to 0.61 <0.001 
Ethnicity       
White Ref   Ref   
South Asian 1.87 1.46 to 2.40 <0.001 1.15 0.86 to 1.53 0.35 
Black 1.93 1.38 to 2.69 <0.001 1.95 1.37 to 2.77 <0.001 
Other 2.43 1.00 to 5.90 0.05 1.66 0.61 to 4.52 0.32 
Co-morbidities       
DM 0.99 0.79 to 1.23 0.90    
IHD 1.02 0.78 to 1.33 0.88    
Cerebrovascular disease 0.88 0.61 to 1.27 0.50    
PAD 0.98 0.68 to 1.43 0.94    
COPD 0.48 0.30 to 0.77 0.002    
Malignancy 0.61 0.42 to 0.90 0.012    
Smoking status       
Never Ref      
Previous 0.75 0.58 to 0.95 0.019    
Current 1.09 0.79 to 1.49 0.60    
Cause of CKD       
Vascular Ref   Ref   
Diabetes 1.89 1.33 to 2.70 <0.001 0.99 0.64 to 1.54 0.97 
Glomerular 0.98 0.66 to 1.44 0.91 0.86 0.54 to 1.35 0.51 
Tubulointerstitial 0.76 0.48 to 1.19 0.23 0.52 0.32 to 0.84 0.008 
Cystic or congenital 2.46 1.70 to 3.55 <0.001 3.92 2.60 to 5.91 <0.001 
Other or unknown 1.20 0.86 to 1.68 0.28 1.18 0.81 to 1.70 0.38 
MAP 1.35 1.21 to 1.50 <0.001 1.00 0.88 to 1.14 0.98 
eGFR 1.23b 1.18 to 1.27 <0.001 0.94b 0.92 to 0.95 <0.001 
 1.08c 1.06 to 1.09 <0.001 3.93e 3.23 to 4.77 <0.001 
Urine ACR 1.49d 1.39 to 1.60 <0.001 4.21f 3.20 to 5.54 <0.001 
    1.00a 1.00 to 1.00 0.011 
Continuous variables are linear per +1 SD unless indicated. Two rows for a continuous 
variable indicate the HR for each power from an FP2 model. Fractional polynomial 






HR 95% CI P HR 95% CI P 
LC-MG+ 1.49 0.80 to 2.80 0.21 1.24 0.66 to 2.35 0.50 
Age 1.00a 1.00 to 1.00 <0.0001 0.74 0.68 to 0.80 <0.001 
Male sex 1.00 0.85 to 1.18 0.99 1.12 0.94 to 1.34 0.20 
Ethnicity       
White Ref   Ref   
South Asian 1.82 1.44 to 2.29 <0.001 1.08 0.84 to 1.39 0.56 
Black 1.80 1.31 to 2.49 <0.001 1.94 1.38 to 2.74 <0.001 
Other 2.54 1.20 to 5.38 0.015 1.27 0.58 to 2.78 0.55 
Co-morbidities       
DM 1.01 0.84 to 1.20 0.95    
IHD 1.13 0.91 to 1.41 0.26    
Cerebrovascular 0.96 0.72 to 1.27 0.76    
PAD 1.08 0.84 to 1.39 0.56    
Smoking status       
Never Ref      
Previous 0.78 0.65 to 0.94 0.008    
Current 1.18 0.93 to 1.51 0.17    
MAP 1.28 1.18 to 1.38 <0.001 1.07 0.98 to 1.17 0.15 
eGFR 1.21b 1.18 to 1.24 <0.001 0.96b 0.95 to 0.97 <0.001 
 1.07c 1.06 to 1.08 <0.001 2.56f 2.25 to 2.91 <0.001 
Urine ACR 1.00d 1.00 to 1.00 <0.001 1.55e 1.42 to 1.70 <0.001 
 1.58e 1.49 to 1.67 <0.001 1.01g 1.01 to 1.02 <0.001 
Continuous variables are linear per +1 SD unless indicated. Two rows for a continuous 
variable indicate the HR for each power from an FP2 model. Fractional polynomial 





RESULTS FROM CAUSE-SPECIFIC HAZARD MODELS (CHAPTER VI) 
Univariable and multivariable cause-specific hazards of kidney failure using data from Chapter VI. 




HR 95% CI P HR 95% CI P 
Age 0.72 0.62 to 0.83 <0.001 0.52 0.43 to 0.64 <0.001 
Sex (male) 0.87 0.64 to 1.18 0.37 0.95 0.69 to 1.31 0.76 
Ethnicity       
White Ref   Ref   
South Asian 1.91 1.34 to 2.71 <0.001 1.17 0.79 to 1.73 0.44 
Black 1.46 0.89 to 2.41 0.14 1.77 1.04 to 3.03 0.037 
Other 1.30 0.32 to 5.27 0.71 1.19 0.28 to 5.04 0.81 
Cause of CKD       
Vascular Ref   Ref   
Diabetes 2.13 1.22 to 3.69 0.007 0.95 0.52 to 1.72 0.87 
Glomerular 1.14 0.69 to 1.88 0.60 0.83 0.47 to 1.46 0.51 
Cystic and congenital 2.69 1.61 to 4.49 <0.001 3.46 1.96 to 6.11 <0.001 
Tubulointerstitial 0.97 0.54 to 1.76 0.93 0.76 0.39 to 1.48 0.42 
Other/uncertain 1.26 0.78 to 2.01 0.34 1.16 0.71 to 1.91 0.55 
Co-morbidities       
Cerebrovascular disease 0.85 0.50 to 1.45 0.56    
COPD 0.43 0.23 to 0.81 0.009    
DM 0.85 0.61 to 1.17 0.32    
IHD 1.00 0.69 to 1.46 0.99    
Malignancy 0.51 0.30 to 0.89 0.017    
PAD 0.71 0.39 to 1.28 0.25    
Smoking status       
Never Ref      
Previous 0.82 0.59 to 1.13 0.23    
Current 0.85 0.53 to 1.35 0.49    
MAP 1.40 1.21 to 1.61 <0.001 1.13 0.96 to 1.33 0.14 
eGFR 7.64a 5.42 to 10.8 <0.001 17.9a 10.8 to 29.7 <0.001 
Urine ACR 1.50b 1.36 to 1.66 <0.001 4.15c 3.02 to 5.70 <0.001 
Serum endotrophin 0.00a 0.00 to 0.01 <0.001 1.14 0.95 to 1.35 0.16 
HR for continuous variables are per +1 SD, unless fractional polynomial transformation 
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